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1 Introduction 
1.1 The Immune System 
 In response to an infection, cells of the innate and adaptive immune system 
are activated sequentially to eliminate the invading pathogen. Innate immune cells 
like macrophages, NK cells and neutrophils are poised to respond quickly to an 
invading pathogen, by phagocytosis and secretion of anti-microbial mediators. 
Adaptive immune cells like T and B cells, are equipped with receptors that are 
antigen-specific and are activated during later stages of the immune response. 
These cells are important effectors, since their responses are tailored to the 
pathogenic insult. Effector mechanisms include antibody secretion, cytotoxic killing, 
and cytokine secretion. 
 Many microbicidal mediators (e.g. cytokines, chemokines, anti-microbial 
peptides) are potent inflammatory agents. Excess inflammation is dangerous for the 
host, since it can lead to severe pathology. Therefore, it is important that the immune 
response is balanced to ensure clearance or containment of the pathogen, and at the 
same time protect the host from pathology. 
 This thesis focuses on the role of arginine modifying enzymes in immune 
regulation. More specifically, I will focus on effects of arginine posttranslational 
modifications on cytokine production from macrophages and T helper cells. In 
addition, I will evaluate histone arginine deimination in primary neutrophils. 
1.1.1 Macrophages 
 Macrophages are monocyte-derived phagocytes. They play an essential role 
in both innate and adaptive immunity. As professional phagocytes, tissue-resident 
macrophages are important for clearance of cellular debris. This process is mediated 
by phagocytic receptors like Fc receptors, scavenger receptors, complement 
receptors, etc (for review: (Aderem and Underhill, 1999)). Macrophages also express 
pattern recognition receptors (PRR), e.g. TLRs. Encounter of pathogens through 
PRRs is followed by rapid activation and secretion of cytokines, chemokines, and 
other microbicidal agents (Gordon, 2002). These soluble immune mediators play an 
important role in clearance of the pathogen as well as the recruitment of other 
immune cells to the site of infection. Microbial phagocytosis activates pathogen killing 
and subsequent antigen processing and presentation to the cells of the adaptive 
immune system, placing macrophages in the group of antigen-presenting cells 
(APCs) (for review: (Gordon, 2003)). 
 Macrophage activation is influenced by external stimuli (for review: (Duffield, 
2003; Ma et al., 2003; Mosser and Edwards, 2008)). Two major forms of 
macrophage activation can be distinguished: classical and alternative activation. 
Classical activation requires priming of the macrophage by IFNγ and subsequent 
encounter with a pathogen-derived stimulus like LPS (Dalton et al., 1993; Ehrt et al., 
2001; Mackaness, 1964). Hallmarks of this type of activation are a highly 
proinflammatory response including IL-6, TNFα, and IP-10 secretion as well as 
upregulation of NOS2. NOS2 metabolizes L-arginine to nitric oxide (NO), an 
important bactericidal mediator. The type II cytokines IL-4 and IL-13 stimulate 
alternative activation (Gordon, 2003; Stein et al., 1992). This activation state is 
associated with resolution of an infection, since the mediators released have anti-
inflammatory, fibrotic, and proliferative properties (Gordon, 2003). A hallmark of 
alternative activation is the upregulation of Arginase I, which metabolizes L-arginine 
to urea and L-ornithine (Munder et al., 1998; Munder et al., 1999). Ornithine is further 
metabolized into proline and polyamines, which can mediate the production of 
collagen and induce cell proliferation, respectively. 
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1.1.2 Neutrophils 
 Neutrophils are the most abundant immune cells in the blood. They are 
rapidly activated and recruited to sites of infection via a gradient of chemoattractants 
composed of chemokines and the bacterially derived tripeptide formylated Met-Leu-
Phe (Downey, 1994). Neutrophils are equipped with potent microbicidal mediators, 
including anti-microbial peptides, proteases, and peroxidases, prepackaged in 
granules that can be released upon stimulation (for review: (Nathan, 2006; Nauseef, 
2007). In addition, neutrophils produce reactive oxygen species (ROS), a highly 
efficient bactericidal mediator (Nathan and Shiloh, 2000). Neutrophils can release 
web-like extracellular traps that can bind and kill pathogens. Those neutrophil 
extracellular traps (NETs) are assembled from nuclear and cytoplasmic components 
(Brinkmann et al., 2004; Ermert et al., 2009). NETs are made of antimicrobial 
mediators bound to chromatin. Their release mechanism involves a novel cell death 
pathway that is dependent on ROS generation (Fuchs et al., 2007). 
 The importance of neutrophils in immunity is revealed in patients with 
inherited neutrophil defects that suffer from frequent and severe microbial infections 
(for review: (Malech and Nauseef, 1997)). Besides their direct microbicidal activities, 
neutrophils are also important for recruitment and activation of monocytes, 
macrophages, dendritic cells, and T cells (Nathan, 2006). 
1.1.3 T Helper Cells 
 During an immune response, naïve CD4+ T cells encounter their cognate 
antigen in the context of an antigen-presenting cell, which drives them to differentiate 
into a specific T helper lineage (see Figure 1). Lineage commitment is determined by 
environmental cues, including cytokines (O'Garra, 1998), which instruct 
differentiation towards the Th1, Th2, Th17, inducible T regulatory (iTreg), or T 
follicular cell fate (Tfh) (for review: (O'Shea and Paul, 2010; Zhou et al., 2009; Zhu 
and Paul, 2010)). T helper cell subsets are defined by their cytokine secretion 
profiles. Cytokines are not only essential during the initial steps of differentiation but 
also play an important role in reinforcing the cell fate decision. 
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FIGURE 1: T Helper Cell Differentiation Schematic (adapted from (O'Shea and Paul, 
2010)). When naïve CD4+ T cells encounter their cognate antigen presented by an antigen-
presenting cell (APC), they become activated and differentiate towards a Th cell lineage. This 
cartoon gives an overview of the cytokines involved in differentiation to a certain fate, as well 
as the transcription factors that are essential for lineage commitment. The effector cytokines 
secreted by the various Th cell subsets are listed on the right side. 
 
1.1.3.1 Overview of T Helper Cell Differentiation 
 Th1 cells play an essential role in cellular immunity by aiding the clearance of 
intracellular bacteria and viruses through IFNγ secretion. IL-12 and IFNγ, mainly 
produced by activated monocytes, dendritic cells, and NK cells, drive Th1 
differentiation. This process is dependent on the lineage-specifying transcription 
factor T-bet (Szabo et al., 2003). Th2 cells are important in defense against 
extracellular pathogens, like helminths. Exposure to exogenous IL-4 during the 
activation of the naïve CD4+ T cell drives differentiation towards the Th2 lineage in a 
process dependent on the transcription factor GATA3. Th2 cells secrete IL-4, IL-5, 
and IL-13 to aid in humoral immunity against parasites as well as to reinforce their 
cell fate decision (Ansel et al., 2006). The more recently identified Th17 subset 
derived its name from its signature cytokine IL-17 and plays an important role in 
defense against extracellular bacterial and fungal infections. Th17 differentiation is 
driven by TGFβ in combination with proinflammatory cytokines, especially IL-6, and 
is dependent on the transcription factor RORγt (Harrington et al., 2005; Park et al., 
2005). Tfh cells play an important role in regulation of B cell maturation, especially 
the germinal center reaction, including class switch recombination and affinity 
maturation. IL-21 drives Tfh differentiation, and the transcription factor Bcl-6 is 
required. It is not clear whether Tfh cell are truly a separate lineage, since they are 
very heterogeneous and can secrete IFNγ, IL-4 or IL-17 in addition to IL-21 (King et 
al., 2008).  
 The effector T cell response requires tight regulation, since all of the secreted 
cytokines can induce pathology if inappropriately expressed. Aberrant Th1 and Th17 
responses are implicated in organ-specific autoimmunity (Damsker et al., 2010). 
Hyperactive Th2 cells are culprits in allergy and asthma (Passalacqua and Ciprandi, 
2008). Therefore, regulatory T cells (Tregs) can suppress an immune response, and 
Tregs play an important role to maintaining the balance between control of infection 
and prevention of excessive pathology (Shevach, 2009). Tregs characteristically 
express Foxp3, which is required for specifying and maintaining the functional 
program of all regulatory T cells. There are two types of regulatory T cells, the natural 
Tregs (nTregs) derived from the thymus and the inducible Tregs (iTregs), which are 
generated in the periphery from naïve CD4+ T cells. The iTreg differentiation shares 
similarities with the Th17 differentiation pathway since it also requires TGFβ (for 
review: (Vignali et al., 2008)). 
1.2 Posttranslational Modifications of Arginines 
 Many proteins are chemically modified in a process referred to as post-
translational modification (PTM). Since PTMs can change a protein’s physical 
properties, these modifications broaden the spectrum of protein function, including 
activity, stability, or localization. More than 400 PTMs have been identified (Creasy 
and Cottrell, 2004), with the best-studied being phosphorylation, ubiquitination, 
acetylation, glycosylation, and methylation (Farley and Link, 2009). Many of the 
previously described PTMs can act as reversible on/off switches as exemplified by 
the antagonistic action of receptor tyrosine kinases and phosphatases in many signal 
transduction events (Hunter, 1998; Rogers, 1962). 
           INTRODUCTION 
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 Reports of the posttranslational modification of arginines go back over 50 
years with the identification of the unnatural amino acid citrulline in proteins (Rogers, 
1962; Rogers and Simmonds, 1958), a process referred to as deimination. Arginine 
methylation was first described nearly ten years later (Paik and Kim, 1967). The 
functional analysis of arginine methylation and deimination in cell biology is a more 
recent development and will be discussed in more detail later. 
 Arginine is a positively charged amino acid that is often involved in hydrogen 
bonding and amino aromatic interactions with nucleic acids. Peptidylarginines can be 
modified by protein arginine methyltransferases (PRMTs) through addition of 
monomethyl or dimethyl groups to the guanidine nitrogen atoms (Figure2) (Gary and 
Clarke, 1998). Three states of arginine methylation have been identified in 
eukaryotes, monomethylated arginine (MMA), asymmetric dimethylated arginine 
(aDMA), and symmetric dimethylated arginine (sDMA). These PTMs do not affect the 
positive charge of the arginine, but increase its bulkiness and overall hydrophobicity. 
Arginine deimination is catalyzed by members of the family of peptidylarginine 
deiminases (PADs) (Rogers et al., 1977; Takahara et al., 1986). The conversion from 
arginine to citrulline results in a concomitant loss of the positive charge, which 
transforms the former strongly basic residue into a neutral amino acid (Figure 2).  
 A major question in the field of arginine posttranslational modification 
research is whether methylation and deimination are reversible. It has been 
proposed that PADs and PRMTs might have antagonistic activities, since PADs, 
specifically PAD4, can convert histone MMA but not DMA to citrulline (Cuthbert et al., 
2004; Wang et al., 2004) (Figure 2). Furthermore, arginine methylation can be 
blocked by preemptive deimination. However, PADs are not true demethylases, 
since they cannot convert the MMA back into the original arginine. In 2007 Chang et 
al., demonstrated that JMJD6, a Jumonji-domain containing enzyme, could act as an 
arginine-specific demethylase (Chang et al., 2007). The biological role of JMJD6 in 
demethylation of targets other than methylated arginines in histones still needs to be 
elucidated. To date, no enzyme has been identified that can catalyze the conversion 
of peptidyl-citrulline back into arginine. 
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FIGURE 2: Overview of Arginine PTMs. (adapted from (Boisvert et al., 2005a)). 
Peptidylarginines can be monomethylated on a guanidino nitrogen atom by type I and type II 
arginine methyltransferases (PRMTs). Type I enzymes catalyze the addition of a second 
methyl group to the same nitrogen atom in a process referred to as asymmetric dimethylation. 
Type II PRMTs catalyze symmetric dimethylation by adding a second methyl group to the 
opposite nitrogen atom. Both types of PRMTs use S-adenosyl-methionine (SAM) as the 
methyldonor, releasing S-adenosylhomocysteine (SAH) in the process. Both arginines and 
monomethylated arginines can be deiminated by the peptidylarginine deiminase protein 
family (PAD), resulting in the formation of citrulline. 
1.3 Protein Arginine Methyltransferases (PRMTs) 
 Arginine methylation has been linked to many cellular processes like 
chromatin remodeling, signal transduction, RNA processing, gene transcription, 
cellular transport, etc (for review: (Bedford and Clarke, 2009; Bedford and Richard, 
2005; Lee and Stallcup, 2009; Wolf, 2009)). The PRMT enzyme family has been 
found in nearly all groups of eukaryotes. PRMT1 and PRMT5 can be traced back 
early in the eukaryote evolution (Krause et al., 2007). Eleven human PRMT genes 
have been identified so far. 
 PRMT enzymes catalyze the transfer of methyl groups from the universal 
methyl-donor S-adenosyl-L-methionine (SAM) to the terminal nitrogen atom of the 
guanidinium side chain of an arginine residue. The methylation reaction is a two-step 
process that involves a monomethylated intermediate (MMA). The PRMTs can be 
classified into two different groups: Type I enzymes (PRMT1, PRMT2, PRMT3, 
PRMT4, PRMT6, and PRMT8) catalyze the formation of MMA and aDMA; type II 
enzymes (PRMT5, PRMT7, and PRMT9) catalyze the formation of MMA and sDMA 
(Figure 2). PRMT10 and PRMT11 have not been demonstrated to exhibit enzymatic 
activity. 
1.3.1 The PRMT Family Members 
 All PRMTs have a common catalytic core, which consists of the 
methyltransferase domain and subdomains involved in methyldonor and substrate 
binding (Bachand, 2007). The family members can be distinguished by their unique 
N-terminal domains (Figure 3).  
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FIGURE 3: Overview PRMT Enzyme Family (adapted from (Wolf, 2009)). This cartoon 
depicts the schematic structure of PRMT1 through PRMT11. Features unique for each 
enzyme are indicated. The catalytic core domain is conserved between all family members. 
 
 Even though PRMTs share many features, they are involved in highly diverse 
processes. PRMT1 was the first arginine methyltransferase to be identified 
(Abramovich et al., 1997; Lin et al., 1996). It represents the predominant type I 
PRMT and has broad tissue expression (Katsanis et al., 1997; Tang et al., 2000a; 
Tang et al., 2000b). PRMT1 activity accounts for 85% of the observed cellular PRMT 
activity (Tang et al., 2000a). PRMT1 knockout mice have been generated but die 
during an early stage of embryogenesis (Pawlak et al., 2000). PRMT2 has an N-
terminal SH3-domain, which plays an important role in protein-protein interactions 
(Kzhyshkowska et al., 2001). Though PRMT2 was long thought to be enzymatically 
inactive, in a more recent in vitro characterization PRMT2 demonstrates type I 
arginine methyltransferase activity towards histone H4R3. This finding needs to be 
confirmed under more physiological circumstances (Lakowski and Frankel, 2009). 
PRMT2 – deficient mice have been generated and are viable (Yoshimoto et al., 
2006). PRMT2-deficient MEFs have a defect in E2F1-mediated cell cycle entry, 
positioning PRMT2 as a negative regulator of E2F1 (Yoshimoto et al., 2006). PRMT3 
belongs to the type I methyltransferases and has a wide tissue distribution (Tang et 
al., 1998). The most distinctive feature of PRMT3 is its zinc finger domain (ZnF), 
which confers substrate specificity (Bachand and Silver, 2004). PRMT4 was 
originally described as coactivator associated arginine methyltransferase (CARM1) 
(Chen et al., 1999) and will be discussed in more detail below (see section 1.3.3). 
PRMT5, the first type II enzyme to be identified, has a wide tissue distribution 
(Branscombe et al., 2001). Homozygous deletion of PRMT5 in the mouse leads to 
immediate death of the zygote (Krause et al., 2007). PRMT6, another member of the 
type I family, displays predominantly nuclear cellular distribution (Frankel et al., 
2002). Little is known about PRMT7, PRMT9, PRMT10, and PRMT11. PRMT8 is 
highly homologous to PRMT1 but has a very narrow tissue distribution and is the 
only PRMT with a N-terminal myristoylation sequence, which targets the enzyme to 
the membrane (Lee et al., 2005b; Sayegh et al., 2007). 
1.3.1.1 PRMT Substrates 
 The list of substrates for PRMTs is continuously growing and encompasses 
proteins that regulate almost all cellular processes (Bedford and Richard, 2005; Lee 
and Stallcup, 2009; Wolf, 2009). Identification of a consensus sequence for PRMTs 
has remained elusive. PRMT1, 3, 6, and 8 favor glycine/arginine-rich (GAR) motifs. 
Substrates for PRMTs can be loosely categorized into four major cellular processes: 
RNA processing, transcriptional regulation, signal transduction and DNA repair 
(Figure 4). 
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FIGURE 4: Overview of PRMT Cellular Function (adapted from (Bedford and Richard, 
2005).  
 
 
 
RNA processing:  
 RNA-binding proteins (RBPs) like small nuclear ribonucleoprotein particles 
(snRNPs) and heterogeneous ribonucleoprotein particles (hnRNPs) encompass 
major targets for PRMTs. Many of those RBPs harbor glycine/arginine-rich regions, 
which are favored by PRMT1/3/6 and PRMT5/7 (Bedford and Richard, 2005; Cote et 
al., 2003; Herrmann et al., 2004). Arginine methylation of RBPs bears functional 
consequences. For example, Sam68 hypomethylation results in mislocalization to the 
cytoplasm (Cote et al., 2003; Lukong and Richard, 2004). Further, arginine 
methylation of several Sm family members by PRMT5 is required for their proper 
assembly into mature snRNPs (Brahms et al., 2001; Friesen et al., 2001; Meister et 
al., 2001). PRMT3 methylates ribosomal protein S2, thereby, influencing ribosomal 
protein biosynthesis and, consequently, translation (Swiercz et al., 2005). The RBP 
polyA-binding protein (PABP) is methylated by CARM1 (Lee and Bedford, 2002) and 
PRMT1 (Smith et al., 1999), but the functional consequences of PABP methylation 
are unknown. 
Transcriptional regulation: 
 The dynamic modification of chromatin during transcription illustrates the 
interplay of PTMs. N-terminal posttranslational modifications of the various histones 
serve as docking sites for chromatin-associated proteins. Different combinations of 
PTMs can lead to transcriptional activation or silencing. The combinatorial nature of 
histone PTMs has been described as the ‘histone code’ (Jenuwein and Allis, 2001; 
Strahl and Allis, 2000). Histone tails are targets for many PTMs, including 
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phosphorylation, ubiquitination, acetylation, methylation (lysine and arginine), and 
deimination. PRMTs, as well as PAD4, can modify histone tails. PRMT1 targets 
histone H4 R3; CARM1 targets histone H3 R17/R26; PRMT5 can methylate histone 
H3 R8 and H4 R3; and PRMT6 can modify H3 R2 and H4 R3 (Figure 5). PRMT1 and 
CARM1-mediated histone methylation are linked with transcriptional activation, while 
PRMT5 and PRMT6-mediated methylation are thought to correlate with repression 
(Bedford and Clarke, 2009; McBride and Silver, 2001). 
 
FIGURE 5: Arginines Targeted by PRMTs or PAD4 in Histone H3 and H4 (adapted from 
(Bedford and Clarke, 2009)) 
 
 Transcriptional regulation through arginine methylation occurs on several 
levels (Lee and Stallcup, 2009; Pahlich et al., 2006). First, as detailed in the 
preceding paragraph, histones are PRMT substrates (Paik and Kim, 1967). Second, 
transcription is regulated during initiation and elongation. Third, several 
transcriptional co-activators are targets for arginine methylation. For example, the 
histone acetyltransferases and transcriptional coactivators CBP and p300 are both 
substrates for CARM1 and PRMT1 activity (Chevillard-Briet et al., 2002; Xu et al., 
2001). Additionally, methylation of peroxisome proliferator-activated receptor gamma 
coactivator 1 alpha (PGC1α) by PRMT1 facilitates the induction of downstream 
targets involved in mitochondrial biogenesis (Teyssier et al., 2005). Fourth, 
methylation of the transcriptional elongation factor SPT5 by PRMT1 and PRMT5 
modulates its interaction with RNA polymerase II (Kwak et al., 2003). Fifth, 
transcriptional regulation occurs on the level of the transcription factor itself. A 
multitude of novel transcription factor targets of PRMTs have been identified. Some 
of the more prominent examples include RUNX1 (Zhao et al., 2008), FOXO1 
(Yamagata et al., 2008), and p53 (Durant et al., 2009; Jansson et al., 2008). 
Signal transduction: 
 Signal transduction is a process highly regulated by PTMs, which often affect 
protein-protein interactions. Arginine methylation can influence those interactions. 
The RNA-binding protein Sam68 is methylated on arginines adjacent to proline-rich 
regions. Methylation prevents the association with other SH3-domain containing 
binding partners of Sam68 (Boisvert et al., 2005a). The Tudor domains of splicing 
factor SPF30 interact specifically with GAR motifs containing sDMA (Chen et al., 
2001; Cote et al., 2003). The SMN protein Tudor domain facilitates the assembly of 
methylated Sm proteins to snRNPs (Cote et al., 2003). The methylation of histone 
H3R2 blocks the binding of most H3-tail binding domains, including chromo, PHD, 
WD40, and Tudor domains (Iberg et al., 2008). 
  A role for arginine methylation has been linked to several steps of type I IFN 
signaling (Abramovich et al., 1997; Mowen et al., 2001). PRMT1 directly interacts 
with the cytoplasmic tail of the type I IFN receptor alpha (Abramovich et al., 1997), 
and knockdown of PRMT1 in HeLa cells impairs type I IFN responses (Altschuler et 
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al., 1999). IFN and cytokine signaling is mediated by the JAK/STAT signaling 
pathway (Shuai and Liu, 2003). STAT1 is methylated by PRMT1, and this 
modification blocks STAT1 interaction with the inhibitor PIAS1, thereby, increasing 
transcriptional activation of IFN-responsive genes upon IFNα stimulation (Mowen et 
al., 2001). 
 Naïve T cell differentiation requires costimulation via the CD28 receptor 
together with the TCR signal. TCR engagement triggers the translocation of Nuclear 
Factor of Activated T cells (NFAT), a family of transcription factors that regulate 
multiple cytokine genes. Stimulation through CD28 increases PRMT1 activity and 
arginine methylation of several substrates, including Itk and Vav-1 (Blanchet et al., 
2005; Blanchet et al., 2006; Lawson et al., 2007). NFAT-mediated transcription is 
regulated by PRMT1 mediated arginine methylation of the NFAT– interacting protein 
of 45 kDa (NIP45), which will be discussed in more detail below (Fathman et al., 
2010; Mowen et al., 2004).  
DNA repair: 
 DNA double strand breaks (DSBs) induced by ionizing radiation or during 
replication require efficient repair. MRE11, a key protein involved in the DNA double-
strand break repair machinery, is a substrate for PRMT1. Its posttranslational 
modification has no effect on DNA binding ability but rather influences the 
exonuclease activity (Boisvert et al., 2005b) and recruitment to the DSB (Boisvert et 
al., 2005c). Additionally, arginine methylation of 53BP1 by PRMT1 modifies its ability 
to bind DNA (Boisvert et al., 2005d). The physiological role of 53BP1 methylation 
during DSB repair is not fully understood. Another important DNA damage repair 
enzyme, DNA polymerase β (Polβ) interacts with PRMT1 and PRMT6. These two 
enzymes target different arginines for methylation. PRMT6-mediated methylation 
enhances Polβ DNA-binding and processivity (El-Andaloussi et al., 2006). PRMT1-
mediated methylation negatively regulates Polβ by blocking the interaction with the 
processivity factor PCNA (El-Andaloussi et al., 2007).  
1.3.2 PRMT1-Mediated Regulation of Th2 Cell Cytokine Production 
 Upon T cell receptor (TCR) stimulation of Th2 cells, a signaling cascade is 
initiated that culminates with transcription factors binding to the IL-4 promoter and 
subsequent cytokine secretion. Nuclear-factor of activated T cells (NFAT) family 
members play an important role in this signal transduction pathway (for 
review:(Hermann-Kleiter and Baier, 2010; Rao et al., 1997)). In unstimulated Th 
cells, NFAT is found in the cytoplasm in a highly phosphorylated state. TCR ligation 
mediates Ca2+-flux leading to the activation of the calmodulin-dependent 
phosphatase calcineurin (Clipstone and Crabtree, 1993). In turn, calcineurin 
dephosphorylates NFAT, which induces a conformational change, exposing a 
nuclear localization signal (NLS), and allowing the subsequent NFAT translocation to 
the nucleus. NFATs heterodimerize with various nuclear factors, like AP-1 and IRF-4, 
which affect their promoter binding (Macian, 2005). 
 NFAT-interacting protein of 45 kDa (NIP45) was identified through its 
interaction with the Rel-homology domain of NFAT (Hodge et al., 1996). 
Coexpression of NIP45 with NFAT and Th2-specific transcription factor c-Maf is 
sufficient to turn a non-producer B cell line into an IL-4-producing cell line. The 
arginine- and glycine-rich amino terminus of NIP45 is a target of arginine methylation 
by PRMT1 (Mowen et al., 2004). The N-terminus also mediates the interaction of 
NIP45 with PRMT1 and NFAT. Interestingly, PRMT1 is highly expressed in Th1 and 
Th2 cells and its expression is further upregulated upon TCR-stimulation. 
Furthermore, arginine methylation of the N-terminus of NIP45 by PRMT1 facilitates 
the formation of a tripartite complex of NFAT, PRMT1 and NIP45, and, thereby, 
promoting IL-4 transcription. NIP45 knockout mice (Fathman et al., 2010) have a 
severe impairment in Th2-mediated immune responses both ex vivo and in vivo. In 
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the absence of NIP45, recruitment of PRMT1 to the IL-4 promoter is reduced, which 
is accompanied by diminished arginine methylation and acetylation of histone H4. 
These posttranslational H4 modifications correlate with transcriptionally active 
chromatin (Stallcup, 2001; Wang et al., 2001), and the diminished levels in the 
NIP45-deficient Th2 cells are reflected by less IL-4 transcription. 
 In summary, the arginine methyltransferase PRMT1 can positively influence 
IL-4 transcription by facilitating NIP45 methylation and therefore increasing the 
interaction with NFAT, which leads to strong activation of the IL-4 promoter. 
1.3.3 Coactivator-Associated Arginine Methyltransferase (CARM1) 
 CARM1 (also referred to as PRMT4) was identified through its interaction with 
the C-terminal domain of the p160 coactivator GRIP1 (Chen et al., 1999), therefore 
the name coactivator-associated arginine methyltransferase. CARM1 
methyltransferase activity preferentially targets histone H3, in contrast to the 
methylation of histone H4 by PRMT1 (Chen et al., 1999). The specific residues that 
are modified by CARM1 are located in the N-terminal tail of histone H3 at positions 
H3 R2, R17 and R26 (Schurter et al., 2001).  CARM1 methylates glycine-arginine 
rich (GAR) motifs very inefficiently, thereby, setting it apart from other type I PRMTs 
like PRMT1 and PRMT3. The structure of the catalytic core of CARM1 has unique 
features compared to the other known PRMT structures of PRMT1 and PRMT3. The 
CARM1 dimer encompasses a substantially larger central cavity and different charge 
distribution, which is one possible explanation for CARM1’s unique substrate 
specificities (Yue et al., 2007). 
 The biochemical control of CARM1 enzymatic activity involves several 
mechanisms. The enzymatically active form of CARM1 is a homodimer (Yue et al., 
2007). In addition, phosphorylation inactivates CARM1 (Feng et al., 2009; 
Higashimoto et al., 2007). The serine 228 (S228) phosphorylation site is conserved 
in CARM1 among species, but not present in other PRMT family members. The 
kinase(s) responsible for this PTM have not been identified yet. Phosphorylation of 
S228 impairs cofactor binding, dimerization, and thereby catalytic activity. Moreover, 
coexpression of a S228E phospho-mimic mutant CARM1 with SRC-2/GRIP-1 leads 
to a loss of synergistic transcriptional activation of an estrogen-response element 
(Higashimoto et al., 2007). A second serine phosphorylation site in CARM1 at S217 
is conserved among all type I PRMTs, so it potentially serves as a common PTM 
site. Mutation of S217 to glutamic acid leads to loss of AdoMet binding and arginine 
methyltransferase activity but has no effect on dimerization. Surprisingly, the S217E 
mutation impacts the subcellular localization of CARM1, mislocalizing it to the 
cytoplasm. Interestingly, during mitosis, increased levels of phosphorylated CARM1 
during the G2/M transition correlate with translocation of CARM1 from the nucleus to 
the cytoplasm, suggesting a potential physiological role for CARM1 phosphorylation 
in cell cycle regulation (Feng et al., 2009). CARM1 also automethylates, but the 
functional consequences of this PTM are not clear yet (Xu et al., 2001). 
1.3.3.1 CARM1 and Nuclear-hormone Receptor-mediated Transcription 
 Nuclear hormone receptors (NRs) are a group of transcription factors that are 
activated by hormone binding. NR family members include the estrogen receptor 
(ER), androgen receptor (AR), and the glucocorticoid receptor (GR). Transcriptional 
activation of NR-target genes requires the presence of coactivators of the p160 
coactivator family, which is comprised of steroid receptor coactivator 1 (SRC-1), 
SRC-2/GRIP1, and SRC3/pCIP/ACTR. These coactivators modify the local 
chromatin structure and help recruit RNA polymerase II to the transcription start site. 
The p160 family also associates with several histone acetyltransferases (HATs) like 
CREB-binding protein (CBP) and p300 that mediate histone acetylation, a chromatin 
modification associated with actively transcribed genes.  
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 CARM1 acts as a secondary coactivator for NR-transcription in synergy with 
the p160 coactivator family. The coactivator function of CARM1 requires its catalytic 
activity (Chen et al., 1999). p160 coactivators recruit HATs, like p300 and CBP, to 
NR target gene promoters. A trimeric coactivator complex of SRC-3, p300 and 
CARM1 is required for maximal enhancement of retinoic acid-mediated transcription 
as well as ER, AR, and TR-induced transcription (Lee et al., 2002). 
 CARM1 directly interacts with p300/CBP and methylates both p300/CBP and 
SRC-3. Methylation of CBP/p300 in the N-terminal KIX domain selectively impairs 
CREB-dependent signaling pathways (Lee et al., 2002; Xu et al., 2001). Moreover, 
CARM1–mediated methylation of p300 in the C-terminal region affects its interaction 
with p160 coactivator SRC-2/GRIP1. Methylation of p300 R2142 reduces its 
interaction with GRIP1, whereas coexpression of active deiminase PAD4 enhances 
the interaction between p300 and GRIP1 (Lee et al., 2005c). Though coexpression of 
CARM1 with p300 and GRIP1 or other p160 coactivators enhances NR-mediated 
transcription, p300 methylation destabilizes the coactivator complex, thereby 
providing a mechanism to terminate transcription (Lee et al., 2005c). Similarly, 
methylation of SRC-3 by CARM1 interferes with the SRC-3/CBP interaction. 
Furthermore, unmethylated SRC-3 coactivates estrogen-receptor mediated pS2 
transcription more potently than the methylated SRC-3. Interestingly, SRC-3 
methylation also enhances its degradation (Naeem et al., 2007). 
 CARM1 is recruited to glucocorticoid-responsive promoters upon 
dexamethasone treatment and to the pS2 estrogen-responsive promoter upon 
estrogen stimulation. The recruitment of CARM1 coincides with the appearance of 
methylated histone H3 at position R17, linking this histone mark to active 
transcription (Bauer et al., 2002; Ma et al., 2001). The appearance of acetylated 
histone H3 at K18 precedes methylation at R17 at the pS2 promoter following 
estrogen stimulation, revealing functional synergy between HATs and CARM1 
(Daujat et al., 2002). Further, preacetylation of H3K18 does not increase the affinity 
for the substrate but rather enhances the catalytic activity (Yue et al., 2007). 
 In summary, CARM1 is a potent secondary coactivator of NR-mediated 
transcription. Its coactivator function involves interaction with and methylation of 
primary coactivators like p300/CBP and the p160 family, as well as direct 
modification of histone H3, a modification associated with active gene transcription. 
Furthermore, CARM1-mediated methylation may serve as an off-switch to initiate the 
disassembly of the coactivator complex and thereby the termination of transcription. 
1.3.3.2 CARM1, a Coactivator for many Transcription Factors 
 Besides its prominent role as a coactivator for nuclear-hormone receptor 
mediated transcription, CARM1 interacts with many transcription factors. CARM1 
synergizes with PRMT1 and p300 to drive a subset of p53 target genes (An et al., 
2004). This synergy requires a specific order of assembly: In ChIP assays of the p53 
target gene promoter of GADD45, PRMT1-mediated H4R3 methylation appears first, 
followed by p300-binding and H4 acetylation, and last CARM1 binding and H3R17 
methylation (An et al., 2004). 
 CARM1 is also a promoter-specific regulator of NFκB-dependent gene 
expression (Covic et al., 2005; Hassa et al., 2008; Jayne et al., 2009; Miao et al., 
2006). CARM1 interacts directly with p65, a process not requiring methyltransferase 
activity. MIP2, MCP-1, G-CSF, ICAM-1, and IP-10 are CARM1-dependent NFκB 
target genes downstream of TNFα stimulation (Covic et al., 2005). The recruitment of 
CARM1 to several NFκB target gene promoters coincides with the appearance of 
H3R17 methylation and decreased H3 citrulline levels (Miao et al., 2006). p300 and 
p160 together with active CARM1 are required for optimal coactivation of the p65 
target genes. Similar to p53 coactivation, PRMT1, CARM1, and p300 synergize to 
coactivate p65-driven expression of MIP2 (Hassa et al., 2008). This synergy requires 
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the methyltransferase activity of both PRMT1 and CARM1, as well as the p300 
acetyltransferase activity. The overall requirement for CARM1 enzymatic activity is 
unclear because reconstitution of CARM1-deficient MEFs with either catalytically 
active or inactive CARM1 revealed four TNFα-induced genes that were dependent 
on CARM1 but independent of its catalytic activity, including Cxcl5, IL-6, Mpa2l, and 
MIP2. These data imply that CARM1 might function as a scaffolding protein at a 
subset of p65-dependent gene promoters (Jayne et al., 2009). 
 CARM1 coactivates many transcription factors. The mechanism of 
coactivation involves histone H3 methylation at the target gene promoters and/or 
methylation of coactivators like p300/CBP or p160 family members. IFNγ-induced 
MHC class II expression is mediated by coactivation through CARM1 and CBP via 
CIITA, the master regulator of class II expression (Zika et al., 2005). Additionally, 
CARM1 potentiates cAMP-induced expression of PEPCK and G6Pase, suggesting a 
role for CARM1 in hepatic gluconeogenesis. Furthermore, there is a stimulus-
dependent interaction between CARM1 and the cAMP-responsive element-binding 
factor CREB (Krones-Herzig et al., 2006). Other examples of CARM1-regulated 
coactivation include E2F1-mediated transcription of the Cyclin E1 gene (El 
Messaoudi et al., 2006), synergistic activation of LEF-1/TCF-4 together with β-
catenin (Koh et al., 2002), stimulation of the activity of myogenic transcription factor 
MEF2C (Chen et al., 2002), positive regulation of c-Fos mediated target gene 
expression (Fauquier et al., 2008), and cooperative upregulation of CITED2 
expression upon IL-4 stimulation in concert with STAT5 and PRMT1 (Kleinschmidt et 
al., 2008). All these reports describe a coactivator function of CARM1 that usually 
does not involve direct methylation. Recently, the pleiotropic transcription factor 
C/EBPβ has been identified as a target of CARM1-mediated methylation (Kowenz-
Leutz et al., 2010). Interestingly, phosphorylation of the C/EBPβ regulatory domain 
abrogates its interaction with CARM1, which is required for transcriptional activity. 
Arginine methylation of C/EBPβ inhibits the interaction with the SWI/SNF and 
Mediator complexes, thereby negatively regulating activation of myeloid and 
adipogenic genes via C/EBPβ (Kowenz-Leutz et al., 2010). 
1.3.3.3 CARM1 and mRNA Processing 
 Two members of the mRNA-stabilizing Hu protein family, HuR and HuD are 
methylated by CARM1 (Fujiwara et al., 2006; Li et al., 2002). LPS stimulation of the 
macrophage cell line RAW264.7 increases methylated HuR protein levels. Also, LPS 
stimulation induces HuR-mediated TNFα mRNA stabilization, suggesting a possible 
link between methylation of HuR and its activity (Li et al., 2002). In a study 
addressing the role of CARM1 in c-Fos mediated transcription, CARM1 has both a 
stabilizing and destabilizing effect on mRNA stability of c-Fos target genes (Fauquier 
et al., 2008). 
 Several splicing and transcription elongation factors (SmB, SAP49, U1C, and 
CA150) are CARM1 substrates (Cheng et al., 2007; Ohkura et al., 2005). The 
methylation sites map to a common protein interaction domain, the PGM motif, a 
proline-, glycine-, methionine-, and arginine-rich stretch (Bedford et al., 1998) found 
in splicing factors. Interestingly, the same splicing factors serve as substrates for the 
type II enzyme PRMT5 (Brahms et al., 2001; Cheng et al., 2007). Symmetric 
methylation of SmB mediates its interaction with spinal muscular atrophy gene 
product SMN Tudor domain (Brahms et al., 2001; Friesen et al., 2001). CARM1-
mediated methylation of the PGM-motif of CA150 facilitates its interaction with the 
Tudor domain of SMN. Furthermore, catalytically active CARM1 synergizes with the 
splice factor CA150 to enhance splicing (Cheng et al., 2007). Overall, all studies 
combined suggest a role for CARM1 in the regulation of alternative splicing. 
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1.3.3.4 CARM1 and Development 
 CARM1 is important for development, since embryos with a targeted 
disruption of CARM1 are smaller in size and die either in utero or shortly after birth 
due to a defect in proper lung inflation (Yadav et al., 2003). CARM1-deficient MEF 
lines derived from E12.5 embryos are defective in estrogen-driven transcription. 
Transcription of estrogen-responsive genes is reduced to background levels in MEFs 
from CARM1 KO mice but is rescued by ectopic expression of functional CARM1 
(Yadav et al., 2003).  
 CARM1-deficient embryos display aberrant thymocyte development. This 
defect includes reduced thymocyte numbers, especially pronounced in the DN and 
DP subsets, with an accumulation of DN1 cells. Thymocyte cyclic AMP-regulated 
phosphoprotein (TARPP) has been identified as a CARM1 substrate (Lee and 
Bedford, 2002). This defect in early thymocyte development might therefore be linked 
to the hypomethylation of TARPP in CARM1-deficient thymocytes (Kim et al., 2004).  
 A transcriptome analysis of E18.5 CARM1 WT or KO embryos stimulated with 
synthetic estrogen revealed a selective downregulation of genes of estrogen-
regulated transcripts and lipid-associated transcripts (Yadav et al., 2008). Many of 
the downregulated genes in the CARM1-deficient embryos are involved in 
adipogenesis. Interestingly, the identified genes include peroxisome proliferator-
activated receptor gamma (PPARγ) target genes, suggesting a role for CARM1 as a 
PPARγ coactivator. Furthermore, knockdown of CARM1 in preadipocytes reduces 
their differentiation capacity towards adipocytes (Yadav et al., 2008).  
The small size of CARM1-deficient embryos has been linked to an endochondral 
ossification defect (Ito et al., 2009). CARM1 transgenic mice show enhanced 
endochondral bone formation. This differentiation process is tightly controlled by the 
transcription factor Sox9. CARM1 can both interact with and methylate Sox9. 
Methylation inhibits the interaction of Sox9 with β-catenin, allowing it to drive 
CyclinD1 expression and chondrocyte proliferation. In the absence of CARM1, Sox9 
remains in complex with β-catenin, thereby, inhibiting chondrocyte proliferation (Ito et 
al., 2009). 
 Since CARM1 acts as a coactivator for many different transcription factors 
involved in pleiotropic cellular functions, it will be interesting to further the 
understanding of the physiological consequences of CARM1 deficiency with the help 
of celltype- or tissue-specific knockouts. 
1.4 Peptidylarginine Deiminases (PADs) 
 The peptidylarginine deiminase (PAD) family catalyzes the conversion of 
peptidylarginine to a citrulline residue in a process referred to as citrullination or 
deimination (see Figure 6). Deimination was identified as early as 1939 (Fearon, 
1939), but the first description of the PAD enzyme responsible for this modification 
did not come until the late 1970s (Rogers et al., 1977). Since arginine deimination 
changes the charge of the positively charged arginine to the neutral uncharged 
citrulline, this PTM can have profound effects on the modified protein (Figures 6+7). 
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FIGURE 6: Conversion of Arginine to Citrulline (adapted from (Vossenaar et al., 2003b)) 
 
 Conversion from arginine to citrulline results in an overall loss of 1 Da mass 
for each modified arginine. More importantly, the loss of the positive charge has an 
effect on the overall charge distribution, isoelectric point, as well as ionic and 
hydrogen bonding properties of the modified proteins, leading to altered intra- and 
intermolecular interactions or even protein tertiary structure (Tarcsa et al., 1996; van 
Venrooij and Pruijn, 2000)(Figure 7). 
 
FIGURE 7: Effects of Arginine Deimination on Protein Structure (adapted from 
(Vossenaar et al., 2003b)) 
 
1.4.1.1 The PAD Family Members 
 The peptidylarginine deiminase family is comprised of five Ca2+-dependent 
isoenzymes. All PADI genes are localized in a single gene cluster on human 
chromosome 1 (Chavanas et al., 2004; Vossenaar et al., 2003b). The isotypes 
display extensive sequence homology, but they differ by tissue distribution. PAD1 is 
mainly expressed in the epidermis and the uterus. PAD3 is found in hair follicles. 
PAD4, the only member with a putative NLS, can be detected in granulocytes, 
especially neutrophils. PAD6 is expressed in eggs, ovaries and the early embryo. 
PAD2 is the only family member with a broad tissue distribution, and it is expressed 
at high levels in skeletal muscle, brain, secretory glands, and spleen (for review: 
(Vossenaar et al., 2003b)).  
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1.4.1.2 Regulation of PAD Activity 
 Binding of calcium ions is a requirement for PAD activation (Arita et al., 
2004). In vitro studies suggest that deimination requires very high concentrations of 
calcium, which are not found inside the cell under physiological conditions. There are 
several possibilities for the regulation of cellular PAD activity. First, PADs could be 
kept inactive inside the cell and be activated only under conditions that involve high 
intracellular Ca2+ concentrations, like apoptosis or terminal differentiation. Second, 
PADs might be released into the extracellular space (actively or passively), where 
they encounter activating calcium concentrations. Or third, accessory proteins might 
be involved that can lower or even abolish the requirement for high Ca2+ 
concentration for PAD activation. It is likely that all of the above mentioned 
mechanisms play a role in PAD activation.  
 PAD enzymes have autoregulatory capacity. Two recent studies identified a 
novel mechanism of PAD inactivation through autocitrullination (Andrade et al., 2010; 
Mechin et al., 2010). 
1.4.1.3 PAD Substrates 
 Not much is known about the substrate specificity of PADs. In vitro, almost 
any accessible arginine can serve as a substrate, though there are considerable 
kinetic differences (Kubilus et al., 1980; Senshu et al., 1999). Substrate specificity in 
vivo is more likely determined by subcellular localization and accessibility of Ca2+ or 
accessory proteins. Several attempts to assign a consensus sequence around the 
targeted arginine have not resulted in deimination site predictability (Arita et al., 
2006; Stensland et al., 2009). 
 A physiological role for deimination has been implicated in various cellular 
processes (for overview see Figure 8). 
 
FIGURE 8: Cellular Deimination Processes (adapted from (Gyorgy et al., 2006)) 
 
 PADs play an important role in the terminal differentiation of keratinocytes. 
During this process keratinocytes migrate from the basal epithelial layer upward 
culminating in the death of these cells, which involves exposure of intracellular 
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proteins to high Ca2+ concentrations. PADs, especially PAD1, deiminate keratins and 
the keratin-associated fillagrin (Senshu et al., 1995; Senshu et al., 1996). The 
deimination of profillagrin is important for its maturation that is required for its function 
in crosslinking keratins, an important step in the cornification of the epidermis (Ishida-
Yamamoto et al., 2002).  
 PAD enzymes are involved in many cellular processes. PAD3 deiminates the 
cytoskeletal protein trichohyalin (Rogers et al., 1999; Rogers et al., 1997). PAD2 
activity is directed towards more diverse substrates, likely a reflection of its wide 
tissue distribution. The intermediate filament protein vimentin has been shown to be 
a target of PAD2-mediated deimination, especially under apoptotic conditions (Asaga 
et al., 1998). The loss of positive charge on the headgroup of vimentin has dramatic 
consequences as it favors depolymerization of filaments and subsequently results in 
the loss of the vimentin structural network (Inagaki et al., 1989). Another important 
target of PAD2 activity is myelin basic protein (MBP) (Pritzker et al., 2000). More 
recently, a number of novel PAD targets have been identified, but it is not quite clear 
which PAD family member is responsible for the PTM. These novel targets include: 
antithrombin (Chang et al., 2005a; Ordonez et al., 2009; Pike et al., 1997), CXCL10 
and CXCL11 (Loos et al., 2008), CXCL8 (Loos et al., 2009; Proost et al., 2008), 
CXCL12 (Struyf et al., 2009), and other targets that will be discussed in more detail 
in the next two sections. 
1.4.2 Peptidylarginine Deiminase 4 (PAD4) 
 PAD4, for historic reasons also referred to as PAD5 (Asaga et al., 2001; 
Nakashima et al., 2002), was originally characterized and cloned from the human 
myeloid cell line HL-60. Differentiation of HL-60 cells either down the granulocyte or 
monocyte lineages, leads to an increase in PAD enzymatic activity (Nakashima et al., 
1999), facilitating the cloning and characterization of PAD4. Overexpressed GFP-
tagged PAD4 localizes predominantly to the nucleus, making it the only nuclear PAD 
enzyme (Nakashima et al., 2002). PAD4 is expressed in various cells of the 
hematopoietic lineage, most prominently in granulocytes and monocytes (Asaga et 
al., 2001; Nakashima et al., 2002; Vossenaar et al., 2004) and to a lesser extent in 
cells of the B, T and NK cell lineages (Vossenaar et al., 2004). 
 Like all other family members, PAD4 enzymatic activity is dependent on Ca2+. 
The crystal structure of PAD4 (Arita et al., 2004) revealed two domains: an N-
terminal domain containing two immunoglobulin-like subdomains (Igl1 and Igl2) and 
a C-terminal domain comprised of an α/β-propeller structure that is highly conserved 
among all family members. PAD4 contains five calcium-binding sites. Ca2+-binding 
induces major conformational changes important for binding of the artificial substrate 
benzoyl-L-arginine amide (BAEE) (Arita et al., 2004). 
1.4.2.1 PAD4 and Histones 
 PAD4 deiminates histones and nucleophosmin/B23 in granulocytes upon 
calcium-ionophore stimulation (Hagiwara et al., 2002; Nakashima et al., 2002). 
PAD4-dependent histone modifications map to the N-terminal tails of H2A (R3), H3 
(R2, 8, 17, 26), and H4 (R3) (Cuthbert et al., 2004; Hagiwara et al., 2005; Wang et 
al., 2004). Interestingly, almost all of those deimination sites are also targets for 
arginine methylation by PRMT1, CARM1 and PRMT5. Indeed, PAD4 catalyzes 
demethylimination of histones, a process in which the monomethylated arginine 
(MMA) is converted into a citrulline. PAD4 exhibits no activity towards dimethylated 
arginines (Cuthbert et al., 2004; Wang et al., 2004). The activity of PAD4 towards 
MMA has been questioned in several subsequent studies (Kearney et al., 2005; 
Raijmakers et al., 2007), focused on in vitro activity towards artificial peptides. 
Deiminated histones can no longer be methylated by PRMTs. Therefore, PAD4 
activity indirectly antagonizes arginine methylation (Figure 9). 
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FIGURE 9: Histone Deimination in Transcriptional Regulation. Exemplified for histone H3 
(adapted from (Cuthbert et al., 2004)) 
1.4.2.2 PAD4 as a Corepressor 
 PRMTs often act as transcriptional coactivators, and histone arginine 
methylation is associated with transcriptional activation. Conversely, PAD4-mediated 
deimination antagonizes methylation, thereby, mediating transcriptional repression. 
In the human breast-cancer cell line MCF-7, estrogen stimulation leads to PAD4 
upregulation (Dong et al., 2007) dependent on estrogen-receptor α and the 
transcription factors AP-1, Sp1, and NF-Y. PAD4 associates with the endogenous 
estrogen-responsive pS2 promoter, coinciding with increased histone deimination. 
Estrogen-induced PAD4 binding to the promoter leads to decreased promoter 
transcription. Catalytic activity is required for the transcriptional corepressor function 
of PAD4 (Cuthbert et al., 2004; Wang et al., 2004). PAD4 interacts with histone 
deacetylases (HDACs), a class of enzymes that is associated with transcriptional 
repression, forming a corepressor complex on the pS2 promoter upon estrogen 
stimulation (Denis et al., 2009) and on p53 target gene promoters (Li et al., 2010). 
Overall, the collaboration between PAD4 and HDACs seems to be an emerging 
theme in transcriptional corepression. 
1.4.2.3 PAD4 and Apoptosis 
 Apoptosis-mediated Ca2+-influx into the cell or release of intracellular PADs 
has been proposed to induce PAD activation. In addition, PAD4 is implicated in the 
regulation of apoptosis. Overexpression of PAD4 in Jurkat T cells or HL-60 cells 
leads to an increase in cell cycle arrest and apoptosis (Hung et al., 2007; Liu et al., 
2006). In contrast, chemical inhibition of PAD4 activity, as well as siRNA-mediated 
knockdown of PAD4, promotes apoptosis (Li et al., 2008; Yao et al., 2008) in a 
process mediated by p53. The role for PAD4 in p53-mediated transcription is still 
unclear, but a corepressor function for PAD4 for a subset of p53-target genes is 
suggested (Li et al., 2010). Interestingly, PAD4 itself is a direct transcriptional target 
of p53 (Tanikawa et al., 2009). 
1.4.2.4 PAD4 in Neutrophils 
 Neutrophils, the most abundant leukocyte in mammalian blood, express high 
levels of PAD4 (Asaga et al., 2001). These innate effectors are part of the acute 
phase inflammatory response directed against bacterial infections, and they migrate 
out of the blood towards the site of infection. In neutrophils from peripheral human 
blood, PAD4 deiminates histone H3 upon a plethora of inflammatory stimuli (TNF, 
fMLP, LPS and H2O2) but not upon induction of apoptosis via chemical inducers. 
Moreover, neutrophils release deiminated H3 during neutrophil extracellular trap 
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(NET) formation (Neeli et al., 2008). Furthermore, TNFα stimulation of neutrophils 
leads to a strong increase of histone H4 deimination, which is localized within NETs 
and decondensed chromatin (Wang et al., 2009). Additionally, histone deimination 
influences chromosome compaction by promoting decondensation of the 
nucleosomes during NET formation (Wang et al., 2009). 
1.4.3 PADs and Disease 
 Rheumatoid arthritis (RA) is a systemic autoimmune disorder that involves 
chronic inflammation of the synovial joint, culminating in joint erosion and bone 
destruction. Both genetic determinants and environmental factors increase the risk of 
developing RA (Wegner et al., 2010). Autoantibodies are a feature of RA, and they 
have been used as serological markers for diagnosis of RA patients. Rheumatoid 
factor (RF), an autoantibody against the Fc portion of human IgG, is present in 70-
80% of patients with RA but is also observed in patients with other inflammatory 
diseases (Silveira et al., 2007). Anti-perinuclear factor (APF) and anti-keratin 
autoantibodies (AKA) are both more specific markers of disease (Silveira et al., 
2007).  
 PAD involvement in disease was first appreciated in 1998, with the 
recognition of citrullinated proteins by autoantibodies associated with rheumatoid 
arthritis (RA) (Schellekens et al., 1998). Both APF and AKA react with mature 
fillagrin, more precisely with deiminated epitopes of fillagrin (Girbal-Neuhauser et al., 
1999; Hoet et al., 1991; Schellekens et al., 1998; Sebbag et al., 1995; Simon et al., 
1995). This discovery led to the development of enzymatic assays containing cyclic-
citrullinated peptides (CCP) to screen for autoantibodies in the diagnosis of RA 
patients. anti-CCP assays have a diagnostic sensitivity at least equivalent to that of 
RF detection in serum, but a much higher specificity for RA (98%) (van Venrooij et 
al., 2008). Interestingly, anti-CCP reactivity can develop more than 10 years prior to 
clinical diagnosis of RA, and high antibody levels are closely associated with a very 
severe and erosive form of the disease (Nielen et al., 2004; Vencovsky et al., 2003). 
Moreover, the presence of anti-CCP is closely linked to the MHC class II HLA DRB1 
allele that predisposes for RA (Klareskog et al., 2006; van der Helm-van Mil et al., 
2007). The analysis of anti-CCP antibodies from RA patients has led to the discovery 
of many deiminated antigen targets: fibrinogen (Vander Cruyssen et al., 2006), 
vimentin (Dejaco et al., 2006), α-enolase (Kinloch et al., 2005), collagen type II 
(Burkhardt et al., 2005), and many more (Kinloch et al., 2008; Klareskog et al., 2008; 
Wegner et al., 2010). 
 Since PADs are the only known enzymes that catalyze the peptidylarginine to 
citrulline conversion, the presence of citrullinated proteins in the synovium of RA 
patients suggests the involvement of PAD activity in the joint (Masson-Bessiere et 
al., 2001). Both PAD2 and PAD4 are expressed in the joints of RA patients co-
localizing with tissue inflammation and citrullinated protein deposits (Chang et al., 
2005b; Foulquier et al., 2007). Moreover, there is a genetic association of functional 
haplotypes of the PADI4 gene with RA (Suzuki et al., 2003). The SNPs in the 
disease-associated haplotype lead to stabilization of PAD4 mRNA and could, 
therefore, result in increased deimination activity. Replication studies in Japan and 
Korea confirmed this association (Ikari et al., 2005; Kang et al., 2006). In contrast, 
several European studies could not detect a significant association between PADI4 
and RA (Barton et al., 2004; Caponi et al., 2005; Martinez et al., 2005). Although 
there is a clear link between PAD activity and RA, the specific involvement of PADs 
in disease still needs to be elucidated. It is not clear if protein deimination represents 
an RA disease trigger or if it is just a consequence of high levels of joint 
inflammation. 
 Besides RA, PAD family members are associated with several other 
pathological conditions. Abnormal deimination of MBP is detected in the brains of 
           INTRODUCTION 
19 
patients suffering from multiple sclerosis (MS), a progressive demyelinating disease 
(Moscarello et al., 2007; Wood et al., 1996). Elevated levels of both PAD2 and PAD4 
are found in brain extracts from MS patients (Wood et al., 2008). MBP is an essential 
part of the myelin sheath surrounding neurons. The myelin sheath is dependent on 
ionic interactions between negatively charged lipids and basic proteins like MBP. 
Since deimination of MBP involves loss of positive charges, this influences the MBP 
lipid interaction. The ratio of citrullinated MBP to normal MBP affects the packing of 
the myelin sheath (Beniac et al., 2000). In children under the age of two years, 
almost all MBP is deiminated, which correlates with more loosely packed myelin and 
likely reflects the high plasticity of the brain during this developmental stage. By the 
age of four and throughout adulthood, the percentage of citrullinated MBP is reduced 
to about 18% (Moscarello et al., 1994). In addition, deimination of MBP makes it 
more susceptible to degradation by cathepsin D (Pritzker et al., 2000). Therefore, 
hypercitrullination of MBP has been implicated in the pathogenesis of diseases like 
multiple sclerosis and Alzheimer’s disease. 
 Elevated PAD4 levels are detected in some malignant tumors (Chang and 
Fang, 2009). Increased PAD4 protein levels are also reflected in the patients’ blood 
and correlate with elevated citrullinated antithrombin levels (Chang et al., 2009). 
Deimination of antithrombin is proangiogenic because it results in increased thrombin 
activity that, in turn, leads to elevated VEGF and integrin β3 levels (Maragoudakis et 
al., 2002). As described above, PAD4 is also a corepressor for p53, an important 
tumor suppressor (Li et al., 2008). Elevated levels of PAD4 could, therefore, promote 
tumorigenesis by inhibition of p53 target genes. 
 PAD dysregulation is a common theme in the pathological conditions 
described above, and more diseases that involve PAD enzymatic activity are 
emerging. Therefore, it is of great importance to better understand the physiological 
role of the PAD family members to determine if they might be suitable therapeutic 
targets for any of the above-mentioned diseases. 
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1.5 Specific Aims 
 Arginine modifying enzymes are important regulators of many cellular 
functions including signal transduction, mRNA splicing, apoptosis and transcription. 
PRMT and PAD family members mediate transcriptional regulation by both 
interaction with transcription factors to form coactivator or corepressor complexes 
and posttranslational modification of histones in gene regulatory regions.  
 
 Arginine methylation of NIP45 positively regulates IL-4 cytokine gene 
expression. Since arginine deimination can antagonize arginine methylation, I 
propose that NIP45-mediated IL-4 expression might be negatively regulated by 
arginine deimination: 
 
Objective 1: Regulation of NIP45-mediated IL-4 expression by arginine 
deimination 
I will test if NIP45 is a target for arginine deimination in vitro and in vivo. These 
studies will focus on the peptidylarginine deiminase PAD4. Further, I will evaluate the 
functional consequences of PAD4-mediated deimination of NIP45 on IL-4 cytokine 
expression. 
 
 
 The peptidylarginine deiminase PAD4 has been described as a corepressor 
for nuclear hormone receptor signaling and p53 signaling. In addition, PAD4 
dysregulation is associated with several pathological conditions including RA, MS, 
and malignant tumors. To further the understanding of PAD4 biology, I propose to 
generate a PAD4 conditional KO mouse strain: 
 
Objective 2: Generation and characterization of PAD4 conditional KO mice 
I will generate PAD4 conditional KO mice by conventional gene targeting strategies. 
The KO will be analyzed for defects in hematopoietic development. In addition, I will 
analyze IL-4 expression in PAD4-deficient Th2 cells, to confirm PAD4 as a negative 
regulator of IL-4 transcription.  
 
 
 The arginine methyltransferase CARM1 is an important coactivator of nuclear 
hormone receptor signaling and NFκB signaling. This coactivation is mediated both 
by formation of a coactivator complex and methylation of histone H3R17, a 
posttranslational modification associated with active transcription. To date, not much 
is known about the role of CARM1 in immune regulation. Therefore, I propose to 
evaluate the role of CARM1 in proinflammatory cytokine production by macrophages: 
 
Objective 3: Analysis of CARM1-deficient bone marrow-derived macrophages 
I will generate mice with a macrophage-specific deletion of CARM1. I will differentiate 
BMDMs from these mice to test the proinflammatory cytokine expression in 
macrophages. In addition, I will test if glucocorticoid-receptor mediated suppression 
of proinflammatory cytokine expression is dependent on CARM1 coactivation. 
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2 Materials and Methods 
2.1 Chemicals and Reagents 
All standard lab chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or 
Fisher Scientific (Hampton, NH). Other specific reagents used will be described in 
the relevant sections below. 
2.1.1 Kits 
Amersham RediPrime II Labelling System  GE Healthcare, Waukesha, WI 
Anti-Citrulline (modified) Detection kit  Millipore, Billerica, MA 
BCA Protein Assay Kit    Thermo Scientific, Rockford, IL 
BD Cytofix/ Cytoperm Plus    BD Biosciences, San Jose, CA 
Griess Reagent System     Promega, Madison, WI 
illustra ProbeQuant G50 Microcolumns  GE Healthcare, Waukesha, WI 
iScript cDNA synthesis kit    Bio-Rad, Hercules, CA 
MACS CD4+ T Cell Isolation Kit   Miltenyi Biotec, Bergisch 
Gladbach 
MACS CD4+CD62L+ T Cell Isolation Kit II  Miltenyi Biotec, Bergisch 
Gladbach 
PrepEase His Tagged Protein Purification  
Midi Kit – High Specificity    USB, Cleveland, OH 
PureLink HiPure Plasmid MaxiPrep Kit  Invitrogen, Carlsbad, CA 
QIAquick Gel Extraction Kit    Qiagen, Hilden, Germany 
Qiaquick PCR Purification Kit    Qiagen, Hilden, Germany 
QIAshredder      Qiagen, Hilden, Germany 
QuickChange Lightning Site-Directed Mutagenesis Agilent Technologies, La Jolla, 
CA 
RNeasy Midi Kit     Qiagen, Hilden, Germany 
RNeasy Plus Mini Kit     Qiagen, Hilden, Germany 
TOPO XL PCR Cloning Kit    Invitrogen, Carlsbad, CA 
Zero Blunt TOPO PCR Cloning Kit   Invitrogen, Carlsbad, CA 
2.1.2 Molecular Weight Markers 
Precision Plus Prestained Protein Standard  Bio-Rad (Hercules, CA) 
100 bp DNA ladder     Invitrogen, Carlsbad, CA 
1 kb DNA ladder     Invitrogen, Carlsbad, CA 
 
2.1.3 Antibodies 
 
Antibody Clone Conjugate µg/stain Vendor 
Anti-mouse F4/80 BM8 PE 0.125 eBioscience 
Anti-mouse CD11b M1/70 FITC 0.25 eBioscience 
Anti-mouse B220 RA3-6B2 APC 0.125 eBioscience 
Anti-mouse B220 RA3-6B2 PE 0.25 eBioscience 
Anti-mouse TCRβ H57-597 APC 0.06 eBioscience 
Anti-mouse CD4 RM4-5 PE 0.1 Caltag Lab. 
Anti-mouse CD4 RM4-5 PE-Cy7 0.25 eBioscience 
Anti-mouse CD8α 53-6.7 FITC 0.25 eBioscience 
Anti-mouse CD3 17A2 PE 0.25 BioLegend 
Anti-mouse IgM II/41 PerCP-eFluor710 0.25 eBioscience 
Anti-mouse IgD 11-26c FITC 0.5 eBioscience 
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Anti-mouse CD16/32 2.4G2 unconjugated 1.0 Bio Express 
Anti-mouse IFNγ XMG1.2 FITC 0.5 eBioscience 
Anti-mouse IL-4 11B11 APC 0.25 BD Bioscience 
TABLE 1: FACS Antibody List 
 
Antibody Clone Dilution Vendor 
Anti-mouse IFNγ AN-18 1:250 eBioscience 
Biotin anti-mouse IFNγ R4-6A2 1:500 eBioscience 
Anti-mouse IL-4 11B11 1:250 eBioscience 
Biotin anti-mouse IL-4 BVD6-24G2 1:500 eBioscience 
Anti-mouse IL-6 MP5-20F3 1:250 eBioscience 
Biotin anti-mouse IL-6 MP5-32C11 1:500 eBioscience 
Anti-mouse IL-10 JES5-2A5 1:250 BD Pharmingen 
Biotin anti-mouse IL-10 JES5-16E3 1:500 BD Pharmingen 
Anti-mouse IL-17A eBio17CK15A5 1:250 eBioscience 
Biotin anti-mouse IL-17A eBio17B7 1:500 eBioscience 
Anti-mouse TNFα Goat IgG 1:250 R&D Systems 
Biotin anti-mouse TNFα Goat IgG 1:500 R&D Systems 
TABLE 2: ELISA Antibody List 
 
Antibody Species Dilution Vendor 
Gata 3 (HG3-31) mouse 1:1000 (WB) Santa Cruz 
Biotechnologies 
H4 cit 3 (07-596) rabbit 1:500 (IF) 
2 µl/ IP (ChIP) 
Millipore 
H4R3(me)2 (39275) rabbit 3 µl/ IP (ChIP) Active Motif 
H4 acetyl (17-229) rabbit 1 µl/ IP (ChIP) Millipore 
CARM1 (ab51742) rabbit 1:1000 (WB) abcam 
tubulin (ab6046) rabbit 1:3000 (WB) abcam 
citrulline (17-347) rabbit 1:1000 (WB) Millipore 
H3cit (ab5103) rabbit 1:100 (IF) abcam 
H3R17(me)2 (07-214) rabbit 1:1000 (WB) Millipore 
huPAD4 rabbit 1:3000 (WB) 
1:100 (IF) 
gift from  
2206 A rabbit 1:2000 (WB) generated in collaboration 
with Imgenex 
MPO (A 0398) rabbit 1:300 (IF) DAKO 
NIP45 mix mouse 1:1000 (WB) gift from Laurie Glimcher 
T-bet (4B10) mouse 1:1000 (WB) gift from Laurie Glimcher 
FLAG M2 HRP (F1804) mouse 1:3000 (WB) Sigma 
FLAG M2 agarose mouse 5 µl/ IP Sigma 
myc tag (71D10) rabbit 1:1000 (WB) Cell Signaling 
Technologies 
HA agarose (A2095) mouse 5 µl/ IP Sigma 
HA HRP (3F10) mouse 1:2000 (WB) Roche 
GFP (A6455) rabbit 1:5000 (WB) Invitrogen 
normal rabbit IgG rabbit 1:200 (IF) 
1 µl/ IP (ChIP) 
Millipore 
rabbit HRP (G21234) goat 1:10000 (WB) Invitrogen 
mouse HRP (81-6720) rabbit 1:10000 (WB) Invitrogen 
rabbit Oregon Green 488 goat 1:1000 (IF) Invitrogen 
TABLE 3: Antibody List (WB, IF, ChIP) 
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2.1.4 Primers 
Name    Sequence (5’ to 3’)       Annealing (°C) 
PAD4 mice 
Padi4 5’ lox F   CAGGAGGTGTACGTGTGCA        59°C 
Padi4 3’ lox F   CTAAGAGTGTTCTTGCCACAAG    
Padi4 3’ lox R   AGTCCAGCTGACCCTGAAC    
Padi4 3’ FRT R   AGGAAGTCTTCATTGTCAGAAAC    
Cre ERt mice 
IMR 1084    GCGGTCTGGCAGTAAAAACTATC       65°C 
IMR 1085    GTGAAACAGCATTGCTTGTCACTT    
IMR 3621   CGTGATCTGCAACTCCAGTC    
IMR 3622   GGAGCGGGAGAAATGGATATG    
Flp deleter mice 
IMR 1348 (Flp F)  CACTGATCTTGTAAGTAGTTTGC       56°C 
IMR 1349 (Flp R)  CTAGTGCGAAGTAGTTGATCAGG    
CARM1fl/fl mice 
CARM1 FOR   CCCACTTCTGTTACCTCCTTTG       53°C 
CARM1 REV   TAACTAAAAGAAAATGGAATGG    
CMV-Cre, Lck-Cre, lysM-Cre 
CRE FOR   GACGGAAATCCATCGCTCGACCAG       60°C 
CRE REV   GACATGTTCAGGGATCGCCAGGCG    
TABLE 4: Genotyping Primer List 
 
Name    Sequence (5’ to 3’)       Annealing (°C) 
Exon 9-10 SalI FOR  TAGTCGACTAACTCCTGCCCTCAGCCTCT      62°C 
Exon 9-10 SalI REV  TAGTCGACATGATGCCCAAGAGATGGAACTCT  
5’ ARM BamHI FOR  TAGGATCCTCTGTGTAGCCTTGCCTGTC      62°C 
5’ ARM BamHI REV  TAGGATCCTATTTTGCCATTCCCAGAAAATGC  
3’ ARM FseI FOR  TAGGCCGGCCTGTCCTTTGGGGGCTACACTG    68°C 
3’ ARM FseI REV  TAGGCCGGCCTCACGGCTGGCTGCCTCTG   
5’ probe 9-10 FOR  TGCCTAACATGTCTGATGTCATA       62°C 
5’ probe 9-10 REV  TGACTTTGGTAGGTCACTTGC    
3’ probe 9-10 FOR  TGAATCAAGTCCATGGATGATGG       62°C 
3’ probe 9-10 REV  TGTGCCTGGTGCCCGAGGA     
rat PAD4 F2   GTGGATGCAGGATGAAATGGAGA       61°C 
rat PAD4 T7P R  GAATTAATACGACTCACTATAGGGAGAGCACGTTGGTG 
    CCACAGTGA       
mu GAPDH F   ATGGTAAAGGTCGATGTGAAC       58.5°C 
mu GAPDH T7P R  GAATTAATACGACTCACTATAGGGAGACATGTAGGTCC 
    ACCACCCT       
TABLE 5: Cloning Primer List 
 
Name    Sequence (5’ to 3’)      
NIP45 R32Q   TCCTCGCGCCCAGCAGTCTCCGG 
NIP45 R32Q AS  CCGGAGACTGCTGGGCGCGAGGA    
NIP45 R32K   GTGTCCTCGCGCCAAGCAGTCTCCGGCT 
NIP45 R32K AS  AGCCGGAGACTGCTTGGCGCGAGGACAC   
NIP45 R37Q   CCGGCAGTCTCCGGCTCAGCTCATTCCAGACA 
NIP45 R37Q AS  TGTCTGGAATGAGCTGAGCCGGAGACTGCCGG  
NIP45 R37K   GGCAGTCTCCGGCTAAGCTCATTCCAGAC 
NIP45 R37K AS  GTCTGGAATGAGCTTAGCCGGAGACTGCC   
NIP45 R37F   CCGGCAGTCTCCGGCTCAGCTCATTCCAGACA 
NIP45 R37F AS   TGTCTGGAATGAGCTGAGCCGGAGACTGCCGG  
NIP45 R103Q   CGGCGGCGGCAGCGGCTGCTG 
NIP45 R103Q AS  CAGCAGCCGCTGCCGCCGCCG    
NIP45 R103K   CGAAGTCTCCGGCTAAGCTCATTCCAGAC   
NIP45 R103K AS  TCCAGCAGCCGCTTCCGCCGCCGTCG   
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NIP45 R103F   GCGACGGCGGCGGTTCCGGCTGCTGGATC 
NIP45 R103F AS  GATCCAGCAGCCGGAACCGCCGCCGTCGC   
NIP45 R104Q   GCGGCGGCGGCAGCTGCTGGATC    
NIP45 R104Q AS  GATCCAGCAGCTGCCGCCGCCGC    
NIP45 R104K   CGGCGGCGGCGGAAGCTGCTGGATCC 
NIP45 R104K AS  GGCTCCAGCAGCTTCCGCCGCCGCCG   
NIP45 R104F   ACGGCGGCGGCGGTTCCTGCTGGATCCCG  
NIP45 R104F AS  CGGGATCCAGCAGGAACCGCCGCCGCCGT   
TABLE 6: Mutagenesis Primer List 
 
Name    Sequence (5’ to 3’)          
Reference 
mTNFα FOR   AGCCGATGGGTTGTACCT      (Nomiyama et al., 2007) 
mTNFα REV   TGAGTTGGTCCCCCTTCT     
IL-6 F    GGACCAAGACCATCCAATTC     (Kim et al., 2007) 
IL-6 R    ACCACGTGAGGAATGTCCA     
HPRT FOR   GCCCTTGACTATAATGAGTACTTCAGG  
HPRT Rev   GAGTACTTCCGCTCATCTTAGG       (Sandler et al., 2003) 
CARM1 FOR   TGGCTCAGCATGCAGAGG    (in house) 
CARM1 REV   TGCCAGGGATGACCACG     
IP10 FOR   CCTGCCCACGTGTTGAGAT   (Doyle et al., 2002) 
IP10 REV   TGATGGTCTTAGATTCCGGATTC    
 
Name    assay number             
supplier 
mouse IL-4 AOD  Mm 00445259_m1  Applied Biosystems 
mouse ACTB   4353933E  Applied Biosystems 
TABLE 7: qPCR Primer and Probe List 
 
Name    Sequence (5’ to 3’)          
Reference 
IL-4 pr FOR   GGCCCAGAATAACTGACAATCT (Ansel et al., 2004) 
IL-4 pr REV   GCAATGCTGGCAGAGGTC     
IFNγ pr FOR   GCTTTCAGAGAATCCCACAAGAAT (Ansel et al., 2004) 
IFNγ pr REV   GCTATGGTTTTGTGGCATGTTAGA    
HS IV FOR   TGCCCACATGAAATACCAGC  (Doyle et al., 2002) 
HS IV REV   GCATACCTTCCCTGATTGGC     
CNS I Th2 FOR   CACACACTGGTCCACTGTGATG  (Hayashida et al., 2006) 
CNS I Th2 REV   GACGCAGGCACCAAAATTAAA    
TABLE 8: ChIP Primer List 
2.2 Technical Equipment 
5415D Eppendorf Table-top Centrifuge  Eppendorf, Hauppauge, NY 
5415R Eppendorf Table-top Centrifuge   Eppendorf, Hauppauge, NY 
5810R Eppendorf Centrifuge    Eppendorf, Hauppauge, NY 
7900HT Fast Sytem Real-Time PCR machine Applied Biosystems, Foster City, 
CA 
Accumet Basic AB15 pH Meter   Fisher Scientific, Pittsburgh, PA 
Autoclave Amsco Scientific Series   Steris Corporation, Mentor, OH 
Axiovert 100 Microscope    Zeiss, Goettingen, Germany 
Bioruptor      Diagenode Sparta, NJ 
CO2 Incubator Forma Series II water-jacketed Thermo Scientific, Waltham, MA 
Forma -86C ULT Freezer    Thermo Scientific, Waltham, MA 
Owl Gel Separation System    Thermo Scientific, Waltham, MA 
Gene Amp PCR System 2700   Applied Biosystems 
Gene Pulser XCell     Bio-Rad, Hercules, CA 
Isotemp 125D Heating Blocks   Fisher Scientific, Pittsburgh, PA 
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Isotemp Freezer     Fisher Scientific, Pittsburgh, PA 
Isotemp Hybridization Incubator   Fisher Scientific, Pittsburgh, PA 
Isotemp Incubator     Fisher Scientific, Pittsburgh, PA 
Labline Lab Rotator Platform    Barnstead, Dubuque, IA 
Legend T centrifuge     Thermo Scientific, Waltham, MA 
MACS Multi Stand     Miltenyi Biotec, Bergisch 
Gladbach 
Micromaster Inverted Microscope   Fisher Scientific, Pittsburgh, PA 
Mini Protean 3 Cell     Bio-Rad, Hercules, CA 
Model 583 Gel Dryer     Bio-Rad, Hercules, CA 
Power Pac 3000     Bio-Rad, Hercules, CA 
Power Pac Basic     Bio-Rad, Hercules, CA 
PTC-100 Peltier Thermal Cycler   MJ Research, Waltham, MA 
RC5C Sorvall Centrifuge    Thermo Scientific, Waltham, MA 
Refrigerator Isotemp     Fisher Scientific, Pittsburgh, PA 
Scale Adventurer AR5120    Ohaus Corp, Pine Brook, NJ 
Series 25 Incubator Shaker    New Brunswick Scientific Co., 
Inc 
Smart Spec Plus Spectrophotometer   Bio-Rad, Hercules, CA 
Spectrolinker XL-1000 UV Crosslinker  Spectromics Corp., New York, 
NY 
SRX-101A Medical Film Processor   Konica Minolta, Wayne, NJ 
Sterilgard Hood class II    Baker Company, Sanford, ME 
Stirrer/ Hot Plate     Corning Inc., Corning, NY 
Thermolyne Labquake Shaker   Barnstead, Dubuque, IA 
Thermolyne Labquake Shaker/Rotisserie  Barnstead, Dubuque, IA 
Transfer Blot Semi Dry Transfer Cell   Bio-Rad, Hercules, CA 
Vmax kinetic microplate reader   Molecular Devices, Sunnyvale, 
CA 
Vortex Genie 2     Scientific Industries, Bohemia, 
NY 
Water Bath Isotemp 3016     Fisher Scientific, Pittsburgh, PA 
Water Purification System    Millipore, Billerica, MA 
2.2.1 Computer Programs 
AxioVision AC 4.2     Zeiss, Goettingen, Germany 
Endnote X      Endnote, Carlsbad, CA 
FACS DIVA 6.0     BD Biosciences, San Jose, CA 
FlowJo 8.8.4      Tree Star, Ashland, OR 
Prism 5 (for MAC OS X)    GraphPad Software, La Jolla, CA 
SerialCloner 1.3     Serial Basics 
SoftMax Pro 4.7.1     Molecular Devices, Sunnyvale, 
CA 
2.2.2 Internet Tools 
http://biogps.gnf.org 
http://uswest.ensembl.org/index.html 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed 
http://www.stratagene.com/sdmdesigner/default.aspx 
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2.3 Tissue Culture 
2.3.1 Cell Culture Media 
RPMI 1640        (HyClone) 
DMEM/ High Glucose       (HyClone) 
IMDM Modified       (HyClone) 
HEPES 1M Solution (100x)      (Cellgro) 
Sodium Pyruvate 100mM Solution (100x)    (HyClone) 
MEM Non-Essential Amino Acids (NEAA) (100x)   (HyClone) 
L-Glutamine 200mM Solution (100x)     (HyClone) 
Penicillin-Streptomycin Solution (P/S) (10000 units/ml) (200x) (HyClone) 
β-Mercaptoethanol (βME)      (Sigma-Aldrich) 
Trypsin 0.25% (1x)       (HyClone) 
DPBS/ Modified       (HyClone) 
Fetal Bovine Serum (FBS)(Advantage)    (Atlanta 
Biologicals) 
OptiMEM I        (Gibco) 
2.3.2 Cytokines, Antibodies, and Stimuli 
IFNγ      (10µg/ml)   (R&D Systems) 
IL-4      (10µg/ml)   (PeproTech Inc.) 
IL-12     (10µg/ml)   (eBioscience) 
IL-2     (100U/µl)   (NCI) 
IL-6     (10µg/ml)   (R&D Systems) 
IL-23     (10µg/ml)   (eBioscience) 
hTGFβ     (10µg/ml)   (R&D Systems) 
α CD3 (2C11)    (4.33mg/ml)   (BioExpress) 
α CD28 (37.51)   (1.2mg/ml)   (BioExpress) 
α IL-4 (11B11)   (4.2mg/ml)   (BioExpress) 
α IFNγ  (R4-6A2)   (5mg/ml)   (BioExpress) 
LPS (E.coli 0111:B4 strain)  (5mg/ml stock)  (Invivogen) 
dexamethasone   (10mM stock in EtOH) (Sigma-Aldrich) 
cycloheximide    (10mg/ml stock in H2O) (Sigma-Aldrich) 
ionomycin    (10mM stock in DMSO) (EMD) 
phorbol-12-myristate-13-acetate (1mg/ml in DMSO)  (EMD) 
Z-(4)-Hydroxytamoxifen   (1mM stock in EtOH)  Alexis 
Biochemicals 
2.3.3 Cell Lines: Maintenance and Transfection 
 All cell lines were maintained in humidified tissue culture incubators at 37°C 
under 5% CO2. Cell numbers were determined by counting in a Neubauer counting 
chamber. Dead cells were excluded by trypan blue staining (HyClone). 
2.3.3.1 M12 Cells 
 The murine B cell lymphoma cell line M12 was grown in RPMI 1640 
supplemented with 10% FBS, HEPES, P/S, L-glutamine, NEAA, sodium pyruvate, 
and 50 µM βME (RPMI complete). The cells grow semi-adherently and were 
passaged by scraping. 
 24h prior to transfection, the cells were plated with fresh media to ensure 
optimal growth conditions. M12 cells were transfected by electroporation. 20 µg total 
plasmid DNA was mixed with 5x106 cells resuspended in 400 µl OptiMEM I. The 
mixture was transferred to 4mm electroporation cuvettes (Genesee Scientific) and 
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pulsed at 280V, 975 µF in a Gene Pulser XCell (Bio-Rad). After electroporation, the 
cells were allowed to rest for 5min at RT prior to addition of 800 µl RPMI complete. 
The transfected cells were transferred into 5ml prewarmed media and split into two 
wells of a 6-well tissue culture plate (Costar). Half of the wells were analyzed by IF 
the next day or for IL-4 transcript 30h post-transfection, and the other half was 
harvested 72h post-transfection. Overexpression of the transfected constructs was 
analyzed by WB, and the supernatants were screened for IL-4 secretion by ELISA. 
2.3.3.2 293T Cells 
 The human kidney cell line HEK293T was maintained in DMEM 
supplemented with 10% FBS, HEPES, P/S, and L-glutamine. The cells grow in an 
adherent monolayer and were passaged by trypsinization. 
 293T cells were utilized for overexpression studies. 3.0x106 cells were plated 
per 6-well tissue culture plate the day prior to transfection in 2ml media/well. 293T 
cells were transfected using the LTX reagent (Invitrogen). 2.5µg total plasmid DNA 
was resuspended in 500µl OptiMEM I for each transfection. 6.25 µl LTX reagent was 
added to the solution. The tube was vortexed briefly and incubated at RT for 30min. 
The mixture was added dropwise to the cells. Transfections were analyzed 24h later. 
Cells were rinsed once with ice-cold PBS and stored at -80C prior to lysis. 
2.3.3.3 L929 Cells 
 The L929 murine fibroblast cell line was maintained in DMEM supplemented 
with 10% FBS, HEPES, and P/S. The cells were passaged by trypsinization. 
 L929 cells were used as a source for colony-stimulating factor (CSF), which is 
an important growth factor for bone- marrow derived macrophage culture. To 
produce L929 conditioned media, 1x106 cells were plated in 150ml DMEM complete 
per 162cm2 tissue culture flask. The supernatant was harvested twice ten days apart, 
yielding 300ml of conditioned media from each flask. The supernatants were 
combined and stored at -20C in 15ml aliquots. 
2.3.3.4 HL60 Cells 
 The human promyelocytic leukemia cell line HL60 was cultured in RPMI 
complete (see M12 cell culture section). HL60 cells can be differentiated towards a 
granulocyte-like cell by addition of 1.25% DMSO to the culture medium. Cells were 
seeded at a density of 4.0x105 cells/ml and were grown in 30ml media in 15cm tissue 
culture plates. DMSO was added at a final concentration of 1.25%, or cells were left 
untreated. After 72h in culture, the cells were harvested by pipetting. Pellets were 
rinsed in ice-cold DPBS and frozen at -80C until lysates were prepared. 
2.3.4 Primary Cell Culture 
2.3.4.1 T Helper Cell Isolation and Differentiation 
 Murine CD4+ T cells were isolated from pooled spleen and lymph nodes of 
four to six week old mice. A single-cell suspension was obtained by passing the 
organs through 70µm sterile cell strainers (Fisher Scientific). The cells were lysed in 
red blood cell lysis buffer (RBC) and resuspended in MACS buffer. The cell mixture 
was purified either with the MACS CD4+ T Cell Isolation Kit (Miltenyi Biotec) for ChIP 
assays and RNA prep or with the MACS CD4+CD62L+ T Cell Isolation Kit II (Miltenyi 
Biotec) for all other applications following the manufacturer’s suggestions. 
 MACS-purified cells were differentiated in vitro on αCD3 (1µg/ml)/ αCD28 
(2µg/ml)- coated 24 well tissue culture plates. Cells were grown in RPMI complete for 
Th1 and Th2 differentiation and in IMDM complete for Th17 differentiation. IMDM 
complete contained the same supplements as RPMI complete.  
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 To differentiate the cells towards the various lineages, a cytokine cocktail was 
added for each condition: Th1 cells were differentiated by addition of 100U/ml IL-2, 
5ng/ml IL-12, and 10µg/ml αIL-4. For Th2 cells, 100U/ml Il-2 were added together 
with 10ng/ml IL-4, and 10µg/ml αIFNγ. On day 3, the cells were taken off the coated 
plates and plated into 6 well plates containing fresh RPMI complete supplemented 
with IL-2 (100U/ml) and grown until they were ready for harvest or restimulation. 
Th17 differentiation required the addition of 10ng/ml IL-23, 20ng/ml IL-6, 0.3ng/ml 
hTGFβ, 10ug/ml αIL-4, and 10ug/ml αIFNγ. The cells were cultured continuously on 
αCD3/ αCD28-coated plates and harvested on day 4. 
 
RBC lysis     MACS buffer 
10mM KHCO3    DPBS 
150mM NH4Cl    0.5% BSA 
1mM EDTA     2mM EDTA 
filter sterilized     filter sterilized and degassed 
2.3.4.2 Bone-Marrow Derived Macrophage (BMDM) Culture 
 Bone marrow was harvested from front and hind legs of mice. Femur and 
tibia of the legs were prepped and placed in ice-cold sterile DPBS. Excess muscle 
and tendon were removed. The bone marrow was flushed with sterile DPBS and 
collected by centrifugation. Red blood cells were lysed by addition of RBC lysis 
buffer. The cells were resuspended in 10ml DMEM containing 10% FBS, HEPES, 
and P/S (DMEM complete) and passed through a sterile cell strainer to obtain a 
single cell suspension. Bone marrow was plated on one 10cm plastic dish per mouse 
(untreated plastic) and placed in the tissue culture incubator for 3-4h to allow 
fibroblasts to adhere. The non-adherent cells were harvested and resuspended in 
100ml conditioned DMEM (10%FBS, HEPES, P/S, 30% L929 sup) and distributed 
among ten 10cm plates (untreated plastic). The media was replaced on d3 of culture 
and the cells were harvested on d6. 
 For CreERt-mediated deletion during BMDM differentiation, 10 nM 4-
hydroxytamoxifen (4-OHT) was added to the supplemented media at the start of the 
culture and at d3 during refeeding of the cells. After cell harvest on d6, the cells were 
maintained in DMEM complete without 4-OHT. 
 To detach the BMDMs from plastic, the culture media was removed and 
replaced with 5ml detachment solution per plate. After incubation at 37C for 15min, 
the cells were detached with a cell lifter and pooled by centrifugation. The cells were 
resuspended in DMEM complete. For stimulations, cells were replated at the 
following densities: 1.25x105 cells/ well for 48 well plates, 2.5x105 cells/well for 24 
well plates, and 1.0x106 cells/well for 6 well plates. 
 BMDM maturation was assayed by FACS analysis of CD11b and F4/80 
expression levels. After six days of culture, more than 95% were double-positive for 
those markers.  
Detachment solution: 
1:1 mixture of   RPMI with 20% FBS 
and   DPBS with 2mM EDTA 
2.4 Molecular Biology 
2.4.1 Cloning 
 All cloning primers and annealing temperatures are listed in Table 5. In 
general, DNA was amplified by polymerase chain reaction (PCR) using the KOD Hot 
Start Polymerase (Novagen) with the following cycling conditions: 
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 5µl 10x KOD buffer   95°C  2:00min 
 3µl 25nM MgSO4   95°C  0:20min 
 5µl dNTPs (2mM each)  variable 0:10min 
 1µl KOD Pol    70°C  0:20min/ kb 
 1µl template DNA   go to step 2 for 34 cycles 
 1.5µl 10µM FOR primer  70°C  5:00min 
 1.5µl 10µM REV primer  4°C  hold 
 32µl H2O 
 
All PCR products were gel purified using the Qiagen Gel Extraction kit following the 
manufacturer’s instructions. The purified DNA was subcloned using the TOPO blunt 
cloning kit (Invitrogen). 
 The only exception was the amplification of the 3’ARM for the targeting vector 
cloning, which was amplified using the TaKaRa LA Taq polymerase (Takara) with the 
following cycling conditions: 
 
 5µl 10x buffer    94°C   1:00min 
 8µl dNTP mix    98°C  0:05min 
 1µl template DNA   68°C  4:00min 
 1µl 10µM FOR primer   go to step 2 for 34 cycles 
 1µl 10µM REV primer   72°C  10:00min 
 0.5µl LA Taq DNA pol   4°C  hold 
 33.5µl H2O 
 
The 3’ARM PCR product was subcloned using the TOPO XL kit (Invitrogen). 
 All subcloned PCR fragments were verified by analytical restriction digest and 
sequencing of mini prep DNA using the Fast Mini prep kit (5Prime). Verified clones 
were further expanded by maxi prep using the HiPure maxi kit (Invitrogen) for further 
cloning steps. 
 All restriction digests were performed using NEB enzymes with conditions 
recommended by the manufacturer. Linearized plasmids and inserts were ligated 
using the T4 DNA ligase (high concentration) from Invitrogen, allowing the ligations 
to proceed overnight at 4°C. 
2.4.1.1 PAD4 targeting vector cloning 
 The PAD4 targeting vector was generated by use of the pRAPIDflirt vector 
(gift from A. Waisman). This vector comprises a FRT-flanked PGKneoR cassette and 
the HSV thymidine kinase gene for positive and negative selection, respectively. All 
cloning fragments were amplified from BAC DNA that contained the whole PAD4 
genomic locus (RP23-48K5). The 5’ and 3’ homology arms (1.9kb and 5.3kb) were 
amplified using the following primers: 5’ ARM BamHI FOR, 5’ ARM BamHI REV, 3’ 
ARM FseI FOR, and 3’ ARM FseI REV. The 5’ ARM was cloned into pRAPIDflirt via 
the BamHI site, and the 3’ ARM was cloned via the FseI site. The conditional region, 
including exons 9 and 10 (1.7kb), was amplified with Exon 9-10 SalI FOR and Exon 
9-10 SalI REV. It was cloned into the targeting vector via the SalI restriction site 
between the two loxP sites. 
 All cloning steps were verified by analytical restriction digests and sequencing 
of the targeting vector. 150µg of a maxiprep of the targeting vector DNA was 
linearized with NotI prior to electroporation into Bruce4 ES cells in the Gene 
Targeting Core at the Scripps Research Institute. 
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2.4.1.2 Northern and Southern Probe Cloning 
 Similar to the targeting vector cloning, the Southern blot probes were 
amplified using BAC DNA as a template. The primers for the 5’ probe were 5’ probe 
9-10 FOR and REV and for the 3’ probe were 3’ probe 9-10 FOR and REV. Both 
primer pairs yielded PCR products of 606bp. 
 Northern blot probes were amplified using the primers rat PAD4 F2, rat PAD4 
T7P R, mu GAPDH F, and mu GAPDH T7P R. The reverse primers contained the T7 
polymerase promoter sequence required for synthesis of the probe. The PAD4 
specific probe (700bp) was amplified from an expression vector containing ratPAD4 
cDNA. The GAPDH probe (1kb) was amplified from C57BL/6 macrophage cDNA. 
2.4.1.3 Mutagenesis 
 All mutagenesis primers were designed using the QuickChange primer 
design program and are listed in Table 6. Mutagenesis was performed using the 
QuickChange Lightning Mutagensis kit (Stratagene). The template was a pEGFPc2-
NIP45 expression plasmid, and the extension time was 3:30min. All mutants were 
confirmed by sequencing. 
2.4.2 Quantitative Real-time PCR (qPCR) 
 qPCR was used to determine transcript levels of stimulated BMDMs or 
transfected M12 cells. Both TaqMan and SYBR green technology was utilized. 
Primers and probes are listed in Table 7. All reactions were analyzed on the 7900HT 
Fast Real-Time PCR System (Applied Biosytems). Data was analyzed in Excel using 
the ΔCt method. In summary, the mRNA amounts of the gene of interest (GOI) were 
standardized against the mRNA levels of a housekeeping gene (HPRT or β-actin) 
and expressed as ΔCt (= Cthousekeeping-CtGOI). The mRNA copy ratio of GOI to 
housekeeping gene was calculated as 2ΔCt and normalized to a reference sample. 
2.4.2.1 RNA Extraction and Purification 
 RNA from BMDMs or M12 cells was prepped using the RNeasyPlus Mini 
Prep kit (Qiagen) following the manufacturer’s instructions. The homogenization step 
was performed using QIAshredder columns (Qiagen). RNA was eluted in 40µl 
RNase-free water supplied with the kit. RNA concentration and quality was 
determined via spectrophotometry. 
2.4.2.2 cDNA Synthesis 
 Depending on the yield of the RNA prep, 200ng- 2µg of RNA were used for 
cDNA synthesis. The RNA was treated with DNaseI (Invitrogen) to remove genomic 
DNA contamination from the samples. RNA was incubated with 1µl of 10xDNaseI 
buffer and 1µl DNaseI for 30min at 37°C. 1µl of 25mM EDTA was added to inactivate 
the enzyme, and the reaction was incubated for 15min at 65°C. 5µl of the DNase-
treated RNA was used to synthesize cDNA with the iScript cDNA synthesis kit (Bio-
Rad) following the manufacturer’s protocol. 
2.4.2.3 qPCR 
 cDNA samples were run in duplicates for each primer pair or probe. RNA 
minus reverse transcriptase and water were included as negative controls. Usually, 
1µl of cDNA was used for each reaction.  
 TaqMan assays-on-demand (20x) probes were used to analyze IL-4 
transcript levels in M12 cells upon overexpression of various proteins. The reactions 
were run in 20µl total volume using the TaqMan Universal PCR MasterMix (2x) 
(Applied Biosystems) reagent with standard settings on the 7900HT cycler. 
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 BMDMs were analyzed for IL-6, TNFα, and IP-10 transcript levels relative to 
HPRT. The reactions were run in 20µl final volume using the 2xPowerSYBR green 
reagent (Applied Biosystems) using standard settings on the 7900HT cycler. The 
primers were used at 187.5nM final concentration. To assess the quality of the 
amplified product, a dissociation stage was added to each run to monitor the product 
peaks. 
2.4.3 Southern Blot 
 Southern blotting refers to the transfer of DNA fragments from an 
electrophoresis gel to a membrane. The transfer immobilizes the DNA fragments, so 
the membrane carries a reproduction of the banding pattern of the gel. The 
membrane can be hybridized with radioactively labeled probes and visualized by 
autoradiography (Southern, 1975).  
 Southern blotting was used to screen for homologous recombination in ES 
cells for the generation of PAD4 ko mice, as well as confirmation of germline 
transmission of the targeted allele in mice. 
2.4.3.1 Genomic ES Cell DNA Preparation 
 The ES cells were electroporated and selected at the Gene Targeting Core 
Facility at the Scripps Research Institute. Cells from confluent 24 well plates were 
lysed by adding 200µl ES cell lysis buffer per well. The plates were incubated 
overnight in a water bath at 55°C. Lysates were transferred to 1.5ml tubes. After 
addition of 400µl EtOH, the tubes were inverted 20x to precipitate the DNA. The DNA 
was pelleted by centrifugation at 13000rpm for 10min. The pellets were rinsed once 
with 70% EtOH and allowed to air-dry at RT. The pellets were resuspended in 150µl 
sterile TE and dissolved or 4h at 55°C. 
 
ES cell lysis buffer 
100mM Tris-HCl, pH 8.5 
5mM EDTA 
0.2% SDS 
200mM NaCl 
100mg/ml proteinase K 
2.4.3.2 Genomic DNA Digest 
 Genomic DNA was digested with HindIII or BamHI (NEB) to generate 
fragments that would yield an altered pattern in gene-targeted ES cells or mice with 
germline-transmission. 15-30µl of genomic DNA were digested with 50-100U of the 
restriction enzyme of choice with the corresponding buffer in a total volume of 50µl. 
To allow efficient digest in the presence of proteins and RNA, spermidine (1mM), 
BSA (100µg/ml), DTT (1mM), and RNaseA (50µg/ml) were added to the restriction 
mix. Digests proceeded overnight at 37°C. The digested DNA was mixed with 5xDNA 
loading dye (50% glycerol with bromophenol blue and xylene cyanol). 
2.4.3.3 DNA Gel and Transfer 
 Large DNA fragments were separated in low percentage agarose gels. 0.7% 
(w/v) agarose gels were prepared in 1xTAE buffer. Digested DNA was separated by 
electrophoresis at 40V in 1xTAE running buffer. A 1kb DNA ladder was run in parallel 
to provide a marker for fragment sizes. The gel was incubated in denaturation buffer 
for 1h at RT to obtain single-stranded DNA. Afterwards, the gel was rinsed with H2O 
and incubated in neutralization buffer for 1h at RT. The gel was transferred onto a 
membrane (Zeta Probe blotting membrane, Bio-Rad) using downward capillary 
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transfer in 10xSSC transfer buffer. The following day, the membrane was rinsed in 
water and crosslinked once (autocrosslink settings, Spectralinker XL-1000). 
 
50xTAE   denaturation buffer  neutralization buffer 
2M Tris base   1.5M NaCl   1.5M NaCl 
1M glacial acetic acid  0.5N NaOH   500mM Tris HCl pH 7.5 
500mM EDTA 
2.4.3.4 Probe Labeling and Hybridization 
 DNA probes were labeled using the Amersham RediPrime II Labelling 
System following the manufacturer’s instructions. The labeled probes were purified 
using illustra ProbeQuant G50 Microcolumns (GE Healthcare). While the probes 
were labeling, the membrane was prehybridized in UltraHyb (Ambion) at 42°C. The 
purified probes were boiled for 5min and added to the prehybridization solution. The 
membranes were incubated overnight at 42°C. The next day, membranes were 
washed twice with 2xSSC, 0.1% SDS for 15min at 42°C and once with 0.1xSSC, 
0.1% SDS for 20min at 42°C. The membranes were exposed to film at -80°C for 
various timepoints. 
2.4.4 Northern Blot 
 Northern blotting is used to analyze gene expression in RNA samples 
isolated from tissue or cells (Alwine et al., 1977). It involves separation of RNA on an 
agarose gel, transfer of the RNA to a membrane and hybridization of the membrane 
with a radioactively labeled probe specific for you gene of interest. 
2.4.4.1 RNA Sample Preparation 
 RNA was isolated from whole tissue or differentiated Th cell subsets using 
the RNeasy midi prep kit (Qiagen) following the manufacturer’s instructions. RNA 
sample concentration and purity was determined by spectrophotometry, measuring 
OD260 versus OD280. 10µg of RNA were precipitated by addition of 1/10 vol. 1M 
NaOAc pH 4.8 and 2.5 vol. ice-cold 100% EtOH. Precipitating samples were 
incubated at -20°C for at least 3h. The precipitate was collected by centrifugation 
(13000rpm, 25min, 4°C), washed with 80% EtOH, and air-dried. The pellet was 
resuspended in 10µl formamide loading dye and incubated overnight at 4°C. 
 
Formamide loading dye (store at -20C) 
5mM EDTA 
in deionized formamide 
0.1% (w/v) bromophenol blue 
0.1% (w/v) xylene cyanol 
 
2.4.4.2 RNA Gel and Transfer 
 Samples were separated on a 1.2% agarose/ formaldehyde gel. 2.0g agarose 
were dissolved in 120ml H2O by boiling. The solution was allowed to cool down to 
65°C, and 16.6ml 10xMOPS and 28.8ml formaldehyde were added. While the gel 
was solidifying, the RNA samples were incubated at 55°C for 15min. The tubes were 
vortexed briefly, and 10µl of 2xMOPS/ formaldehyde LB was added. The samples 
were boiled for 5min and loaded on the gel. The gel was run at 120V on ice in RNA 
running buffer for 4-6h. Afterwards, the gel was washed for 30-60min in 10xSSC with 
slow agitation. The RNA was transferred onto a membrane (Zeta probe blotting 
membrane, Bio-Rad) by downward capillary transfer overnight at RT using 10xSSC 
as transfer buffer. The next day, the moist membrane was crosslinked twice 
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(autocrosslink settings on the Spectrolinker XL-1000) and was ready for 
hybridization. 
 
10xMOPS   2xMOPS/ formaldehyde LB  RNA running 
buffer 
200mM MOPS pH 7.0 2xMOPS    800ml 1xMOPS 
80mM sodium acetate 30% formaldehyde   20ml 
formaldehyde 
10mM EDTA, pH 8.0  5mM EDTA    precool at 4C 
 
20xSSC 
3M NaCl 
0.3M sodium citrate 
pH to 7.0 with HCl 
2.4.4.3 Labeling and Hybridization 
 The crosslinked membrane was placed in a hybridization bottle, and 
prewarmed hybridization solution was added. The bottles were incubated in the 
hybridization oven at 65°C at least 2h prior to addition of the labeled probe. 
 The labeling procedure described here requires that the probe template 
contains the T7 promoter sequence. Labeling reactions were incubated at 37°C for 
5h: 
  4µl  5x T7 Pol buffer 
  1µl  100mM DTT 
  1µl each 10mM ATP, 10mM GTP, 10mM CTP 
  2µl  0.1mM UTP 
  2µl  template (500ng total) 
  3µl  α32P-UTP (10mCi/ml) 
  1µl  RNase inhibitor 
  1.5µl  T7 polymerase 
  2.5µl  H2O 
  20µl 
 
After labeling, 30µl H2O were added to the reaction, and the labeled probe was 
purified with illustra ProbeQuant G50 Microcolumns. The purified probe was mixed 
with 800µl hybridization buffer and boiled for 5min. Then the mixture was added to 
the prehybridized membrane and incubated at 65°C overnight. The next day, the 
membrane was washed with 0.5xSSC, 0.1% SDS for 15min at 65°C and exposed to 
x-ray film at -80°C for various timepoints. 
 
50x Denhardt’s reagent   hybridization solution 
1% (w/v) Ficoll (Type400)   10ml deionized formamide 
1% (w/v) polyvinylpyrrolidone 40  4ml 10x SSC 
1% (w/v) BSA (fraction V)   1ml 10% SDS 
store at -20C     0.5ml 1M Na-phosphate pH 6.5 
      0.5ml 10mg/ml yeast RNA (boiled, 2min) 
      2ml 50x Denhardt’s reagent 
      2ml H2O 
 
 
 
            MATERIALS AND METHODS 
34 
2.5 Mouse Work 
 Scripps Research Institutional guidelines were followed for all procedures 
involving mice. 
2.5.1 Mouse Strains and Genotyping 
 C57BL/6 and Balb/c inbred strains were obtained from the Scripps Custom 
Breeding Facility. C57BL/6 albino (C57BL/6J-Tyrc-2J/J) females were purchased 
from the Scripps Gene Targeting Core Facility and used to screen PAD4 chimeras 
for germline transmission. Mice expressing Flp enzyme (B6.Cg-
Tg(ACTFLPe)9205Dym/J) were purchased from the Gene Targeting Core Facility 
and were used to delete the FRT-flanked neomycin resistance cassette from PAD4 
gene-targeted mice. Cre-deleter mice (B6.C-Tg(CMV-cre)1Cgn/J) were purchased 
from Jackson laboratories. This strain was intercrossed with PAD4fl/+ mice to obtain 
deletion of the loxP targeted region in the gene locus. Other Cre strains, all obtained 
either in house or through Jackson, include the CreERt strain (B6;129-
Gt(ROSA)26Sor<tm1(cre/ERT)Nat>/J), the Lck Cre strain (B6.Cg-Tg(Lck-
cre)548Jxm/J), and lysM Cre mice (B6.129P2-Lyz2tm1(cre)Ifo/J). 
 Strains with conditional alleles included CARM1fl/fl (Yadav et al., 2003) 
obtained from Prof. Bruening and PAD4fl/fl mice that were generated in this thesis. 
The CARM1fl/fl mice were backcrossed for 12 generations onto the C57BL/6 
background. 
 Mice were genotyped using genomic DNA extracted from tail clips of mice. All 
primers and annealing temperatures can be found in Table 4.  
2.5.2 PAD4 Conditional Knockout (cKO) Generation 
 Bruce 4 ES cells were electroporated with the linearized PAD4 targeting 
vector (for cloning see 2.4.1.1) in the Scripps Gene Targeting Core. Cells were 
subjected to positive and negative selection with G418 and ganciclovir, respectively. 
300 clones were picked and screened for homologous recombination by Southern 
blot with the 5’probe. ES cells that carried the targeted insertion in the PAD4 locus 
were injected into C57BL/6 albino blastocysts. Chimeric males were mated with 
C57BL/6 albino females, and black offspring was genotyped by PCR and Southern 
blot for presence of the targeted allele. PAD4fl/+ mice were intercrossed with CMV-
Cre and Flp-deleter strains to yield PAD4flΔneo/+ and PAD4+/- offspring. 
2.5.3 Neutrophil Elicitation, Isolation, and Purification 
 Neutrophils were isolated from mouse peritoneal fluid following a protocol 
published in Current Protocols in Immunology (Luo and Dorf, 2001). This method is 
based on the recruitment of neutrophils into the peritoneal cavity after injection of a 
sterile inflammatory reagent.  
 Seven week old female PAD4-sufficient or –deficient mice were injected intra-
peritoneally (ip) with 1ml sterile casein solution. The mice were injected a second 
time 14h after the first injection. Three hours later, the mice were euthanized by CO2 
asphyxiation. The peritoneal cavity (PC) was flushed with 10ml harvest solution using 
a 10ml syringe and a 23G needle. The cells were pelleted by centrifugation (200xg, 
7min, RT) and rinsed three times with 10ml DPBS. The cells were resuspended in 
1ml DPBS and layered on top of 9ml Percoll gradient solution. The cell mixture was 
purified by ultracentrifugation (Beckman Ultima XL-100; SW41 rotor; 22200rpm, 
20min, 4°C). The band containing polymorphonuclear cells was harvested. Cells 
were resuspended in 1ml DPBS, and total cell numbers were obtained by counting in 
a Neubauer chamber with trypan blue exclusion. This method yielded 1-5x106 
neutrophils per mouse. These cells were adjusted to the appropriate cell density and 
used for immunofluorescence microscopy. 
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casein solution  harvest solution  Percoll gradient solution 
9g casein   DPBS    10ml 10xPBS, pH7.2 
into PBS   0.01% EDTA   90ml sterile Percoll 
with 0.9mM CaCl2  sterile 
and 0.5mM MgCl2 
boil and autoclave 
2.5.4 PAD4 Monoclonal Antibody Production 
 Six eight-week old female Balb/c mice were injected (ip) each with 500µl 
antigen solution containing 22.5µg GST-PAD4 in complete Freund’s adjuvant (CFA; 
Sigma-Aldrich). On day 14 and 35, the injections were repeated, but GST-PAD4 was 
emulsified in incomplete Freund’s adjuvant (IFA). Eye bleeds were collected on day 
24 and 45 and screened by ELISA against untagged recombinant PAD4. On day 56, 
the four best responders were injected with 25µg GST-PAD4 in PBS (ip). On day 59, 
all mice were euthanized by CO2 asphyxiation. The spleen from the best responder 
was harvested. The splenocytes were fused to the Sp2/0 myeloma cell line following 
the instructions from Current Protocols in immunology “Production of Mouse 
monoclonal antibodies” (Yokoyama et al., 2006). Briefly, after fusion of splenocytes 
and myeloma cells, the cells were selected for successful hybridoma generation in a 
96 well format. Surviving clones were expanded, and supernatants from these cells 
were screened for PAD4 reactivity. The best 20 responders were expanded. To 
ensure clonality, the most promising clones were recloned by serial dilution cloning, 
usually for two rounds, and then used for large scale monoclonal antibody 
production. The limiting dilution cloning and final expansion for antibody production 
steps were performed by the Antibody Production Core Facility of the Scripps 
Research Institute. 
2.6 Biochemical Methods 
2.6.1 Recombinant Protein Expression and Purification 
 Recombinant proteins were used in a variety of in vitro methylation and 
deimination assays, as well as for immunization of mice to generate a PAD4 
monoclonal antibody. Protein quality was checked by SDS page and protein staining 
using the Biosafe Coomassie from Bio-Rad. 
2.6.1.1 GST-PAD4 and GST-NIP45 
 Both GST-PAD4 and GST-NIP45 were recombinantly expressed using the 
pGEX4T vector system (GE Healthcare). Briefly, BL21(DE3)CodonPlus RIL cells 
(Stratagene) were transformed with the respective expression plasmids. Bacteria 
were cultured in 2xYT media with 100µg/ml ampicillin in a shaking incubator at 37°C 
until they reached OD600 of 0.6. The cultures were induced with 0.1mM IPTG and 
allowed to grow for an additional 18hrs at RT. The cultures were pelleted (4000rpm, 
10min, 4°C), and the pellets were resuspended in DPBS containing 1% triton X-100 
and protease inhibitors. Cells were lysed by sonication in the Bioruptor. The soluble 
fraction was purified using GST bind resin (Novagen) and eluted with 20mM 
glutathione pH 7.4. The eluted fractions were pooled, dialyzed against PBS for 48h, 
and concentrated to about 0.5mg/ml. In some preps, the GST-NIP45 was kept on the 
GST bind resin. 
 
2xYT 
16g bacto tryptone. 
10g bacto yeast extract. 
5g NaCl. 
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adjust pH to 7.0 with 5N NaOH. 
adjust to 1L with distilled H2O 
autoclave to sterilize 
2.6.1.2 His-NIP45 
 His-tagged NIP45 was expressed using the pET29a-vector. 
BL21(DE3)CodonPlus RIL cells were transformed with the expression plasmid. 
Cultures were grown in 2xYT with 30µg/ml kanamycin at 37°C until they reached an 
OD600 of 0.7, induced with 0.4mM IPTG, and grown for an additional 18h at RT. The 
cells were harvested by centrifugation. Cells were lysed, and His-NIP45 was purified 
using the PrepEase His Tagged Protein Purification Midi Kit (USB). Recombinant 
His-NIP45 was dialyzed against PBS for 48h and concentrated to about 0.5mg/ml. 
2.6.2 In Vitro Methylation Reactions 
 Methylation reactions were performed on GST-NIP45 bound to GST bind 
resin. Beads equivalent to 2µg of protein were incubated with 1µg recombinant 
PRMT1 (gift from J. Hevel) and 2µl of 3H-S-adenosyl-L-methionine (SAM) (1mCi/ml, 
Amersham), a tritiated methyl-donor, in methylation buffer (final volume 20µl). 
Reactions were allowed to proceed for 1h30min at RT and were stopped by addition 
of 5µl of 5xSDS LB. If followed by a deimination reaction, the beads were washed 
three times with high volume of methylation buffer and then resuspended in 
deimination buffer instead. 
 
methylation buffer   5xSDS LB 
20mM Tris HCl pH6.8   312.5mM Tris HCl pH 6.8 
200mM NaCl    50% glycerol 
     10% SDS 
     bromophenol blue 
     5% β-mercaptoethanol 
 
 Methylation was analyzed by autoradiography. To this end, 15µl of the 
reaction sample was run on a 7.5% 10 well SDS gel. The gel was stained with 
Biosafe Coomassie (Bio-Rad) for 1h at RT. After rinsing in several changes of water, 
the gel was fixed for 30min (10% MeOH, 10% acetic acid) and then soaked in 
Amplify reagent (GE Healthcare) for an additional 30min to enhance the radioactive 
signal. The gel was washed in five changes of water and dried onto Whatman paper. 
The dried gel was placed into an intensifying screen (Kodak BioMax, Transcreen LE) 
and exposed to film (Hyperfilm MP, GE Healthcare) for 48h at -80C. 
2.6.3 In Vitro Deimination Reactions 
 In vitro deimination reactions were performed using various sources of PAD4 
enzyme: recombinant PAD4 (gift from P. Thompson), GST-PAD4, or 
immunoprecipitated HA-tagged PAD4. In all cases, reactions were performed in 
deimination buffer in a final volume of 20µl and allowed to proceed for 1h30min at 
50°C. 1µg of recombinant PAD4 were used to deiminate 2µg of GST-NIP45 or His-
NIP45. 2µl 0.5M EGTA were added to reactions to inhibit PAD4 activity. If PAD4 was 
immunoprecipitated from 293T cell lysates, the bead-bound enzyme was 
resuspended in reaction buffer, and recombinant substrate was added. Reactions 
were stopped by addition of EGTA or 5xSDS LB. 
 
deimination buffer 
40mM Tris HCl pH7.5 
4mM CaCl2 
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4mM DTT (added fresh) 
 
 Deimination of NIP45 was analyzed by Western blotting using the Anti-
Citrulline (modified) Detection kit (Millipore). 
2.6.4 Western Blotting 
 Proteins were separated by SDS gel electrophoresis and transferred onto 
either PVDF or nitrocellulose membranes. The systems used were the Mini-Protean 
3 Cell (Bio-Rad) gel electrophoresis system and the Semi-Dry blotting apparatus. 4-
20% gradient gels (10 well or 15 well) or 7.5% SDS gels (10 well or 15 well) were 
purchased from Bio-Rad (Tris-HCl Ready Gels).  
 Protein lysates were prepared in either RIPA or 1% triton lysis buffer. Briefly, 
cells were rinsed in ice-cold DPBS and lysed in lysis buffer containing 1mM PMSF 
and 1mM sodium vanadate for at least 10min on ice. Cell debris was pelleted by 
centrifugation at 13000rpm, 10min, 4°C. Protein concentration was determined with 
the BCA assay kit (Pierce). Equal amounts of protein were mixed with either 
2xLaemmli buffer or 5xSDS LB and boiled for 5min to denature the sample. Samples 
were loaded on SDS gels together with a prestained protein marker (Bio-Rad) and 
run at 120V for 1h10min in 1xSDS running buffer. After separation, proteins were 
transferred onto PVDF or nitrocellulose membranes (Bio-Rad) in 1xTransfer buffer 
using a semi-dry transfer apparatus (Bio-Rad)(15V, 45min). After transfer, 
membranes were blocked in either 5% milk/ TBST or 1% ovalbumin/TBST, 
depending on the antibodies used. Primary antibodies, which can be found in Table 
3, were diluted in 5% BSA/ TBST or 1% OVA/TBST and incubated with the 
membrane for 1h at RT or overnight at 4°C. Membranes were rinsed three times for 
seven minutes and incubated for 1h in secondary species-specific HRP-conjugated 
antibody in 5% milk/ TBST. Membranes were washed as before, and signal was 
developed using Western Lightning Plus reagent (Perkin-Elmer). The membranes 
were exposed to Denville HyBlot CL film. 
 
RIPA buffer   1% triton lysis   2xLaemmli buffer 
50mM Tris HCl pH7.4  20mM HEPES pH7.4  125mM Tris HCl pH6.8 
150mM NaCl   100mM NaCl   20% glycerol 
1mM EDTA   50mM NaF   5% SDS 
1% triton X-100  10mM β-glycerophosphate bromophenolblue 
1% sodium deoxycholate 1% triton X-100  5% β-mercaptoethanol 
0.1% SDS 
 
5xSDS running buffer  1xTransfer buffer  TBST 
5g SDS   2.9g glycine   50mM Tris HCl pH7.5 
15.2g Tris base  5.8g Tris base   150mM NaCl 
72.1g glycine   in 800ml H2O   0.1% Tween-20 
in 1l H2O   add 200ml methanol 
2.6.5 Immunoprecipitation (IP) 
 Immunoprecipitations were carried out to either separate overexpressed 
proteins from 293T lysates for various downstream applications or to check for 
interaction with other coexpressed proteins (CoIP). Both IPs and CoIPs were carried 
out with lysates prepared from transfected 293T cells. Whole cell lysates (WCL) were 
generated with 1% triton lysis buffer. 10% of the lysates were kept aside as an input 
control. The rest of the lysate was precleared for 1h at 4°C by incubation with 
proteinG sepharose (Bio-Rad). The supernatants were incubated with HA- or FLAG-
agarose (5µl/IP) together with 20µl proteinG sepharose and incubated overnight at 
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4°C. The next day, the beads were washed five times with vortexing and 
resuspended in 50µl 2xLaemmli buffer. After boiling the samples for 5min, the 
proteins were separated by SDS page and were analyzed by Western blotting as 
described above. 
2.6.5.1 Endogenous IP of PAD4 
 Endogenous PAD4 was immunoprecipitated from HL-60 lysates to test the IP 
capacity of the PAD4 hybridomas. Those lysates were generated using RIPA buffer. 
Protein content was determined by BCA assay, and 500µg of protein were incubated 
with 200µl of the hybridoma sups in a final volume of 500µl. The IP was allowed to 
proceed overnight at 4°C. The next day, 50µl of proteinG sepharose were added to 
each sample and, after 1h at 4°C, the beads were collected and washed five times 
as described earlier. The beads were resuspended in 50µl 2xLaemmli buffer and 
boiled for 5min. Samples were analyzed by Western blotting. 
2.6.5.2 Chromatin Immunoprecipitation (ChIP) 
 Chromatin immunoprecipitation (ChIP) was used to study the chromatin 
modifications at several genomic regulatory regions in Th2 cells. Briefly, cells were 
crosslinked, the genomic DNA was fragmented by sonication, and antibodies to a 
specific chromatin posttranslational modification were used to precipitate fragments 
that contain those modifications. The DNA pulled down by the antibodies was 
purified and used in a qPCR reaction. This qPCR reaction amplifies regulatory 
regions of interest. The signal can be compared to the input DNA signal, and percent 
enrichment for this modification can be measured for a particular regulatory region. 
 CD4+ T cells were isolated from wt and PAD4 ko mice and differentiated to 
Th2 cells. On day 7, 4.5x107 cells were either stimulated with PMA and ionomycin or 
left untreated. After 2h at 37°C, the cells were fixed with 1% formaldehyde for 10min 
at RT, and quenched by adding 0.125M glycine. The crosslinked cells were rinsed 
with DPBS containing 0.125M glycine and lysed in 400µl SDS lysis buffer by 
incubation on ice for 10min. 600µl ChIP dilution buffer was added to the samples that 
were sonicated in a Bioruptor 3x7min on high (30sec on, 30sec off). Cell debris was 
pelleted, and the supernatants were transferred into 15ml conical tubes containing 
3ml ChIP dilution buffer. The samples were precleared for 1h at 4°C by addition of 
100µl blocked protein A sepharose (Millipore) and 1µl of normal rabbit IgG 
(Millipore). The supernatants were distributed into four Eppendorf tubes and 
antibodies for IP were added (see Table 3). 40µl of the supernatants were set aside 
for the input samples. The IPs were allowed to proceed overnight at 4°C while 
rotating. The next day 30µl proteinA/ sepharose were added to each sample and 
incubated for an additional 45min. The beads were washed sequentially with ChIP 
wash 1, 2, and 3 for 10min each and then washed twice with TE pH8.0, 5min each. 
To elute the DNA, the beads were resuspended in 50µl ChIP elution buffer twice and 
eluted for 15min at RT. The input samples were mixed with 60µl of elution buffer, and 
all samples were incubated at 65°C overnight after addition of 6.6µl 5M NaCl to 
reverse the crosslinks. On d3, the supernatants were treated with proteinase K (2µl 
0.5M EDTA, 2.66µl 1M Tris HCl pH6.5, 1.33µl 10mg/ml proteinase K) for 1h30min at 
37°C. 550µl buffer PB were added to the supernatants and the DNA was purified 
using the QIAquick PCR purification kit. The DNA was eluted with 50µl EB and 100µl 
H2O were added. 
 
SDS lysis buffer  ChIP dilution buffer  ChIP wash 1 
50mM Tris HCl pH8.0  16.7mM Tris HCl pH6.8 20mM Tris HCl pH8.0 
1% SDS   67mM NaCl   150mM NaCl 
10mM EDTA   1.2mM EDTA   2mM EDTA 
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    1.1% trition X-100  1% triton X-100 
        0.1% SDS 
 
ChIP wash 2   ChIP wash 3   ChIP elution buffer 
20mM Tris HCl pH 8.0 10mM Tris HCl pH 8.0 1% SDS 
500mM NaCl   0.25M LiCl   0.1M NaHCO3 
2mM EDTA   1mM EDTA 
1% triton X-100  1% NP-40 
0.1% SDS   1% sodium deoxycholate 
 
 The amount of precipitated DNA was analyzed by qPCR with primers 
described in Table 8. For each primer pair, a standard curve was generated using 
genomic DNA ranging from 40ng to 0.064ng. Data was expressed as % input after 
subtraction of the background IgG samples. All samples were run in duplicates. 
2.6.6 Immunofluorescence (IF) 
 All immunofluorescent pictures were taken on an Axiovert 100 microscope 
and recorded using Axiovision AC. 
2.6.6.1 GFP-NIP45 Localization 
 After identifying potential PTM sites in NIP45, mutants for those residues 
were generated. To ensure that the mutation would not affect subcellular localization, 
M12 cells that overexpressed those GFP-tagged mutants were analyzed by 
fluorescence microscopy.  
 24h after transfection, 2.0x105 M12 cells were seeded onto poly-L-lysine 
(Sigma) coated coverslips (0.01% poly-L-lysine in H2O). The cells were resuspended 
in RPMI containing 0.1% BSA and were allowed to settle for 30min at 37°C. The 
media was removed and replaced with 1% paraformaldehyde (PFA) in PBS and fixed 
for 15min at RT. The cells were rinsed twice with DPBS, and nuclei were stained with 
DAPI (1mg/ml, Sigma) 1:2500 in DPBS for 10min at RT. Cells were rinsed with 
DPBS again and mounted onto microscopy slides with Dako fluorescence mounting 
medium.  
2.6.6.2 Primary Neutrophil IF 
 Elicited mouse neutrophils were plated onto poly-L-lysine coated coverslips 
(0.001% in H2O) in 6 well plates at a density of 1.2x105 cells in RPMI containing 
0.1% BSA. Cells were allowed to adhere for 30min at 37°C. The media was changed 
to RPMI containing 0.1% BSA with 2mM CaCl2 and 100ng/ml LPS. After 4h of 
stimulation at 37°C, cells were fixed and permeabilized in IF Fix for 15min at RT. 
Coverslips were rinsed three times with PBST and blocked for 1h30min in IF Block at 
RT. Primary antibodies (see Table 3) were added in 100µl IF Block per coverslip and 
incubated in a humidified chamber overnight at 4°C. The next day, coverslips were 
washed three times for 5min with PBST, and anti-rabbit Oregon Green 488 was 
added 1:1000 in IF Block and incubated for 2h at RT. Cells were washed twice 10min 
each with PBST and nuclei were stained with DAPI (1mg/ml; Sigma) 1:2000 in PBST 
for 15min at RT. Coverslips were washed twice for 5min in PBST and mounted onto 
microscopy slides with Dako fluorescence mounting medium. 
 
IF Fix   IF Block  PBST 
3.8% PFA  PBST   DPBS 
2% NP-40  2% BSA  0.1% Tween 20 
1% triton X-100 5% goat serum 
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2.7 Cell Biology Assays 
2.7.1 Arginase Activity Assay 
 The upregulation of Arginase I expression and activity is a hallmark of 
alternatively activated macrophages. Stimulation of BMDMs in vitro with type 2 
cytokines like IL-4 or IL-13 can recapitulate this alternative activation pathway. 
Arginase I is involved in the metabolism of L-arginine. It degrades arginine into urea 
and ornithine. 
 To measure Arginase activity in BMDMs, I used a colorimetric assay modeled 
after Corraliza et al. (Corraliza et al., 1994). Cells were grown in 24 well plates and 
stimulated in triplicate with 10ng/ml IL-4 or left untreated. After 48h, the cells were 
rinsed twice with ice-cold DPBS and lysed with 100 µl 0.1% trition lysis buffer for 
30min while shaking. Afterwards, 100µl MnCl2 solution were added to the wells, and 
the plate was incubated for 10min in a waterbath at 55°C. 50µl of the lysates were 
transferred to 1.5ml Eppendorf tubes, mixed with 50µl arginine solution, and 
incubated at 37°C for 30min. After addition of 800µl stop solution and 50µl ISPF 
solution, the tubes were boiled for 45min. A standard curve ranging from 1.5- 
30µg/ml urea was treated using the same conditions (100µl standard + 800µl stop 
sol. + 50µl ISPF sol.). The colorimetric change was monitored by reading the 
samples in a plate reader at OD540. A standard curve was generated with GraphPad 
software by linear regression, which allowed to calculate the amount of urea 
produced by the Arginase enzyme in the BMDM lysates. 
 
0.1% triton lysis buffer MnCl2 solution   arginine solution 
0.1% (v/v) triton X-100 10mM MnCl2   0.5M arginine 
in H2O    50mM Tris pH 7.5  in H2O 
1mM PMSF   (make fresh!) 
1mM sodium vanadate 
 
stop solution   ISPF solution 
1 part H2SO4   9% (w/v) α isonitroso-propiophenone (MP Biomedicals) 
3 parts H3PO4   in ethanol 
7 parts H2O 
2.7.2 Griess Assay 
 In an inflammatory environment, macrophages are exposed to various stimuli, 
like IFNγ and LPS, that lead to classical activation. One hallmark of a classically 
activated macrophage is upregulation of nitric oxide synthase 2 (NOS2). This 
enzyme converts L-arginine into OH-arginine and then into nitric oxide (NO). One 
way to calculate NO formation is by measuring nitrite (NO2-), a primary and stable 
breakdown product of NO. The Griess Reagent System (Promega) can be used to 
measure nitrite production in the supernatants of stimulated BMDMs. This 
colorimetric assay is based on a diazotization reaction that was originally described 
by Griess in 1879. 
 BMDMs were grown in 24 well plates and stimulated in triplicates for 24h. The 
cells were treated with 10ng/ml IFNγ with 5ng/ml LPS or left untreated. After 24h, the 
supernatants were collected and analyzed with the Griess Reagent System following 
the manufacturer’s instructions. Color development was analyzed in a plate reader at 
OD540 and the standards were used to generate a standard curve (linear regression) 
using the GraphPad software. 
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2.7.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
 ELISAs were used to detect cytokine levels in supernatants of αCD3 
stimulated Th cells or of stimulated BMDMs. The general protocol is the same for all 
cell types and is based on standard sandwich ELISA protocols. 
 96 well ELISA plates were coated with 2µg/ml capture antibody diluted in 
carbonate binding buffer (50µl/well). An exception is the TNFα capture antibody, 
which requires dilution in DPBS. The plates were incubated overnight at 4°C. The 
next day, the plates were washed four times with ELISA wash buffer and blocked 
with blocking buffer (200µl/well) for at least 2h to reduce nonspecific binding. 
Supernatants and standards of the cytokine of interest were diluted with dilution 
buffer in a separate low-protein binding plate. 50µl of the dilutions were transferred to 
the blocked 96 well plate and incubated overnight at 4°C. On the final day, the plates 
were washed four times, and 1µg/ml biotinylated detection antibody was added to the 
wells (50µl/well). The plates were incubated at RT for 1h and washed again. Alkaline 
phosphatase conjugated to avidin was used to detect the signal. Avidin-AP (Sigma) 
was diluted 1:1000 in dilution buffer and added to the wells (50µ/well) for 30min at 
RT. 5ml of detection buffer was mixed with 10µl of 1M MgCl2 and one tablet of 
phosphatase substrate (Sigma-Aldrich). The plates were washed six times, and 50µl 
detection solution was added to the well. Color development was monitored, and the 
reaction was stopped by adding 50µl 2N NaOH. The plates were read at OD405 
subtracting the background at OD450. A standard curve was generated with 
SoftMaxPro, and only absorbances within the range were used to generate data. 
carbonate binding buffer  blocking buffer  dilution buffer 
6.15 parts 0.2M Na2CO3  1% BSA (fraction V)  blocking buffer 
1 part 0.2M NaHCO3  in DPBS   with 0.05% Tween 
pH 9.4     (filtered) 
 
detection buffer   wash buffer 
0.65ml 0.5M Na2CO3   DPBS 
1.85ml 0.5M Na2HCO3  0.1% Tween 
47.5ml H2O 
2.7.4 Flow Cytometry 
 Flow cytometry is a technique that allows the analysis of protein expression in 
live cells on the single-cell level. In a flow cytometer, single cells labeled with 
fluorescent dyes pass through a laser beam. The fluorochromes are excited, the 
emitted light is detected by photomultipliers, and the intensity of the signal can be 
visualized. The forward and the sideward scatter of the laser beam gives an 
indication for the size and granularity of the cells. 
 Cells are usually stained with a cocktail of fluorescently- labeled antibodies, 
which can be used to distinguish cell populations in a mixture of cells. Unstained 
cells and single-stained cells were included in every experiment to allow 
compensation of the signal.  All experiments were performed with a FACS Canto (BD 
Bioscience), and the data was analyzed with FloJo software (TreeStar). 
2.7.4.1 Staining of Cell Surface Markers 
 Flow cytometry was used to analyze cell surface expression of in vitro 
generated BMDMs to check for proper maturation and for immune phenotyping of 
PAD4-deficient mice. For both purposes, the basic staining procedures were similar.  
 Cells were kept on ice during the whole procedure and protected from light 
once the antibodies were added. In general, 1x106 cells (single-cell suspension) were 
used for each stain. The cells were washed with 1ml FACS buffer and collected by 
centrifugation (1200rpm, 4min, RT). The pellets were resuspended in 100µl FACS 
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buffer and 0.25µl Fc block antibody (anti-mouse CD16/32) was added to each tube. 
This is important since Fc receptors can unspecifically bind to the constant region of 
antibodies used in subsequent staining steps. The cells were incubated on ice for 
15min. Afterwards, the cells were washed three times with 1ml FACS buffer, 
resuspended in 100 µl FACS buffer, and stained with the desired antibody-cocktails. 
Staining proceeded for 20-30min at 4°C. The cells were washed twice and 
resuspended in 1ml FACS buffer prior to analysis.  
 
FACS buffer 
DPBS 
1% FBS 
2.7.4.2 Intracellular Cytokine Stain (ICCS) 
 Flow cytometry cannot only be used for analysis of molecules on the cell 
surface but also for intracellular stains. This method requires permeabilization of the 
cell.  
 Th1 and Th2 cells were differentiated in vitro from naïve CD4+CD62L+ T cells 
as described in section 2.3.4. At day 7 of the culture, 5x106 cells were resuspended 
at 1x106 cells/ml in culture media and plated into one well of a 6 well plate. T cells 
were stimulated with 50ng/ml PMA and 1µM ionomycin in the presence of 1µg/ml 
brefeldin A for 5h at 37°C. Brefeldin A inhibits transport of proteins from the ER to the 
Golgi, thereby, preventing the secretion of cytokines by the Th cells. After 
stimulation, the cells were rinsed with FACS buffer and fixed in 1ml fixing buffer for 
10min at RT. The cells were washed twice with FACS buffer and resuspended in 
permeabilization buffer at a concentration of 1x106 cells/ 100µl. 1x106 cells were 
used for each stain. Antibodies were added and cells were stained in the dark at 4°C 
for 30min. Cells were rinsed twice with permeabilization buffer and resuspended in 
1ml FACS buffer prior to analysis on the FACS Canto. 
 
Fixation buffer    permeabilization buffer 
4% (w/v) paraformaldehyde  0.1% (w/v) saponin (Sigma-Aldrich) 
in DPBS    1% FBS 
     in DPBS 
2.8 Mass Spectrometry 
 GST-NIP45 was deiminated in vitro with recombinant PAD4. To determine 
the sites of deimination, the proteins were subjected to mass spectrometry. The 
mass analysis was performed in collaboration with the Ali Sarkeshik at the Yeast 
Resource Center (YRC). Briefly, 15µg of GST-NIP45 were deiminated with 15µg 
PAD4 using standard deimination reaction conditions. The deiminated proteins were 
precipitated with TCA, washed with acetone three times, and air-dried. The dried 
samples were submitted for mass spectrometric analysis where they were subjected 
to trypsin digestion. 
2.9 Statistical Analysis 
 Data are presented as mean +/- SEM and were graphed with either 
GraphPad Prism or Excel. Statistical significance was determined using the 
Student’s t-test. P<0.05 was considered as statistically significant. Significance levels 
were *, P<0.05; **, P<0.01; ***, P<0.001. 
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3 Results 
3.1 Deimination of NIP45 and Functional Consequences 
 NIP45, an NFAT-interacting protein, can potentiate IL-4 production in a 
murine B cell line (Hodge et al., 1996). The arginine methyltransferase PRMT1 is a 
positive regulator of this process. Methylation of the arginine-rich N-terminus of 
NIP45 facilitates the interaction of NIP45 with NFAT, thereby, driving IL-4 
transcription (Mowen et al., 2004). Furthermore, NIP45-deficient mice display severe 
defects in type 2 immunity, specifically, a strongly reduced IL-4 secretion by Th2 cells 
(Fathman et al., 2010).  
 Since the PAD family can also modify targets of PRMT-mediated methylation, 
NIP45 might serve as a target for deimination, providing a possible mechanism for 
negative regulation of NIP45 function in IL-4 transcription. Since NIP45 is 
predominantly expressed in the nucleus, PAD4, the only nuclear PAD, is the primary 
candidate for NIP45 deimination. 
3.1.1 Deimination of NIP45 by PAD4 
 In order to test if NIP45 can be deiminated by the arginine deiminase PAD4, 
recombinant GST or GST-NIP45 were subjected to in vitro deimination assays with 
recombinant PAD4. Since PAD4 activity is Ca2+-dependent, addition of EGTA was 
included to inhibit enzymatic activity. Deimination reactions were analyzed by 
Western blotting with an antibody recognizing chemically modified citrulline. GST-
NIP45 could be deiminated by PAD4 in vitro in a Ca2+-dependent manner (Figure 
10A). To rule out the possibility that the GST-tag, which contains arginines, 
compromised the results, the deimination reactions were repeated with His-tagged 
NIP45, confirming the calcium-dependent deimination of NIP45 by PAD4 (Figure 
10B). 
 
 
 
FIGURE 10: In vitro Deimination of Recombinant NIP45. (A) Recombinant GST or GST-
NIP45 was incubated with PAD4 in the presence or absence of EGTA (50mM). The reactions 
were analyzed by Western blot to detect citrullinated protein. Equal amounts of protein were 
confirmed by probing for NIP45 and PAD4. (B) His-NIP45 was incubated with PAD4 with or 
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without EGTA. Citrullination was detected by α citrulline WB. Loading was confirmed with α 
NIP45 and α PAD4. 
 
 Additionally, I immunoprecipitated HA-tagged PAD4 and demonstrated that, 
like recombinant PAD4, HA-PAD4 was able to deiminate GST-NIP45 in vitro (Figure 
11A). As expected, a catalytically inactive PAD4 mutant (HA-PAD4 C645S) failed to 
deiminate NIP45.  
 To address if endogenous NIP45 can be deiminated by PAD4, FLAG-NIP45 
and myc-PAD4 were coexpressed in HEK293T cells. FLAG-NIP45 was 
immunoprecipitated and analyzed by probing with an antibody recognizing 
citrullinated proteins. Indeed, deiminated FLAG-NIP45 could be detected but only 
when myc-PAD4 was coexpressed (Figure 11B). Interestingly, myc-PAD4 co-
immunoprecipitated with NIP45, demonstrating interaction between these two 
proteins. Furthermore, a signal corresponding to the size of myc-PAD4 was also 
visible in the α citrulline blot, confirming studies of auto-deimination by PAD enzymes 
(Andrade et al., 2010; Mechin et al., 2010)(Figure 11B). 
 
 
 
FIGURE 11: NIP45 Deimination In Vivo. (A) 293T cells were transfected with HA-PAD4 
constructs (wt vs mut). Overexpressed PAD4 was immunoprecipitated with HA-agarose 
beads and mixed with recombinant GST or GST-NIP45 in a deimination reaction. 
Citrullination was detected by α citrulline blot. IP efficiency was tested with α HA probe, equal 
amounts of GST-NIP45 were confirmed by α NIP45 blot. (B) FLAG-NIP45 and myc-PAD4 
were coexpressed in 293T cells. Lysates were immunoprecipitated with FLAG-agarose 
beads, and IPs were analyzed by immunoblotting with α citrulline, α myc tag, and α FLAG, 
respectively. 
 
 In conclusion, PAD4 and NIP45 can interact when coexpressed in HEK293T 
cells and NIP45 is deiminated by PAD4 in vitro and in vivo. 
3.1.2 Deimination Can Prevent Arginine Methylation of NIP45 
 PAD and PRMT enzymes target peptidylarginines for posttranslational 
modification. These two enzyme families often compete for the same substrate. In 
many cases, the targeted residues overlap, which is best exemplified in the 
modification of histone H3 and H4 tails (see Figure 5). Several studies have shown 
that monomethylated but not dimethylated arginines can be deiminated by PAD4 
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(Cuthbert et al., 2004; Wang et al., 2004). Conversely, PRMTs have no activity 
towards peptidyl-citrullines. 
 Since PRMT1-mediated methylation regulates NIP45 function, I tested if 
PRMT1 and PAD4 target the same arginine residues in NIP45, by sequential 
methylation and deimination reactions. Figure 12A shows NIP45 methylation. When 
GST-NIP45 was deiminated by PAD4 prior to methylation by PRMT1 using a tritiated 
methyl-donor, the signal for methylated GST-NIP45 was reduced to background 
levels (Figure 12A, lanes 1 and 2). When NIP45 was methylated by PRMT1 prior to 
deimination by PAD4, the overall methylation level did not change (Figure 12A, right 
half). These results suggest that most of the arginines methylated by PRMT1 can 
also be deiminated by PAD4. Interestingly, PAD4 itself was methylated by PRMT1, a 
novel observation (Figure 12A, lanes 3 and 4). Methylation and deimination reactions 
were also analyzed for deimination of GST-NIP45 (Figure 12B). Surprisingly, 
methylation of NIP45 prior to deimination by PAD4 did not interfere with NIP45 
deimination (Figure 12B, lanes 2 and 3), suggesting that PAD4 targets arginines not 
modified by PRMT1. 
 
 
 
FIGURE 12: Deimination of NIP45 Prevents Methylation. Recombinant GST-NIP45 was 
sequentially deiminated with PAD4 (+/- EGTA, 50mM) and then methylated with PRMT1 in 
the presence of 3H-SAM as the radioactively labeled methyl-donor, or methylated first and 
then deiminated by PAD4 (+/- EGTA, 50mM). (A) 15µl of the reactions were run on a 7.5% 
SDS page and stained with Coomassie to confirm equal amounts of protein loading. The 
dried gels were exposed to film to reveal methylation by autoradiography. (B) 4µl of the 
reactions were analyzed by immunoblotting for α citrulline to detect deiminated GST-NIP45, 
and with α NIP45 and α Pad4 to detect equal protein input. 
 
 In conclusion, deimination of NIP45 can prevent subsequent methylation by 
PRMT1, but PRMT1 methylation does not affect subsequent deimination of NIP45 by 
PAD4, suggesting different arginine preferences for PAD4 and PRMT1. 
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3.1.3 Characterization of PAD4 Target Sites in NIP45 
 Methylation of NIP45 is concentrated within the first 32 amino acids, as a 
deletion mutant lacking residues 1-32 (FLAG-NIP45ΔN) cannot be methylated by 
PRMT1 in vitro (Mowen et al., 2004). The results in Figure 12 suggest that PAD4 
deiminates additional residues outside of this arginine-and glycine-rich region. 
Therefore, PAD4 enzymatic activity was tested against a panel of deletion mutants 
(Figure 13). (Note that the mutant lacking the first 32 AA is referred to as 
NIP45ΔRGG from now on, and NIP45ΔN describes a deletion of the first 188 AA). 
 
FIGURE 13: NIP45 Deletion 
Mutants. The schematic overview 
shows the functional domains of 
NIP45. Deletion mutants are indicated 
below (FL= full length). An additional 
mutant ΔNC is comprised of AA 188-
261. 
 
 Myc-PAD4 and FLAG-tagged NIP45 mutants (Figure 13) were coexpressed 
in 293T cells. After immunoprecipitation for the FLAG-tagged constructs, the 
precipitated proteins were analyzed for deimination by immunoblot. Since FLAG-
PRMT4/CARM1 is not a target for deimination in vitro (data not shown), it was 
included as a negative control. The strongest signal for deiminated protein was 
obtained with the full-length NIP45 construct, but all other deletion mutants except 
NIP45ΔNC were also detected (Figure 14, top panel). The NIP45ΔNC mutant could 
not be resolved in the citrulline blot due to unspecific background signal in this size 
range. Of note, the NIP45ΔC mutant was detected in the citrulline blot, though it 
expressed very poorly and was not detectable in the α FLAG reprobe blot (Figure 14, 
bottom panel). 
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FIGURE 14: Deimination of NIP45 Deletion Mutants. FLAG-tagged expression constructs 
were coexpressed with myc-PAD4 in 293T cells. Cells were lysed and proteins were 
immunoprecipitated with FLAG-agarose beads. The immunoprecipitates were analyzed for 
citrulline modification and IP efficiency by immunoblotting. 
 
 To summarize, NIP45 deimination sites were broadly distributed throughout 
the whole protein. All of the NIP45 deletion mutants could be deiminated by PAD4. 
The ΔNC mutant could not be resolved properly; therefore it is unclear if it contains 
PAD4 deimination targets.  
3.1.3.1 Mass Spectrometry of Deiminated GST-NIP45 
 To identify specific PAD4 deimination sites in NIP45, in vitro deiminated GST-
NIP45 was subjected to mass spectrometric analysis. This work was performed in 
collaboration with Ali Sarkeshik and John Yates at Scripps through the Yeast 
Resource Center. Although the mass difference between arginine and citrulline is 
only 1Da, we could identify several deiminated arginines in GST-NIP45. 
Unfortunately, the sequence coverage, especially of the glycine- and arginine-rich N-
terminus was very poor. Deiminated arginines are highlighted in red in Figure 15 and 
are at positions R32, R37, R103, and R104. Interestingly, R103 and R104 are part of 
the nuclear localization signal (NLS) sequence (underlined in Figure 15). 
 
 
FIGURE 15: Deimination Sites in Mouse NIP45. The amino acid sequence of murine 
NIP45 is depicted above. Highlighted in red are the deimination sites that were identified by 
mass spectrometry. The NLS sequence is underlined. 
 
3.1.3.2 Characterization of NIP45 Point Mutants 
 Ectopic expression of NFAT, c-Maf and NIP45 in a murine B cell line leads to 
detectable IL-4 secretion (Hodge et al., 1996). To understand the potential role of 
NIP45 deimination in the regulation of IL-4 transcription, I generated three different 
point mutants for each identified site: an arginine to lysine substitution (R->K) to 
conserve the positive charge, an arginine to phenylalanine substitution to mimic 
dimethylation (R->F), and an arginine to glutamine substitution to mimic deimination 
(R->Q) (Bates et al., 2002). 
 The mutants were generated by site-directed mutagenesis using pEGFP-
NIP45 as the template. Since R103 and R104 are part of the NLS, it was important to 
check if the mutants retained nuclear localization. M12 cells, a murine B cell line, 
were cotransfected with HA-NFAT, c-Maf, and the GFP-NIP45 point mutants. The 
deletion mutants NIP45ΔRGG and NIP45ΔN (see Figure 13) were included for 
reference. The transfected cells were analyzed by fluorescence microscopy in four 
independent experiments. With the exception of GFP-NIP45ΔN, all mutants were 
expressed primarily in the nucleus (Figure 16). GFP-NIP45ΔN and GFP (EV) 
displayed cytoplasmic localization. The mislocalization of NIP45ΔN was expected 
since this mutant lacks the NLS. 
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FIGURE 16: Fluorescence Microscopy of NIP45 Mutants in M12 Cells. M12 cells were co-
transfected with HA-NFAT, c-Maf and various pEGFP-NIP45 constructs. The particular 
mutants are indicated on the left. 24h post transfection, the cells were plated onto poly-L-
lysine coverslips, fixed, and stained with DAPI. Pictures were taken with 40x objective. 
Representative pictures from four independent experiments are shown. 
 
 To test the transcriptional potential of all NIP45 mutants, supernatants of the 
cells that were used in the IF studies were analyzed for IL-4 secretion. As expected, 
overexpression of GFP-NIP45 together with HA-NFAT and c-Maf induced 
spontaneous IL-4 secretion in M12 cells (Figure 17A and B). R37F substitution had 
no effect on cytokine secretion, while R37K or R37Q substitutions significantly 
reduced IL-4 secretion by 40-50%. The R103 mutants showed a reverse phenotype 
with R103F and R103K significantly reducing the secretion by 50-60%, but R103Q 
had no effect on IL-4 production. The R104 mutants had little or no effect on IL-4 
secretion (Figure 17A). 
 The R32 mutants were analyzed in a separate experiment and compared to 
NIP45ΔRGG and NIP45ΔN. Both deletion mutants severely impacted IL-4 secretion 
with ΔN reducing it to background levels (compare to EV). The R32K substitution had 
an intermediate effect on IL-4 secretion, and the effect of R32Q was negligible 
(Figure 17B). 
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FIGURE 17: Effect of NIP45 Point Mutations on IL-4 Secretion. M12 cells were 
cotransfected with HA-NFAT and c-Maf in combination with pEGFP-NIP45 expression vectors 
as indicated above. IL-4 secretion was analyzed 72h after transfection. Transfection 
efficiencies were analyzed by immunoblotting of whole cell lysates. (A) Data from four 
independent experiments were combined. ELISA data is represented as % of NIP45 WT 
transfected cells. Statistically significant differences relative to NIP45 WT are indicated for the 
respective constructs. Transfection efficiency of a representative experiment is shown on the 
right. (B) IL-4 ELISA data of respective transfections is shown on the left. Expression levels of 
the relevant constructs are displayed on the right. 
 
 In summary, NIP45 is deiminated by PAD4 inside the glycine- and arginine-
rich N-terminus, both overlapping with PRMT1 methylation sites and throughout 
other parts of the protein. Four specific deimination sites were identified by mass 
spectrometry. Generation of NIP45 point mutants mimicking deimination at those 
sites revealed a potential role for deimination of R37 in negative regulation of IL-4 
secretion. None of the mutants tested enhanced NIP45’s ability to potentiate IL-4 
secretion in M12 cells. 
3.1.4 The Role of PAD4 in NIP45-mediated IL-4 Secretion 
 PRMT1-mediated methylation of the N-terminus of NIP45 facilitates the 
formation of a trimeric NFAT/NIP45/PRMT1 complex that can fully activate IL-4 
transcription. If PRMT1 is inactivated, IL-4 transcription is reduced, making PRMT1 a 
positive regulator of IL-4 transcription (Mowen et al., 2004). Deimination of NIP45 
can prevent arginine methylation (Figure 12), and the NIP45 R37Q deimination 
mimic impairs IL-4 secretion from M12 cells (Figure 17). Together, these data 
suggest a role for PAD4 as a negative regulator of IL-4 transcription. To test this 
notion, M12 cells were transfected with expression constructs for HA-NFAT and c-
Maf in combination with myc-NIP45 and HA-PAD4. Both wildtype (wt) and an 
enzymatically inactive mutant (mut) of PAD4 were used. IL-4 expression was 
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analyzed on the transcript level by qPCR (Figure 18A) and on the protein level by IL-
4-specific ELISA of the supernatants (Figure 18 B). As expected, coexpression of 
NIP45 with NFAT and c-Maf potentiated IL-4 expression and secretion of M12 cells 
(Figure 18A and B, lanes 1&2). Coexpression of PAD4 reduced IL-4 levels to basal 
levels (Figure 18A and B, lanes 3&4). Surprisingly, this effect was independent of 
PAD4’s enzymatic activity. To ensure comparable expression levels of the various 
constructs, whole cell lysates were analyzed by Western blotting (Figure 18C). 
 
 
 
FIGURE 18: PAD4 is a Negative Regulator of IL-4 Transcription in M12 Cells. HA-NFAT, 
c-Maf, myc-NIP45 and HA-PAD4 (wt or mut) were co-expressed in M12 cells as indicated. IL-
4 expression was analyzed 30h post transfection by qPCR (A) and 72h after transfection by 
ELISA (B). Transfection efficiency was analyzed by immunoblotting (C). 
 
 NIP45 can form a trimeric complex with NFAT and PRMT1 (Mowen et al., 
2004). Since PAD4 can deiminate NIP45 and inhibit NIP45-mediated potentiation of 
IL-4 expression, I tested whether NIP45 could form a trimeric complex with PAD4 
and NFAT. Epitope-tagged expression constructs of NIP45, PAD4, and NFAT were 
coexpressed in 293T cells. NIP45 was immunoprecipitated, and the reactions were 
analyzed for interaction with NFAT and PAD4 by Western blotting (Figure 19). 
Indeed, NIP45 interacted with NFAT and PAD4 both alone and in combination. 
Comparable expression was confirmed by immunoblotting of the total lysates (WCL) 
(Figure 19). 
 
           RESULTS 
52 
 
 
FIGURE 19: NIP45 Interaction with PAD4 and NFAT. 293T cells were co-transfected with 
HA-NFAT, myc-PAD4, and FLAG-NIP45. Lysates were immunoprecipitated with FLAG 
agarose. IPs were analyzed by immunoblotting with α HA tag, α myc tag, and α FLAG. To 
ensure comparable protein input, whole cell lysates (WCL) were probed with α HA tag and α 
myc tag. 
 
 In conclusion, NIP45-driven IL-4 expression in M12 cells can be abrogated by 
ectopic expression of PAD4. Interestingly, PAD4’s catalytic activity is not required for 
this process. Furthermore, NIP45 can form a trimeric complex with NFAT and PAD4 
in vivo. 
3.1.5 PAD4 Expression Levels in Th2 Cells 
 The primary IL-4 producers are Th2 cells. The importance of NIP45 for IL-4 
secretion by Th2 cells is signified by the severe reduction of IL-4 production in 
NIP45-deficient Th2 cells (Fathman et al., 2010). PAD4 can negatively regulate 
NIP45-mediated IL-4 expression in M12 cells. Expression analysis has revealed that 
PAD4 is not only expressed in myeloid cells, but also to a lesser extent in CD3+ cells, 
which encompass all T cells (Vossenaar et al., 2004). Therefore, it was important to 
check if PAD4 is expressed in Th2 cells. 
 RNA from total bone marrow (BM), naïve CD4+ T cells (Thp) and 
differentiated Th1 and Th2 cells was prepared and analyzed on a Northern blot. 
PAD4 was detected with a PAD4-specific RNA probe (Figure 20). A strong signal for 
PAD4 was detected in BM after several hours of exposure. The signal for PAD4 in 
Th2 cells could only be detected after 7d exposure at -80C. No signal could be 
detected in either Thp or Th1 cells. To confirm equal loading of RNA, the membrane 
was reprobed with an RNA probe specific for the housekeeping gene GAPDH 
(Figure 20). 
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FIGURE 20: Northern Blot of PAD4 Expression. RNA (10µg/sample) was separated by 
electrophoresis and transferred onto a positively charged nylon membrane. Membranes were 
probed with a radioactively labeled PAD4 RNA probe. The membrane was exposed to film for 
one week. To ensure equal loading, the membrane was reprobed with a labeled GAPDH-
specific probe. 
 
 In summary, NIP45 is deiminated by PAD4 both in vitro and in vivo. Unlike 
arginine methylation of NIP45, deimination is not limited to the glycine- and arginine-
rich N-terminus of the protein, but the sites are dispersed across the whole protein. 
Several novel deimination sites could be identified by mass spectrometry, and at 
least one is implicated in the negative regulation of IL-4 secretion. Moreover, ectopic 
expression of PAD4 reduces NIP45-mediated IL-4 expression to background levels. 
This effect is independent of the enzymatic activity of PAD4. Finally, IL-4-producing 
Th2 cells express low levels of the PAD4 transcript. 
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3.2 Generation and Analysis of PAD4 Conditional Knockout 
Mice 
 The peptidylarginine deiminase PAD4 is the only PAD family member that 
predominantly localizes to the nucleus via its NLS (Nakashima et al., 2002) and, 
thereby, can directly influence transcription by deimination of histone tails (Cuthbert 
et al., 2004; Hagiwara et al., 2005; Wang et al., 2004). Histone deimination is 
associated with negative regulation of transcription (Cuthbert et al., 2004; Denis et 
al., 2009; Wang et al., 2004). In addition, PAD4 is a corepressor of nuclear-hormone 
receptor signaling and p53-mediated signaling (Denis et al., 2009; Li et al., 2010). 
The expression of PAD4 is highly restricted to the hematopoietic lineage, especially 
granulocytes and monocytes (Nakashima et al., 2002; Vossenaar et al., 2004). 
Interestingly, deiminated histones are associated with NETs released by neutrophils, 
linking PAD4 activity to an innate defense mechanism (Neeli et al., 2008; Wang et 
al., 2009). Furthermore, PAD4 has been implicated in the pathogenesis of several 
diseases, including rheumatoid arthritis (Suzuki et al., 2003), multiple sclerosis 
(Wood et al., 2008), and malignant tumors (Chang and Fang, 2009). 
 Since PAD4 is an important regulator of diverse cellular processes and 
dysregulation of its activity has been associated with various pathological conditions, 
I generated a mouse model with targeted disruption of the PADI4 gene. This model 
will be useful in studying many aspects of PAD4 biology and addressing its role in 
various disease models. 
3.2.1 Generation of PAD4 Conditional Knockout Mice 
 PAD4 conditional knockout mice (cKO) were generated by flanking exons 9 
and 10 of the endogenous PADI4 gene with loxP sites. Exons 9 and 10 contain 
aspartate 352, which is part of the active site, as well as four additional residues that 
are essential for Ca2+ binding (Q351, E353, E355, D371). Furthermore, deletion of 
these two exons results in a frameshift. The targeting vector was cloned and 
linearized as described in section 2.4.1.1. C57BL/6-derived Bruce 4 ES cells were 
electroporated with the linearized construct and underwent G418 and ganciclovir 
selection (Figure 21A). Surviving clones were analyzed by Southern blotting. HindIII 
and BamHI digests of genomic ES cell DNA were probed with a radioactively labeled 
5’ probe (Figure 21A). Two successfully targeted clones, 116 and 261, were 
identified (Figure 21B and C). Both clones were expanded and injected into C57BL/6 
albino blastocycts to derive chimeric mice. Chimeric males were bred to C57BL/6 
albino females. Black pups were screened for germline transmission of the targeted 
allele by PCR, and the results were confirmed by Southern blot of HindIII-digested 
tail DNA (Figure 21D).  
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FIGURE 21: PAD4 Gene Targeting Overview. (A) Schematic overview of the PAD4 
targeting strategy. Exons are represented as numbered boxes; HindIII and BamHI restriction 
sites are labeled with B and H, respectively (blue); the placement of the external 5’probe is 
depicted; FRT sites (blue ovals) and loxP sites (red rectangles) are indicated; the selectable 
markers neo (neomycin resistance) and HSV-TK are shown as boxes. The dashed lines 
indicate integration or recombination sites. (B) Genomic DNA from three ES cell clones was 
digested with HindIII and analyzed by Southern blotting with a labeled 5’probe. The wt band 
(9.5 kb) and the floxed band (5.9 kb) sizes are indicated. (C) BamHI digested ES cell DNA 
was screened with the labeled 5’probe. The wt band (15.5 kb) and the targeted band (floxed) 
(6.6 kb) are indicated. (D) Mouse genomic tail DNA was screened for integration of the 
targeting vector. Genotypes as identified by PCR are indicated on top. 
 
 Mice carrying the targeted allele (fl/+) were bred to Flp-deleter or CMV-Cre 
deleter mice to generate PAD4flΔneo/+ and PAD4+/- mice, respectively (Figure 21A 
and Figure 22). PAD4-deficient mice were obtained by intercross of the latter. 
Deletion of the neomycin cassette upon breeding to the Flp-deleter mice was 
confirmed by PCR on genomic tail DNA (Figure 22A and B). CMV-Cre mediated 
deletion of the loxP-flanked exons 9 and 10 was confirmed as well (Figure 22A and 
C). To confirm the absence of PAD4 on the protein level, lysates of peritoneal cavity-
derived cells (mainly granulocytes and monocytes) were probed with all available 
PAD4 antibodies. None of the antibodies could detect protein in the lysates from the 
KO (-/-) mice. A representative immunoblot is shown in Figure 22D. 
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FIGURE 22: Genotyping of Mice with Targeted Insertion into the PAD4 Locus. (A) PCR 
primers used for genotyping of PAD4 gene-targeted mice are indicated. Expected PCR 
product sizes are shown on the right, the corresponding genotype is shown on the left. (B+C) 
Representative pictures of genotyping results are depicted. Sizes (in bp) are indicated on the 
left, genotypes on top. (D) Peritoneal cavity cells were isolated from a PAD4 WT and KO 
mouse. Protein lysates were analyzed by immunoblotting using α 2206, an antibody specific 
for mouse PAD4. The lysates were reprobed with α tubulin to ensure equal loading between 
the samples. 
 
 In conclusion, PAD4 conditional knockout mice have been generated 
successfully. Mice with a complete deletion of PAD4 (PAD4-/-) are viable, with no 
overt developmental defects. PAD4 flΔ/+ mice are currently bred to several Cre-lines 
(Lck-Cre, lysM-Cre, Cre-ERt) to generate cell-type specific or inducible KO strains. 
3.2.2 Immunophenotyping of PAD4 KO Mice 
 PAD4 expression is restricted to the hematopoietic lineage (Vossenaar et al., 
2004). Therefore, PAD4 WT and KO mice were analyzed by flow cytometry to check 
for potential defects in the development of the hematopoietic system. Bone marrow, 
spleen, lymph nodes, thymus, and cells from the peritoneal cavity were isolated and 
stained with a variety of B cell- and T cell-lineage specific surface markers (examples 
are shown in Figures 23 and 24). Overall, there were no obvious differences in 
numbers or percentages of all developmetal stages analyzed. Both B- and T cell 
development progressed normally in PAD4-deficient mice. 
 Thymocytes were analyzed by staining for CD4 and CD8α (Figure 23A) and 
several other maturation markers (data not shown), but no perturbations in 
thymocyte development were found in PAD4-deficient mice. Not surprisingly, normal 
frequencies of CD4+ and CD8+ T cells were detected in the periphery (Figure 23B).  
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FIGURE 23: T Cell Development in Thymus and Lymph Nodes of PAD4 KO Mice. Single 
cell suspensions from thymus and lymph nodes of PAD4 WT or KO mice were stained with 
the indicated fluorescently labeled antibodies. Cells were analyzed by flow cytometry. (A) 
Thymocytes were stained with CD4- and CD8α-specific antibodies to check thymocyte 
development progression. (B) Lymph node cells were stained with B220 and TCRβ to 
discriminate between B and T cells. The TCRβ positive cells were analyzed for CD4 and 
CD8α expressing cells, respectively. Percentages of gated cells are indicated. 
 
 B cell development in PAD4-deficient mice was analyzed in bone marrow, 
lymph nodes, spleen, and peritoneal cavity. All developmental stages analyzed 
showed no perturbations in PAD4 KO mice. As an example, a representative stain of 
splenic B cells is shown in Figure 24. The co-stain for IgM and IgD revealed proper 
development from immature (IgM+, IgD-) to mature peripheral B cells (IgM+IgD+). 
           RESULTS 
58 
 
 
FIGURE 24: Peripheral B Cells in Spleen of PAD4 KO Mice. Splenic cells from PAD4 WT 
and KO mice were stained with α CD3 and α B220 to discriminate between T and B cells 
(upper panel). B220+ cells were costained with IgM and IgD to monitor B cell maturation 
(lower panel). 
 
 Overall, both B and T cell development was not perturbed in PAD4-deficient 
mice. Future studies are needed in order to address the functional capacities of both 
B and T cells in this mouse strain. 
3.2.3 Analysis of PAD4-Deficient Th Cells 
 Since PAD4 can negatively regulate NIP45-mediated IL-4 expression in M12 
cells, Th2 cells, the main source of IL-4 in the mouse, were analyzed for their IL-4 
secretion capacity. I hypothesized that PAD4-deficiency should release inhibition and 
lead to elevated IL-4 levels. 
 CD4+CD62L+ naïve T cells were isolated from spleen and lymph nodes of 
PAD4 WT or KO mice. The cells were differentiated in vitro towards the Th1, Th2, 
and Th17 lineages. The differentiated Th cells were restimulated with αCD3 for 24h, 
and cytokine secretion was analyzed by ELISA. Upon TCR stimulation, Th1 cells 
from PAD4 KO mice produced slightly less IFNγ (Figure 25A). This was not due to a 
change in the level of T-bet, the master regulator of Th1 differentiation (Figure 25D). 
IL-17A production by Th17 cells was not affected in the absence of PAD4 (Figure 
25B). In Th2 cells however, PAD4 deficiency led to increased IL-4 secretion, 
supporting a role for PAD4 as a negative regulator of IL-4 expression (Figure 25C). 
Gata 3 is the master regulator of Th2 differentiation. Furthermore, slightly elevated 
Gata 3 levels in Th2 cells accompanied the increase in IL-4 secretion from PAD4 KO 
mice.  
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FIGURE 25: Th Cell Cytokine Secretion in PAD4 KO Mice. CD4+CD62L+ T cells were 
isolated from WT (white bars) and KO PAD4 (grey bars) mice. The cells were differentiated in 
vitro to become Th1, Th2, or Th17 cells. Cytokine secretion was assessed by restimulation of 
those cells with α CD3 for 24h. Th1 (A) and Th2 cells (C) were restimulated after 7d in 
culture, Th17 cells (B) were restimulated after 4d. (D) Protein lysates from restimulated Th1 
and Th2 cells were analyzed by immunoblotting with α T-bet or α Gata 3, respectively. Equal 
loading was confirmed with an α tubulin blot. 
 
 Additionally, in vitro differentiated Th1 and Th2 cells were analyzed by 
intracellular cytokine staining for IFNγ and IL-4. Th1 cells derived from PAD4 WT or 
KO mice displayed no difference in percentage of IFNγ-producers (39.5% vs 40.6%). 
The amount of IFNγ-production per Th1 cell, which can be analyzed by comparing 
the mean fluorescence intensities (MFI), was indistinguishable (MFI WT: 2388; MFI 
KO: 2406)(Figure 26A). Th2 cells from PAD4-deficient mice contained a higher 
percentage of IL-4 producing cells (WT: 13.5%; KO: 20.0%), and they also 
expressed more IL-4 on a per cell basis (MFI WT: 1842; MFI KO: 1988)(Figure 26B).  
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FIGURE 26: Intracellular Cytokine Staining of Th1 and Th2 Cells. In vitro differentiated 
Th1 and Th2 cells were stimulated with PMA (50ng/ml) and ionomycin (1µM) in the presence 
of brefeldin A (1µg/ml). Cells were fixed and stained with antibodies to detect IL-4, IFNγ, and 
CD4. After staining, the CD4+ Th1 (A) and Th2 cells (B) were analyzed by flow cytometry. 
Percentages of cytokine producing cells are indicated.  
 
 NIP45-mediated IL-4 transcription is positively regulated by arginine 
methylation. PRMT1 methylates the N-terminus of NIP45, enhancing its interaction 
with NFAT, and thereby driving IL-4 transcription (Mowen et al., 2004). In addition, 
recruitment of PRMT1 to the IL-4 promoter also increases the levels of histone H4R3 
methylation, a modification linked to active transcription (Fathman et al., 2010). Since 
PAD4 can deiminate histone H4R3 and can negatively regulate IL-4 expression, IL-4 
promoter histone deimination was analyzed by chromatin immunoprepitation studies. 
 CD4+ T cells were isolated from PAD4 WT and KO mice and were 
differentiated in vitro to Th2 cells. Half of the cells were stimulated for 2h with 
PMA/Ionomycin to mimic a strong TCR signal. Cells were crosslinked, and ChIP 
analysis was performed using antibodies specific for dimethylated histone H4R3, 
deiminated H4R3, or acetylated H4. H4 acetylation and dimethylation are both 
hallmarks of active transcription, but deimination is associated with repression. 
Abundance of these H4 posttranslational modifications was analyzed at both the IL-4 
and IFNγ promoters, as well as at CNS I and HS IV, two important regulatory 
elements in the IL-4 locus control region (Figure 27). Unfortunately, no reproducible 
signal was detectable for deiminated H4R3 for any of the loci. Preferential 
enrichment of both dimethylated H4R3 and acetylated H4 at the IL-4 promoter and 
CNS I were comparable in WT and KO samples. The IFNγ promoter and HS IV 
region had much lower signals for the H4 methylation and acetylation (notice the 
different scales), which was expected, since the IFNγ promoter is silenced in Th2 
cells and the HS IV region is associated with repression of IL-4 transcription (Figure 
27).  Overall, the local chromatin environment in the IL-4 regulatory region showed 
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no differences between PAD4 WT and KO Th2 cells. Deimination of histone H4 was 
not detected in any of the samples. 
 
 
 
FIGURE 27: ChIP Analysis of Th2 Cells. CD4+ T cells were isolated from PAD4 WT or KO 
mice. Cells were differentiated under Th2 conditions for 7 days. Half of the cells were 
stimulated with 50ng/ml PMA and 1µM ionomycin for 2h. Chromatin IPs were performed 
using α H4R3(me)2, α H4R3cit, α H4acetyl, and α IgG control antibodies. The IL-4 promoter, 
the IFNγ promoter, CNS I, and HS IV regions were analyzed for the presence of those 
posttranslational modifications by qPCR. Abundance of the particular modification is 
represented as % of input. All values depicted are after subtraction of α IgG control ChIP. 
Lines between graphs indicate scale differences. 
 
 In conclusion, Th cells derived from PAD4 KO mice displayed several 
defects. Th1 cells had a slight decrease in IFNγ secretion, which was only detectable 
by ELISA. Th17 cells had no observable defect. Th2 cells from PAD4-deficient mice 
showed significantly increased IL-4 expression and secretion, substantiating a 
negative regulatory role for PAD4 in IL-4 expression that is not dependent on PAD4-
mediated H4R3 deimination. 
3.2.4 Analysis of Neutrophils Derived from PAD4 KO Mice 
 Neutrophils, the most abundant member of the granulocyte family, express 
high levels of PAD4 (Asaga et al., 2001). Human peripheral blood neutrophils have 
increased histone deimination when activated with inflammatory stimuli. Furthermore, 
those modified histones are also found in NETs released by neutrophils (Neeli et al., 
2008; Wang et al., 2009). Since histones have bactericidal properties, NET release is 
an important defense mechanism. 
 To study mouse neutrophils, PAD4 WT and KO mice were injected with the 
neutrophil-eliciting agent casein. Neutrophils were isolated from the peritoneal cavity, 
purified, and stimulated with LPS. Cells were stained with various antibodies and 
analyzed by fluorescence microscopy (Figure 28). Staining with an antibody that was 
raised against human PAD4 confirmed PAD4-deficiency in the KO neutrophils 
(Figure 28, middle panel p62). WT neutrophils displayed an exclusively nuclear 
PAD4 staining pattern (Figure 28, middle panel p62). Analysis using antibodies 
specific for deiminated histone H4R3 or H3, revealed a complete absence of those 
modifications in neutrophils derived from PAD4 KO mice (Figure 28 bottom panel 
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p62 and top panel p63). Staining for the neutrophil-specific myeloperoxidase (MPO) 
was comparable between WT and KO (Figure 28, bottom panel p63). 
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FIGURE 28: Immunofluorescence of PAD4-deficient Neutrophils. Neutrophils were 
isolated from WT or PAD4 KO mice and allowed to settle on poly-L-lysine coverslips. Cells 
were stimulated with 100ng/ml LPS for 4h in the presence of 2mM CaCl2. The stimulated cells 
were stained with a panel of antibodies (listed on the right) and counterstained with DAPI to 
reveal the nuclei. Representative pictures from two independent experiments are shown. All 
pictures were taken with the 40x objective. 
 
 To summarize, analysis of PAD4-deficient mouse neutrophils confirmed 
studies of the role of PAD4 in human neutrophils (Neeli et al., 2008; Wang et al., 
2009). PAD4 was expressed predominantly in the nucleus. Histone deimination was 
detected in LPS-treated neutrophils but was completely absent in PAD4-deficient 
neutrophils. Future studies are required to elucidate the role of PAD4 and 
deimination in neutrophil biology. 
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3.3 The Role of CARM1 in Bone Marrow-Derived 
Macrophages 
 The arginine methyltransferase CARM1 is a coactivator of several 
transcription factors, including nuclear-hormone receptors, p53, and NFκB (An et al., 
2004; Chen et al., 1999; Covic et al., 2005; Miao et al., 2006). This coactivation is 
mediated in part by methylation of histone H3R17, a modification associated with 
active transcription. CARM1 has pleiotropic functions during development, which is 
best exemplified by the perinatal death of CARM1-deficient mice due to a lung 
inflation defect (Yadav et al., 2003). 
 Studies with CARM1-deficient MEFs identified a subset of NFκB target genes 
that is regulated by recruitment of CARM1 to their promoter (Covic et al., 2005; Miao 
et al., 2006). The requirement for CARM1 enzymatic activity in this process is under 
debate (Hassa et al., 2008; Jayne et al., 2009). The list of genes regulated by 
CARM1-mediated coactivation of NFκB includes several proinflammatory factors like 
IL-6, MIP-2, and IP-10 (Covic et al., 2005; Jayne et al., 2009). Since macrophages 
produce all of these factors upon LPS-stimulation, mice with a macrophage-specific 
deletion of CARM1 were generated. 
3.3.1 Generation of CARM1-Deficient BMDMs 
 CARM1fl/fl mice (Yadav et al., 2003) were obtained, backcrossed to a pure 
C57BL/6 background, and intercrossed with lysM-Cre mice (Clausen et al., 1999). 
Several sets of CARM1fl/fl and CARM1fl/fl x lysMCre BMDMs were analyzed, but the 
deletion efficiency on both the protein and the mRNA level were very poor. On 
average 42% residual CARM1 mRNA was still detectable (Figure 29). 
 
 
 
FIGURE 29: Residual CARM1 mRNA after Cre-Mediated Deletion in BMDMs. RNA was 
isolated from unstimulated BMDMs; the genotypes are indicated on the bottom of the figure. 
CARM1 mRNA content was determined by qPCR analysis. Data is plotted as % residual 
CARM1 mRNA, which was calculated in comparison to the matching controls, CARM1fl/fl and 
CARM1+/+ x CreERt, respectively. 
 
 Therefore, CARM1fl/fl mice were intercrossed with CreERt mice, a strain that 
allows for tamoxifen-inducible Cre-mediated gene ablation (Badea et al., 2003). 
BMDMs were differentiated in vitro in the presence of 10nM 4-hydroxy-tamoxifen (4-
OHT). The CARM1-deletion efficiency was improved to 22% residual CARM1 mRNA, 
as compared to 42% mRNA in BMDMs from lysM-Cre deleted BMDMs (Figure 29). 
 All further studies were performed with CARM1 x CreERt mice. Unfortunately, 
BMDM differentiation in the presence of 4-OHT gave poor yields of mature BMDMs 
Figure 30). However, this was not due to toxic effects of 4-OHT itself but rather to the 
induction of Cre activity. When comparing BMDM differentiation at d6 from three 
different genotypes that were all generated in the presence of 4-OHT, only the bone 
marrow derived from CARM1fl/fl Cre- mice yielded normal amounts of BMDMs 
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(about 4x107 cells per mouse). Bone marrow from both CARM1+/+ x CreERt and 
CARM1fl/fl x CreERt mice yielded less than 2.0x107 cells/ mouse. Therefore, 
CARM1+/+ x CreERt mice were used as controls in all further studies, to account for 
nonspecific effects caused by the tamoxifen-mediated induction of Cre activity in 
those cells. 
 
 
 
 
FIGURE 30: BMDM Cell Numbers After Tamoxifen Treatment. Bone marrow derived from 
the indicated genotypes was differentiated into BMDMs in the presence of 10nM 4-
hydroxytamoxifen. After six days of culture, the mature cells were harvested, and total cell 
numbers were calculated. 
 
 Immunoblotting of in vitro generated CARM1-deficient BMDMs confirmed the 
absence of CARM1 on the protein level (Figure 31A). Lysates from those 
macrophages were also probed with an antibody against dimethylated histone 
H3R17. This antibody crossreacts with at least seven arginine methylated  CARM1 
substrates, including the splicing factors SmB and CA150 (Cheng et al., 2007; Yadav 
et al., 2003). Deletion of CARM1 in BMDMs also revealed reduced CARM1-
dependent methylation as detected by the H3R17me antibody (Figure 31B). To 
ensure proper in vitro differentiation of the BMDMs, macrophage maturation was 
analyzed by flow cytometry. Mature macrophages express high levels of intergrin α 
M (CD11b) and the glycoprotein F4/80. CARM1-deficiency had no impact on 
macrophage maturation, since more than 99% of the cells expressed both CD11b 
and F4/80 (Figure 31C). 
 
 
 
FIGURE 31: Initial Characterization of CARM1-Deficient BMDMs. Bone marrow from mice 
with the indicated genotypes was differentiated in vitro into BMDMs in the presence of 4-OHT. 
Cells were isolated after six days. (A) Protein lysates were prepared and analyzed for CARM1 
expression levels by WB. (B) Lysates from the same cells were probed with α H3R17(me)2-
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specific antibody. Relevant molecular weights are indicated on the left. Equal protein loading 
was confirmed by probing for α tubulin (A+B). (C) The maturation status of the differentiated 
BMDMs was assessed by flow cytometry. Cells were stained with the pan-macrophage 
markers CD11b and F4/80. Cells positive for both markers are considered to be mature. 
Relevant percentages are indicated in the FACS plots. Data shown here are representative 
examples of all BMDM preps analyzed. 
 
 In conclusion, CARM1 expression was efficiently abrogated in CARM1fl/fl x 
CreERt BMDMs upon tamoxifen-induction of Cre activity. CARM1-deficiency did not 
influence the in vitro maturation of BMDMs. Interestingly, Cre activation by tamoxifen 
reduced the yields of BMDM cultures independent of CARM1. 
 
3.3.2 Classical and Alternative Activation of CARM1-Deficient 
Macrophages 
 CARM1-suffcient and –deficient BMDMs were cultured with stimuli promoting 
classical or alternative activation. Alternative activation was assessed by detection of 
urea formation in an Arginase I activity assay (Figure 32A). Urea production was 
slightly increased in IL-4 treated CARM1-deficient macrophages, but this increase 
was not statistically significant. NO production by classically activated BMDMs was 
measured with the Griess assay (Figure 32B). Deletion of CARM1 had no influence 
on NO production by BMDMs. Therefore, CARM1 is dispensable for L-arginine 
metabolism in macrophages activated with stimuli for classical or alternative 
activation. 
 
 
 
FIGURE 32: Classical vs Alternative Activation of CARM1-Deficient BMDMs. CARM1-
sufficient (white bars) or –deficient BMDMs (grey bars) were stimulated in triplicates with IL-4 
(10ng/ml) for 48h or IFNγ (10ng/ml) and LPS (5ng/ml) for 24h. (A) BMDM lysates were 
analyzed in an Arginase activity assay. Urea production was calculated by generation of a 
Urea standard curve. (B) Nitrite production was measured in BMDM supernatants with the 
Griess assay. Absolute concentrations were calculated from a standard curve. 
 
 Another hallmark of classically activated macrophages is the secretion of 
proinflammatory cytokines including IL-6 and TNFα. LPS-mediated induction of those 
cytokines is an NFκB-dependent process. NFκB-mediated expression of IL-6 is 
abrogated in CARM1-deficient MEFs (Jayne et al., 2009). Reconstitution of the MEFs 
with either active or enzymatically inactive CARM1 is sufficient to recover IL-6 
production (Jayne et al., 2009). Therefore, I analyzed proinflammatory cytokine 
secretion in LPS-stimulated CARM1-deficient BMDMs. Surprisingly, both IL-6 and 
TNFα secretion was significantly elevated in CARM1-deficient BMDMs (Figure 33A 
and B). This effect was seen both upon LPS stimulation and upon combined IFNγ 
and LPS stimulation (Figure 33A and B). LPS-mediated induction of IL-10 secretion, 
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a MAP kinase dependent process, was not affected by the absence of CARM1 
(Figure 33C). 
 
 
 
FIGURE 33: Cytokine Production by CARM1-Deficient BMDMs. CARM1-sufficient (white 
bars) and –deficient BMDMs were stimulated in triplicates with 5ng/ml LPS and 10ng/ml IFNγ 
as indicated. (A) IL-6 secretion was analyzed by ELISA 24h after stimulation. (B) TNFα 
secretion was measured 6h after stimulation. (C) IL-10 secretion was assessed 24h post 
stimulation. Data are represented as mean +/- SEM. 
 
 In conclusion, alternatively activated CARM1-deficient BMDMs had normal 
Arginase I activity. Upon classical activation, NO production was unaffected by 
CARM1 deletion. IL-6 and TNFα levels were elevated in CARM1-deficient BMDMs 
upon LPS or IFNγ + LPS stimulation, but IL-10 levels were unaffected. These data 
suggest that CARM1 may act as a negative regulator of NFκB-mediated IL-6 and 
TNFα production in BMDMs. 
 
3.3.3 Glucocorticoid-Mediated Suppression of Inflammatory Cytokine 
Production in CARM1-Deficient BMDMs 
 CARM1 is a potent coactivator of nuclear hormone receptor signaling 
(Stallcup et al., 2003). Glucocorticoid-receptor (GR) signaling represses 
transcriptional responses to inflammatory signals (for review: (De Bosscher et al., 
2003)). Treatment of primary macrophages with the GR-agonist dexamethasone 
(dex) represses a subset of LPS-induced genes, including IL-6, TNFα, and IP-10 
(Ogawa et al., 2005). Interestingly, IL-6 and IP-10 expression is sensitive to CARM1-
mediated coactivation of NFκB-signaling in MEFs (Covic et al., 2005; Jayne et al., 
2009). Therefore, CARM1-deficient BMDMs were stimulated with LPS in the 
presence or absence of dexamethasone, to elucidate the role of CARM1 in GR-
mediated repression of inflammatory cytokine production (Figure 34). Supernatants 
from BMDMs were analyzed 6h (Figure 34A) and 24h (Figure 34B) after stimulation 
to analyze the secretion of IL-6 and TNFα. LPS stimulation recapitulated the results 
from Figure 33. Dexamethasone treatment reduced cytokine production in both 
CARM1-sufficient and –deficient MEFs, but not to the same extent. CARM1-deficient 
BMDMs secreted significantly more IL-6 and TNFα than CARM1-sufficient BMDMs, 
both upon LPS and LPS + dex stimulation (Figure 34A and B). 
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FIGURE 34: Dexamethasone-Mediated Suppression of IL-6 and TNFα Secretion by 
BMDMs. BMDMs from CARM1-sufficient (white bars) and –deficient (grey bars) mice were 
stimulated in triplicates with 100ng/ml LPS in the absence or presence of 1µM 
dexamethasone. IL-6 and TNFα cytokine secretion was measured by ELISA 6h (A) or 24h (B) 
post stimulation. Values are presented as mean +/- SEM. 
 
 To understand if the dysregulation of IL-6 and TNFα is a direct or indirect 
consequence of CARM1-deficiency, BMDMs were stimulated with LPS or LPS + dex 
for 3h in the presence or absence of the protein biosynthesis inhibitor cycloheximide 
(CHX). The cells were harvested, and mRNA levels were quantified by qPCR. 
Transcript levels of IL-6, TNFα, IP-10 and CARM1 were analyzed relative to the 
housekeeping gene HPRT (Figure 35). qPCR analysis of CARM1 mRNA levels 
confirmed the efficient deletion of CARM1 to about 20% of the WT levels (Figure 35, 
lower right). IL-6 mRNA levels reflected the elevated IL-6 secretion that was 
observed in the cytokine ELISAs (Figure 34). CARM1-deficient BMDMs exhibited 
increased IL-6 transcript levels upon LPS and LPS + dex stimulation compared to 
their wildtype counterparts. Cycloheximide-treatment abolished the increase in IL-6 
transcripts in CARM1-deficient BMDMs upon LPS stimulation but not upon LPS + 
dex stimulation (Figure 35, upper left). TNFα transcript regulation was not affected by 
CARM1 deletion (Figure 35, lower left). IP-10 transcript was regulated in a similar 
fashion as IL-6. CARM1-deficient BMDMs had elevated IP-10 mRNA levels upon 
LPS and LPS + dex stimulation compared to CARM1-sufficient BMDMs. The effect of 
cycloheximide on IP-10 levels will require further analysis because of the large error 
bars in those samples (Figure 35, upper right). 
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FIGURE 35: qPCR Analysis of CARM1-deficient BMDMs. RNA was isolated from cells 
that had been stimulated for 3h with LPS (100ng/ml), dexamethasone (1µM), and 
cycloheximide (10µg/ml) as indicated. White bars represent RNA derived from CARM1-
sufficient BMDMs, and grey bars represent CARM1-deficient BMDMs. Transcript levels of IL-
6, TNFα, IP-10, and CARM1 were analyzed relative to HPRT using the ΔΔCt method. Data is 
expressed relative to results obtained with cDNA from unstimulated CARM1-sufficient 
BMDMs. 
 
 In conclusion, LPS stimulated CARM1-deficient cells produced significantly 
more IL-6 and TNFα than the CARM1-sufficient counterparts, but dexamethasone 
treatment potently reduced cytokine expression in both sets of cells. Therefore it 
seems that CARM1-deficiency in BMDMs has little or no effect on GR-mediated 
suppression of IL-6 and TNFα secretion. qPCR analysis revealed that the effect of 
CARM1 on IL-6 and IP-10 was at least partially regulated at the transcript level, but 
the effect of CARM1-deletion on TNFα was regulated posttranscriptionally. 
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4 Discussion and Outlook 
 Arginine modifying enzymes are potent regulators of many cellular processes. 
In this thesis, I focused on two arginine modifying enzymes, PAD4 and CARM1, and 
their roles in immune regulation. The first part of my thesis focused on the role of the 
peptidylarginine deiminase PAD4. I discovered that PAD4 can interact with and 
deiminate NIP45. Furthermore, PAD4 is a negative regulator of NIP45-mediated IL-4 
secretion in Th2 cells. In addition, I generated PAD4-deficient mice. The mice are 
viable and display normal B and T cell development. In the second part of this thesis, 
I analyzed the role of the arginine methyltransferase CARM1 in macrophages. 
CARM1-deficiency leads to dysregulation of proinflammatory cytokine production in 
BMDMs.  
4.1 Regulation of NIP45-mediated IL-4 Transcription by PAD4 
 Cytokine secretion by Th cells is a highly regulated process. Th2 cells secrete 
IL-4 upon antigen encounter. IL-4 is a potent mediator of humoral immunity and 
clearance of extracellular pathogens. In addition, Th2 cells require IL-4 during 
differentiation and lineage maintenance, as IL-4 mediated signals are potent 
suppressors of Th1 lineage choice. Th2 responses need to be tightly controlled, 
since elevated type 2 cytokine levels are associated with allergy, asthma, and 
fibrosis. 
 
 The NFAT-interacting protein NIP45 is a central regulator of type 2 immunity 
(Fathman et al., 2010; Hodge et al., 1996; Mowen and David, 2001; Mowen et al., 
2004). NIP45-deficient mice show severe defects in Th2-mediated immune 
responses, including a strong reduction in IL-4 secretion by Th2 cells. Furthermore, 
NIP45 KO mice display delayed expulsion of worms in a Trichinella spiralis infection 
model, a process driven by type 2 cytokines (Fathman et al., 2010). NIP45-mediated 
IL-4 expression is regulated by arginine methylation. The arginine methyltransferase 
PRMT1 methylates multiple arginines in the N-terminus of NIP45, thereby, facilitating 
the formation of a tripartite NFAT/NIP45/PRMT1 complex. This complex binds to the 
IL-4 promoter and drives gene expression (Mowen et al., 2004). NIP45 deficiency 
leads to a reduction of dimethylated histone H4R3 levels at the IL-4 promoter, 
underscoring a positive regulatory role for PRMT1 under physiological conditions 
(Fathman et al., 2010). In summary, PRMT1 activity drives the assembly of the 
NFAT/NIP45/PRMT1 complex that is required for full transcriptional activity of the IL-
4 promoter. IL-4 transcription needs tight control, since aberrant expression has 
severe consequences for the host. Therefore, I set out to study the negative 
regulation of IL-4 expression. Since arginine methylation is a positive regulator of 
NIP45-mediated IL-4 transcription, I hypothesized that arginine deimination could 
negatively regulate this process.  
 Histone arginine methylation is regulated by arginine deimination. Besides 
catalyzing the conversion of arginine to citrulline, the peptidylarginine deiminase 
PAD4 also converts monomethylated arginine into citrulline, a process referred to as 
demethylimination (Cuthbert et al., 2004; Wang et al., 2004). Deiminated arginines 
cannot be methylated by PRMTs. Methylation of NIP45 might be regulated similarly. I 
focused on the role of PAD4 in NIP45-mediated IL-4 transcription in Th2 cells for two 
reasons: First, PAD2 and PAD4 are the only PAD family members expressed in T 
cells (Vossenaar et al., 2004). Second, PAD4 is the only nuclear PAD family member 
(Nakashima et al., 2002), which is relevant since NIP45 is a nuclear protein as well. 
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 PAD4 expression in Th2 cells, albeit at low levels, was confirmed on the RNA 
transcript level. Furthermore, PAD4 could deiminate NIP45 both in vitro and in vivo. 
Interestingly, deimination of NIP45 with recombinant PAD4 could prevent subsequent 
methylation by PRMT1, whereas PRMT1-mediated methylation of NIP45 had no 
influence on subsequent deimination. This data suggests that the arginines modified 
by PAD4 and PRMT1 only partially overlap. Indeed, deimination analysis of NIP45 
deletion mutants revealed that deimination of NIP45 was not confined to the PRMT1-
targeted glycine- and arginine-rich N-terminus (Mowen et al., 2004) but was 
distributed throughout the protein. To identify the actual deiminination sites, in vitro 
deiminated NIP45 was analyzed by mass spectrometry. Though we obtained poor 
sequence coverage, I identified four deiminated arginine residues at positions R32, 
R37, R103, and R104. R103 and R104 are part of the NLS of NIP45, but mutation of 
these residues to a glutamine residue to mimic deimination had no effect on nuclear 
localization of NIP45. I engineered R->Q point-mutants for all four sites and tested 
the capacity of those mutants to potentiate IL-4 secretion from M12 cells. The R37Q 
mutation negatively affected NIP45-mediated IL-4 secretion; all other mutants 
showed little or no defect. It is of interest to address how deimination of R37 affects 
endogenous IL-4 transcription. It will be important to test whether the R37Q mutation 
destabilizes the NFAT/NIP45/PRMT1 complex. Generation of a NIP45 mutant with all 
four R->Q substitutions might reveal an additive effect for those deimination sites. 
Since neither the N-terminal sequence of NIP45 nor the C-terminus could be 
resolved in our mass spectrometric studies, future analyses are needed to resolve 
the modifications at the N-terminus and the C-terminus. 
 To address the effects of PAD4 on NIP45-mediated IL-4 transcription in a 
more direct way, I performed coexpression studies of PAD4, NIP45 and NFAT in 
M12 cells. PAD4 suppressed NIP45-mediated IL-4 expression and secretion. 
Interestingly, the same effect could be achieved by coexpression of an enzymatically 
inactive point mutant of PAD4. This suggests that PAD4 negatively regulates NIP45-
mediated IL-4 secretion independent of its catalytic activity. In addition, Th2 cells 
from PAD4-deficient mice secreted significantly more IL-4 than their WT 
counterparts. An initial analysis of the IL-4 locus control region by ChIP revealed no 
differences between PAD4 WT and KO Th2 cells.  
 There are several mechanisms for PAD4-mediated suppression of NIP45-
driven IL-4 expression conceivable: First, since PAD4 could interact with NIP45 and 
NFAT, PAD4 might compete with PRMT1 for NFAT/NIP45 binding. Competitive 
expression of PAD4 and PRMT1 with NFAT/NIP45 should address if the arginine-
modifying enzymes are vying for the same binding sites. Coexpression of PAD4 with 
PRMT1/NFAT/NIP45 followed by immunoprecipitation of NIP45 should reveal a 
decreased association of PRMT1 with NIP45/NFAT, if PAD4 competes for binding of 
NIP45. In addition, the NIP45 deletion mutants could be used to map PRMT1-, 
PAD4-, and NFAT-binding sites on NIP45. 
 Second, deimination of NIP45 might be required under circumstances when 
the amount of cellular PAD4 is limited. Endogenous PAD4 levels are likely to be 
much lower than the levels observed in experiments using overexpression systems, 
and they might not be sufficient to compete for binding. Therefore, PAD4-mediated 
deimination of NIP45 may inhibit PRMT1 and NIP45 association. To test if PAD4 
enzymatic activity would be required under physiological conditions, PAD4-deficient 
Th2 cells could be retrovirally transduced with active or inactive PAD4. The 
transduced cells could be sorted into high- and low-expressing cells and analyzed for 
their IL-4 expression capacities. If PAD4 catalytic activity were required, PAD4 KO 
Th2 cell IL-4 production would only be restored to WT levels in the presence of the 
catalytically active PAD4. 
 Third, PAD4 might inhibit IL-4 expression independent of NIP45. To identify a 
role for PAD4 in IL-4 expression independent of NIP45, I will try to identify novel 
interaction partners of PAD4. To this end, I have generated two monoclonal 
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antibodies against PAD4, which will be used to immunoprecipitate PAD4 from Th2 
cells. The IPs will then be analyzed by mass spectrometry to identify interacting 
proteins. In my preliminary analysis, both antibodies could immunoprecipitate 
endogenous PAD4 (data not shown). In addition, these antibodies will also be useful 
for ChIP-Seq studies, a technique that combines chromatin immunoprecipitation with 
high-throughput DNA sequencing to reveal genomic binding sites of PAD4. 
 
 In conclusion, I propose that PAD4 is a negative regulator of IL-4 secretion. 
PAD4 can deiminate NIP45, but the requirement for deimination of NIP45 in IL-4 
transcriptional regulation remains unclear. Since PAD4 can interact with NIP45 and 
NFAT, it might displace PRMT1 from the trimeric NFAT/NIP45/PRMT1 complex. In 
addition, PRMT1 can methylate PAD4 in vitro, which might serve to regulate PAD4 
activity or binding (Figure 36). 
 
 
FIGURE 36: Model of PAD4-mediated Regulation of IL-4 Transcription (adapted from 
Kerri Mowen) 
 
 It is interesting to speculate about a role for PAD4-mediated deimination of 
NIP45 in a broader sense. Not much is known about the biology of NIP45. NIP45 is 
part of the RENi protein family comprised of Rad60, Esc2, and NIP45. The RENi 
family is characterized by the presence of two carboxyterminal Small Ubiquitin-like 
Modifier (SUMO)-like domains (Novatchkova et al., 2005). The SUMO-like domain of 
NIP45 can interact with the E2 SUMO ligase Ubc9, thereby, inhibiting 
polysumoylation of Ubc9 targets (Sekiyama et al., 2010). Since PAD4 could 
deiminate residues throughout NIP45, PAD4 might also modify residues in the two 
SUMO-like domains, potentially affecting the interaction of NIP45 with Ubc9. 
Interestingly, NFAT1, the interaction partner of NIP45, is a target of Ubc9-mediated 
sumoylation (Terui et al., 2004). The sumoylation of NFAT is important for nuclear 
retention and transcriptional activity of NFAT1. NIP45 might be required to limit NFAT 
sumoylation to mono- or di-sumoylation and prevent polysumoylation, which would 
target NFAT for degradation. If deimination of NIP45 would decrease the interaction 
of NIP45 with the E2 SUMO-ligase Ubc9, this could lead to polysumoylation of NFAT 
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and subsequent degradation, providing another possible mechanism for negative 
regulation of IL-4 expression. Therefore, I will test the effect of PAD4-mediated 
deimination of NIP45 on the sumoylation of NFAT by coexpression of NFAT, NIP45, 
PAD4 and SUMO1, and subsequent immunoprecipitation of NFAT to analyze how its 
sumoylation status is affected by the presence of PAD4. 
 NIP45 interacts with members of the TNF Receptor Associated Factor 
(TRAF) family (Bryce et al., 2006; Lieberson et al., 2001). TRAFs are intracellular 
signaling mediators of the TNF-receptor superfamily (for review: (Ha et al., 2009)). 
TRAF signaling mediates pleiotropic cellular activities, including survival, 
proliferation, inflammation, and lymphocyte activation. Interaction of NIP45 with 
TRAF1 (Bryce et al., 2006) or TRAF2 (Lieberson et al., 2001) negatively affected IL-4 
expression in IL-4 reporter assays and overexpression studies in M12 cells. It is 
interesting to speculate that PAD4-mediated deimination of NIP45 might facilitate 
binding of TRAFs to potentiate negative regulation of IL-4. This hypothesis can be 
tested by overexpression of NFAT, NIP45, PAD4 and TRAF1 or TRAF2 in M12 cells. 
If PAD4 and TRAFs cooperate in the negative regulation of IL-4 expression, I would 
expect to see even stronger repression of IL-4 secretion when PAD4 and TRAF1 or 
TRAF2 are coexpressed. 
 
4.2 Generation of PAD4-Deficient Mice 
 Although PAD4 has a restricted expression pattern (Vossenaar et al., 2004), 
PAD4 dysregulation has been associated with severe pathological conditions, 
including RA (Anzilotti et al., 2010), MS (Wood et al., 2008), and malignant tumors 
(Chang and Fang, 2009). The PAD4-specific conditional KO strain will be an 
important tool to further the understanding of PAD4 biology, especially in difficult-to-
access cell types like neutrophils. The PAD4fl/fl mice are currently being bred onto 
the lysM-Cre strain, the Lck-Cre strain, and the Cre-ERt strain. The initial 
characterization was performed in mice that had been crossed with the CMV-Cre 
mouse line that deletes the floxed gene segments in all tissues. PAD4-/- mice are 
viable and display no overt developmental phenotypes. B and T cell development 
was analyzed more closely, but was comparable between WT and KO PAD4 mice. 
 Th2 cells from PAD4-deficient mice displayed elevated IL-4 secretion, 
substantiating a proposed role for PAD4 in negative regulation of IL-4 secretion (see 
4.1). Thus it will be interesting to challenge mice with a T cell-specific deletion of 
PAD4 (PAD4 x Lck-Cre) with Trichinella spiralis, a parasitic nematode, which elicits a 
strong type 2 immune response. The working hypothesis would be that PAD4-
deficient mice should have an overactive type 2 response with elevated serum IL-4 
levels and faster expulsion kinetics of the parasites. PAD4-deficient Th1 cells 
displayed a small but significant decrease in IFNγ secretion upon TCR stimulation. 
Therefore, it would be of interest to challenge the mice with Leishmania major. 
C57BL/6 mice are resistant to infection but defects in type 1 immunity will convert the 
resistant strain into a susceptible strain. If the IFNγ-secretion defect in PAD4-deficient 
Th1 cells is robust, the PAD4-deficient mice should be more susceptible to L. major 
infection, which can be assessed by bacterial burden and serum IFNγ levels. 
 PAD4 is highly expressed in granulocytes, especially neutrophils (Asaga et 
al., 2001). PAD4-mediated histone deimination promotes chromatin decondensation, 
which is a prerequisite for NET release (Neeli et al., 2008; Wang et al., 2009). 
Indeed, I demonstrated that histone deimination in murine neutrophils was absolutely 
dependent on PAD4. The initial characterization of neutrophils derived from PAD4 
mice will be expanded further to analyze the role of PAD4 in neutrophil biology. It will 
be interesting to test, whether PAD4 deficiency will affect neutrophil effector 
functions, especially degranulation, cytokine release, ROS production, and bacterial 
killing. Furthermore, NET formation in PAD4 WT and KO neutrophils will be 
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characterized in vitro both qualitatively (bacterial killing assays) and quantitatively (IF 
enumeration), to address whether PAD4-mediated deimination is important for NET 
release.  
 By generating PAD4fl/fl x lysM Cre mice, I will have a valuable tool to address 
the role of PAD4 in neutrophil and macrophage function in vivo. Subcutaneous or 
pulmonary challenge with C. albicans can be used to assess NET-mediated trapping 
of the pathogen (Urban et al., 2009). PAD4 protein is expressed in monocytes and 
macrophages, but PAD4 mRNA is only detected in monocytes (Vossenaar et al., 
2004). Therefore, it will be of interest to study both PAD4 mRNA and protein stability 
in monocytes and macrophages. Furthermore, PAD4fl/fl x lysM Cre mice will be used 
to characterize macrophage function both in vitro and in vivo. The initial in vitro 
characterization will include the assessment of classical versus alternative activation 
in BMDMs. I am especially interested in the glucocorticoid-receptor mediated 
suppression of proinflammatory cytokines since PAD4 is a negative regulator of 
nuclear-hormone receptor transcription (Cuthbert et al., 2004; Wang et al., 2004). If 
PAD4-mediated negative regulation of GR-mediated signaling were important in 
macrophages, I would expect to see enhanced suppression of proinflammatory 
cytokine secretion in PAD4-deficient BMDMs. 
 
 Since PAD4 dysregulation has been implicated in various diseases, cell type-
specific deletion of PAD4 will be a useful tool to elucidate the contribution of PAD4 to 
disease. PAD4 has been implicated in RA in several ways: PAD4 mRNA and protein 
can be found in the arthritic joint (Chang et al., 2005b; Foulquier et al., 2007). 
Autoantibodies against citrullinated peptides are detected in patients even prior to 
clinical diagnosis of RA (Nielen et al., 2004; Vencovsky et al., 2003). A polymorphism 
in PAD4 has been associated with enhanced susceptibility to RA (Suzuki et al., 
2003). It will be of interest to test the involvement of PAD4 in RA disease 
development and progression. There are several mouse models for RA available.  
 The K/BxN serum transfer model induces RA-like disease in mice by injection 
of serum containing an autoantibody against GPI (glucose-6-phosphate isomerase) 
(Kouskoff et al., 1996; Monach et al., 2007). This model allows isolated analysis of 
the effector-phase of the disease downstream of autoantibody production. I will 
examine the susceptibility of PAD4-deficient mice (PAD4-/- and PAD4fl/fl x lysM Cre) 
to inflammatory arthritis using the K/BxN serum transfer model. This model has 
several advantages. Since C57BL/6 mice are susceptible to RA induction in this 
model, the PAD4 mice do not need to be backcrossed onto a different genetic 
background. In addition, previous studies have demonstrated that neutrophils 
contribute to disease development in the K/BxN model (Monach et al., 2010; Wipke 
and Allen, 2001). If PAD4 deficiency diminishes the proinflammatory capacities of 
neutrophils and macrophages, I would predict ameliorated disease in PAD4-deficient 
mice.  
 The collagen-induced arthritis (CIA) model is an antigen-induced model of RA 
(Rosloniec et al., 2001). The CIA model requires backcrossing of the mice onto a 
susceptible mouse strain, e.g. DBA/1. Collagen-induced arthritis depends on the 
breakdown of T cell tolerance and autoantibody production (Monach et al., 2004). 
Importantly, joints from arthritic mice display elevated PAD4 protein expression and 
citrullinated protein deposits (Vossenaar et al., 2003a). Therefore, it will be 
interesting to test how the absence of PAD4 will affect disease onset and severity in 
this model. I hypothesize that in the absence of PAD4 the mice will have ameliorated 
disease. Furthermore, serum and joints from arthritic PAD4 WT and KO mice will be 
analyzed for anti-cyclic citrullinated peptide autoantibodies, to test if PAD4 is required 
for development of citrullinated autoantigens and, subsequently, autoantibodies. 
 
 The role of PAD4 in apoptosis is controversial. PAD4 has been described to 
both promote apoptosis and cell cycle arrest (Hung et al., 2007; Liu et al., 2006) and 
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inhibit apoptosis (Li et al., 2008; Yao et al., 2008). Therefore, I propose to generate 
PAD4-deficient MEFs, which can be used to study the effects of PAD4-deficiency on 
apoptosis induction by chemical induction (doxorubicin, staurosporine, etc) or by 
radiation (UV). If PAD4 promotes apoptosis, PAD4-deficient MEFs should display 
less apoptotic features or a delay in apoptosis progression. 
 
 In conclusion, I generated a PAD4 conditional KO mouse strain that will serve 
as a valuable tool to further the understanding of PAD4 biology. The role of PAD4 in 
neutrophils is of special interest, since it might shed light on the disease mechanism 
of RA. 
4.3 The Role of CARM1 in Bone Marrow-Derived 
Macrophages 
 The arginine methyltransferase CARM1 coactivates several transcription 
factors, including NFκB (Covic et al., 2005; Miao et al., 2006). CARM1 interacts with 
p65, and this association is independent of the arginine methyltransferase activity of 
CARM1 (Covic et al., 2005). CARM1 mediates NFκB coactivation in complex with 
members of the p160 coactivator family and the acetyltransferases p300/CBP (Covic 
et al., 2005; Miao et al., 2006). Recruitment of CARM1 to gene promoters coincides 
with histone H3R17 methylation, a chromatin modification associated with active 
transcription (Covic et al., 2005; Miao et al., 2006). 
 The role of CARM1 in NFκB-mediated transcriptional regulation has been 
studied in CARM1-deficient MEFs. Upregulation of a subset of NFκB target genes, 
including IP-10, MIP2 and ICAM-1, upon LPS or TNFα-mediated stimulation was 
decreased in CARM1-deficient cells (Covic et al., 2005). CARM1-deficiency had no 
effect on activation of NFκB measured by IκB degradation or nuclear translocation of 
p65 (Covic et al., 2005). Furthermore, coactivation by CARM1 was dependent on its 
catalytic activity (Covic et al., 2005). TNFα stimulation of 293T cells after knockdown 
of CARM1 revealed a role for CARM1 in the coactivation of the NFκB target genes 
IL-8, IP-10, and TNFα  (Miao et al., 2006). Complementation of CARM1-deficient 
MEFs with active or enzymatically inactive CARM1 permitted the discovery of a 
group of NFκB target genes that were dependent on CARM1 but independent of its 
enzymatic activity, including IL-6 and MIP2 (Jayne et al., 2009). In contrast, MIP2 
was also described as a CARM1-dependent NFκB target gene that required arginine 
methyltransferase activity (Covic et al., 2005; Hassa et al., 2008).  
 To establish a model system to study the role of CARM1 in proinflammatory 
cytokine production, I generated CARM1-deficient BMDMs to study the role of 
CARM1 in proinflammatory cytokine production. The generation of a macrophage-
specific deletion by breeding of CARM1fl/fl mice to the lysM-Cre strain proved to be 
unsuccessful. The deletion efficiency was variable both on the protein and the mRNA 
level, which led to inconsistencies between experiments. Indeed, other investigators 
have reported inefficient deletion by lysM-Cre in macrophages (Greenblatt et al., 
2010). Therefore, I established a novel model of in vitro deletion of CARM1 by 
crossing CARM1fl/fl mice with the tamoxifen-inducible CreERt strain. In this model 
system, deletion efficiency was improved and sufficient for my studies. It is 
interesting to note that even with tamoxifen-induced CARM1 deletion I could still 
detect residual mRNA. This phenomenon might reflect the existence of a few non-
deleted bone marrow cells that can outcompete CARM1-deficient cells during BMDM 
differentiation. 
 
 According to published data, I expected to see defects in LPS-induced IL-6 
and TNFα expression in CARM1-deficient BMDMs. Surprisingly, CARM1-deficiency 
resulted in significantly increased IL-6 and TNFα cytokine production upon LPS 
                DISCUSSION 
76 
stimulation. These data suggest that CARM1 is required for negative regulation of 
NFκB-dependent proinflammatory cytokine production. Indeed, CARM1-mediated 
methylation of p160 coactivators and p300/CBP has been described to destabilize 
the coactivator complex, thereby, initiating termination of transcription (Lee et al., 
2005a; Naeem et al., 2007). Therefore, I propose to assess coactivator complex 
stability and the kinetics of transcriptional termination in CARM1-deficient BMDMs. I 
have not ruled out the possibility that the observed increase in IL-6 and TNFα 
secretion is due to hyperproliferation of CARM1-deficient BMDMs, but the 
observation that IL-10 secretion is not changed in CARM1-deficient BMDMs would 
argue against that possibility. Nevertheless, I will measure tritiated thymidine 
incorporation to assess proliferation of BMDMs upon LPS stimulation in future 
studies. Furthermore, it is important to study the effect of CARM1-deficieny on NFκB 
signaling by analyzing IκB degradation kinetics as well as p65 translocation to the 
nucleus. Finally, I will address p65 and coactivator binding to the IL-6 and TNFα 
promoters upon LPS stimulation by ChIP and EMSA studies. I would predict to see 
no differences in NFκB signaling between CARM1-sufficient and –deficient BMDMs, 
but prolonged promoter association of p65 and the p160/p300/CBP coactivator 
complex in CARM1-deficient BMDMs, thereby, proposing a role for CARM1 in 
methylation-mediated destabilization of the coactivator complex. 
 Since CARM1 seems to be a negative regulator of NFκB-mediated IL-6 and 
TNFα production, I determined whether this was due to a direct effect of CARM1. I 
performed analysis of IL-6 and TNFα transcription upon LPS stimulation in the 
absence or presence of the protein biosynthesis inhibitor cycloheximide. LPS-
induced expression of the IL-6 mRNA was increased in CARM1-deficient BMDMs in 
parallel to elevated IL-6 secretion and was sensitive to cycloheximide treatment. 
Cycloheximide-sensitivity suggests that CARM1 is an indirect regulator of IL-6 
expression that requires synthesis of other mediators. Microarray-analysis comparing 
LPS-stimulated CARM1-sufficient and –deficient BMDMs will enable identification of 
the cycloheximide-sensitive CARM1 targets that regulate IL-6 expression. 
Interestingly, analysis of LPS-induced TNFα expression revealed no difference 
between CARM1-sufficient and –deficient BMDMs. Since we had observed 
significantly more TNFα production on the protein level in CARM1-deficient BMDMs, 
these results suggest a role for CARM1 in the translational regulation of TNFα. 
Alternatively, CARM1 might regulate TNFα by affecting its mRNA stability, and the 
3h post stimulation timepoint that I analyzed may have missed the window of 
regulation. Indeed, CARM1 methylates the mRNA stabilizer HuR upon LPS 
stimulation in a macrophage cell line (Li et al., 2002). HuR stabilizes TNFα mRNA by 
binding to the AU-rich elements in the 3’UTR of TNFα (Dean et al., 2001). Therefore 
I will perform a more thorough kinetic analysis of the TNFα mRNA levels comparing 
CARM1-sufficient and –deficient BMDMs to elucidate if HuR methylation by CARM1 
could affect the stabilization of TNFα transcript.  
 
 CARM1 was originally identified as a coactivator for nuclear hormone 
receptor-mediated transcription (Chen et al., 1999). Glucocorticoid receptor signaling 
is involved in repression of the transcriptional response to inflammatory stimuli 
(Ogawa et al., 2005). The glucocorticoid receptor agonist dexamethasone is a potent 
anti-inflammatory drug that is used in treatment of inflammatory conditions like RA 
(Bijlsma et al., 2002). Glucocorticoid-receptor stimulation leads to Transrepression of 
NFκB family members (De Bosscher et al., 2003). Since CARM1 is a coactivator of 
glucocorticoid receptor-mediated transcription, I tested whether CARM1-deficient 
BMDMs were defective in dexamethasone-mediated transrepression of 
proinflammatory cytokines. LPS-induced IL-6 and TNFα expression was effectively 
repressed by dexamethasone treatment in both CARM1-sufficient and –deficient 
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macrophages. Although the CARM1-deficient cells produced significantly more IL-6 
and TNFα than CARM1-sufficient cells upon LPS + dex treatment, the levels were 
still much lower compared to LPS treatment alone. The significant increase is more 
likely due to the overall loss of CARM1 and elevation in IL-6 and TNFα transcription. 
I conclude that CARM1 is not involved in glucocorticoid-receptor mediated trans-
repression of NFκB-mediated proinflammatory cytokine expression. 
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5 Summary 
 
 Arginine modifying enzymes are important transcriptional regulators involved 
in many cellular processes. Cytokine expression by immune cells is a highly 
regulated process, since cytokine imbalance is associated with severe pathological 
consequences including autoimmunity, autoinflammation and asthma. 
 
 Th2 mediated IL-4 expression is a tightly regulated process. The NFAT-
interacting protein NIP45 is an essential regulator of IL-4 expression by Th2 cells. 
Furthermore, NIP45-mediated IL-4 expression is enhanced by arginine methylation 
of NIP45. Here, I demonstrate that arginine deimination of NIP45 by PAD4 negatively 
regulates IL-4 expression. PAD4 can deiminate NIP45 both in vitro and in vivo. 
Overexpression of PAD4 can suppress NIP45-mediated IL-4 expression. 
Interestingly, the suppressive activity of PAD4 is independent of its catalytic activity. 
Furthermore, Th2 cells from PAD4-deficient mice that I generated for this thesis 
display elevated IL-4 secretion. Taken together, I have established that PAD4 is a 
negative regulator of IL-4 expression. Although PAD4 can deiminate NIP45, the 
catalytic activity of PAD4 is not required for suppression of NIP45-mediated IL-4 
secretion. 
 
 CARM1 coactivates NFκB-mediated transcription of several proinflammatory 
genes including IL-6, TNFα, and IP-10 in MEFs. In contrast, I demonstrate that 
CARM1 is a negative regulator of NFκB-mediated proinflammatory cytokine 
secretion in macrophages. CARM1-deficient BMDMs secrete significantly more IL-6 
and TNFα upon LPS stimulation than CARM1-sufficient BMDMs, without exhibiting a 
difference in IL-10 secretion. In addition, CARM1 is reported to coactivate 
glucocorticoid-receptor mediated transcription. Here, I show that glucocorticoid-
mediated trans-repression of NFκB in BMDMs is not regulated by CARM1. 
 
 In conclusion, the results from this thesis reveal novel roles for arginine 
modifying enzymes in cytokine expression by Th2 cells and macrophages. PAD4 is a 
negative regulator of NIP45-mediated IL-4 secretion in Th2 cells. In addition, the 
generation of the PAD4 conditional knockout strain will allow a more detailed 
analysis of PAD4 in immune regulation. Furthermore, CARM1 is a negative regulator 
of NFκB-mediated proinflammatory cytokine secretion in macrophages, revealing 
cell-type specific differences for CARM1 function in macrophages and MEFs. 
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6 Zusammenfassung 
 
 Die posttranslationale Modifizierung von Argininen durch Arginin-
Methyltransferasen oder Arginin-Deiminasen, spielt eine wichtige Rolle in 
verschiedensten zellulären Prozessen. Die Sekretion von Zytokinen durch Zellen des 
Immunsystems ist stark reguliert, u.a. durch posttranslationale Modifikation. 
Fehlregulation von Zytokinen hat pathologische Konsequenzen, wie z.B. 
Autoimmunität, Inflammation und Asthma. 
 
 Th2 Zellen sind die Hauptproduzenten des Zytokins IL-4, dessen Produktion 
ebenfalls stark reguliert ist. NIP45, ein Protein das mit NFAT interagiert, ist ein 
wichtiger Modulator der IL-4 Sekretion durch Th2 Zellen. Die Methylierung von 
Argininen im NIP45-Protein hat einen positiven Effekt auf IL-4 Expression. Im 
Rahmen dieser Doktorarbeit konnte gezeigt werden, dass die Deimination von 
Argininen im NIP45-Protein durch PAD4 einen negativen Effekt auf IL-4 Protein 
Expression hat. PAD4 deiminiert NIP45 sowohl in vitro als auch in vivo. 
Überexpression von PAD4 führt zu Repression von IL-4 Sekretion durch NIP45. 
Dieser Effekt ist allerdings unabhängig von der enzymatischen Aktivität von PAD4. 
Um den Effekt von PAD4 auf IL-4 Produktion genauer zu untersuchen, wurden PAD4 
cKO Mäuse generiert. Interessanterweise weisen Th2 Zellen, die aus PAD4-
defizienten Mäusen isoliert wurden, erhöhte IL-4 Sekretion auf. Daraus schliesse ich, 
dass PAD4 einen negativen Effekt auf NIP45-induzierte IL-4 Expression hat. Obwohl 
PAD4 NIP45 deiminieren kann, scheint dieser Effekt nicht verantwortlich für die 
Regulierung von IL-4 Sekretion durch Th2 Zellen zu spielen. 
 
 CARM1 ist ein Koaktivator von NFκB. In MEFs konnte gezeigt werden, dass 
CARM1 die Expression der proinflammatorischen Zytokine IL-6, TNFα und IP-10 
positiv reguliert. Im Rahmen dieser Studie konnte erstmalig gezeigt werden, dass 
CARM1 einen negativen Einfluss auf die proinflammatorische Zytokin-Expression in 
Makrophagen hat. CARM1-Deletion in Makrophagen führt zu vermehrter Sekretion 
von IL-6 und TNFα nach Stimulierung der Zellen mit LPS. CARM1 hat keinen 
Einfluss auf die Sekretion von IL-10. Desweiteren wurde die Rolle von CARM1 in der 
Transrepression von NFκB durch Glukokortikoide untersucht. Die Repression der 
proinflammatorischen Zytokin-Expression in CARM1-defizienten Makrophagen ist 
intakt. 
 
 Zusammenfassend konnte im Rahmen dieser Arbeit eine neue Rolle sowohl 
für PAD4 als auch CARM1 in der Immunregulation gezeigt werden. PAD4 ist wichtig 
für die Deaktivierung der NIP45-induzierten IL-4 Expression in Th2 Zellen. 
Ausserdem werden die generierten PAD4-defizienten Mäuse hilfreich in der weiteren 
Analyse von PAD4 sein. Trotz der Funktion für CARM1 in der Koaktivierung von 
NFκB in MEFs, scheint CARM1 einen negativen Effekt auf die Expression der NFκB-
abhängigen Zytokine IL-6 und TNFα zu haben. 
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